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Interrogating Raf-1 Kinase Inhibitor Protein (RKIP) as a Novel Therapeutic Target for 
Modulating Inflammatory Responses 
Kyle T. Wright, M.D., Ph.D. 
University of Connecticut, 2016 
The studies presented here were designed to test if Raf-1 kinase inhibitor protein (RKIP) plays a 
functionally significant role in immunity, and to interrogate its possibility of providing a novel 
therapeutic target for modulating inflammatory responses. Based on previous studies from other 
laboratories that attributed negative regulatory functions to RKIP in the context of MAPK and 
NF-κB signaling in cell lines, we tested the hypothesis that its function was to suppress the 
production of pro-inflammatory cytokines, proliferation, and cell survival. However, after 
extensive investigation, our data clearly demonstrate that RKIP is actually necessary for the 
production of certain cytokines, namely Type-I and Type-II interferons, but had less robust 
effects on cell survivability and proliferation. Specifically, this work shows that RKIP is 
integrated in the signaling pathway downstream of TCR triggering in CD8+ T cells and TLR 
ligation in APCs. Finally, these studies highlight RKIP as a druggable protein, and through its 
targeted inhibition, cytokine responses can be significantly diminished. Thus, this provides 
elementary rationale for its potential clinical applicability in therapeutic interventions for 
inflammatory diseases, especially those associated with dysregulated IFN responses. Through 
this current work, we have provided a solid foundation for future studies that seek to investigate 
further the molecular mechanisms of RKIP function within the immune system, as well as its 
advancement into clinically relevant inflammatory disease models. 
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INFLAMMATION IN HEALTH AND DISEASE: 
HOW UNDERSTANDING DIFFERENT INFLAMMOMES MAY LEAD TO 
ENHANCED THERAPUETIC INNOVATION AND CLINICAL IMPLEMENTATION 
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I. INTRODUCTION 
Inflammation, to use a timeworn axiom, is a double-edged sword. Under normal physiological 
circumstances, it operates as the most significant defense system that the human body has 
developed to ward off incursion of foreign pathogens (1); however, if inappropriately directed or 
poorly regulated, it can lead to significant morbidity and mortality (2). It is truly a unique 
circumstance within physiology that one of the greatest assets for developing Darwinian fitness 
(3), and certainly important for survival and propagation of many species, can abruptly become 
one of the most substantial agents for tissue dysfunction and disease development.    
Although the mechanisms by which inflammation develops have gained significant complexity 
and efficiency over evolutionary time, there are still only but a handful of molecular signaling 
pathways and professional immune cell types that drive the entire effective output of 
inflammatory processes (4). Nevertheless, inflammation as a term in its clinical sense, and 
certainly as it is portrayed to the general public, has been, until recently, used too broadly. This is 
most likely responsible for the stagnation in therapeutic options for patients suffering from 
“inflammatory” diseases until the advent of cytokine-specific biologicals in the 1990 (5, 6). In 
reality, inflammation can vary depending on a myriad of factors including the following: 1) the 
initiating stimulus or trigger (e.g. pathogenic infection, cell injury, molecular mimicry, or 
inappropriate responses to a self and innocuous antigens), 2) the cell types, receptors, and 
signaling pathways involved, 3) the generation of specific effector cytokine-chemokine milieus, 
4) temporality (e.g. acute vs. chronic or early vs. late phase dynamics), and 5) the type of 
pathology that results (e.g. systemic vs. local, tissue destruction vs. repair, etc.). The compilation 
of these factors in a given mechanistic context is the inflammome (7). Humans and other higher 
order mammals have, over evolutionary time, developed several discrete inflammomes in order 
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to antagonize the effects of certain pathogens (Figure 1-1). However, when these inflammomes 
are induced inappropriately, they drive the development of distinctive disease causing effector 
molecules that have become the basis of new interventional therapies (8). The vast majority of 
biological anti-inflammatory treatments currently being researched and developed are focused on 
the post hoc, direct inhibition of these downstream effectors by anti-cytokine monoclonal 
antibodies or through receptor antagonists. This prevailing thought process of “end-point 
treatment” has even directed a new approach to disease classification, namely a cytokine-based 
disease taxonomy (9), as opposed to a traditional diagnosis based on particular tissue or organ 
system dysfunction. Although this approach is a much improved way of organizing groups of 
distinct diseases, it omits the processes that led to the generation of these effectors in the first 
place. In this review, we will focus on delineating not only the pathogenic sequelae of these 
inflammation-driving effector cytokines, but also the distinct inflammomes that lead to their 
synthesis. Through this, we hope to expand the idea of a cytokine-based disease taxonomy into 
an inflammome-based disease taxonomy, while directing the focus of future therapeutic 
development toward those interventions that subvert a priori cytokine development, rather than 
post hoc inhibition.               
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II. THE MAJOR INFLAMMOMES 
A. INNATE (TNF DOMINANT) 
The innate immune response is composed of different cell types that respond to diverse 
endogenous or exogenous signals and mediate distinct downstream effects within minutes to 
hours of activation. However, there are at least three major cytokine milieus that can be 
generated based on all of these factors: tumor necrosis factor (TNF) dominant, interferon (IFN) 
dominant, and inflammasome dominant. The word “dominant” is used because, in reality, all of 
these responses are generated to varying degrees with any given inflammogen. For clinical 
purposes, thinking about the innate response in the context of these three major divisions allows 
one to clearly see that these milieus are generated by separate signaling cascades that provide 
opportunity for specific therapeutic interventions.  
A TNF dominant response can be generated by either pathogenic infection or trauma that results 
in cell injury (10). These initiating triggers are recognized by the innate immune system through 
the production of pathogen associated molecular patterns (PAMPs), or in the case of cell injury, 
damage-associated molecular patterns (DAMPs) ((1, 11, 12). PAMPs, as the name implies, are 
usually structural components of bacteria, viruses, or fungi that are recognized through pattern 
recognition receptors (PRRs) on immune cells such as macrophages, dendritic cells, B cells, and 
others (13, 14). On the other hand, DAMPs are factors found in host cells that are normally 
sequestered away from immune recognition; however, in the face of cell injury or death, these 
DAMPs, such as the nucleosome associated protein HMGB1, are released from cells and are 
recognized by the same PRRs as PAMPs (15, 16).  
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PRRs, such as the toll-like receptors (TLRs) will activate two distinct signaling pathways after 
ligation, depending on which PAMP is recognized by its corresponding TLR. In the case of TNF 
dominated responses, the major contributing pathway involves activation of the MyD88 adaptor 
protein which is activated most strongly in the context of lipopeptides (TLR1/2 or 2/6), LPS 
(TLR4), flagellin (TLR5), profilin (TLR11, 12), ribosomal RNA (TLR13), or CpG 
oligodinucleotide sensing (TLR9) (14). MyD88 is responsible for coupling TLR ligation to the 
activation of the pro-inflammatory transcription factor NF-κB through a complex signaling 
pathway involving interleukin-1 receptor-associated kinase (IRAK) 1 and 4, TNF receptor 
associated factor 6 (TRAF6), TAK1, IκB kinase (IKKα/β/γ), and finally poly-ubiquitinylation 
and degradation of the inhibitor of NF-κB (IκBα) (17, 18). NF-κB function results in the 
transcription of factors important for cell survival, as well as initiating a pro-inflammatory 
program. Specifically, in conjunction with MAPK signaling, this leads to synthesis of the 
transcription factor activator protein 1 (AP-1), which induces transcription of Tnf (19). After 
TNF protein is produced, it exerts pleiotropic effects on the body including: activation of the 
underlying tissue endothelium which directs other immune cells to sites of inflammation, 
activation of the pro-inflammatory acute phase response from the liver (interleukin-6, C-reactive 
protein, serum amyloid A, etc.), enhancement of phagocytosis and oxidative burst from 
phagocytic cells, and during prolonged or systemic exposure, insulin resistance, muscle wasting, 
and substantial vasodilation (10, 20, 21). Additionally, TNF signaling through its receptors can 
lead to further activation of NF-κB, and subsequently more TNF production, creating a very 
potent and potentially dangerous cycle of activation (22, 23). 
TNF is produced in nearly every inflammatory disease; however, there are several where the 
TNF predominates the response, so much so that interventional anti-TNF interventions have 
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been introduced as therapies. These include inflammatory bowel diseases (Chron’s disease and 
ulcerative colitis), rheumatoid arthritis, ankylosing spondylitis, psoriasis, several vasculitides 
including giant cell arteritis, and asthma that is refractory to other therapies ((6, 24, 25)). 
Systemic TNF, via activation of the acute phase response, can also result in a “cytokine storm” 
which leads to the initiation of systemic inflammatory response syndrome (SIRS) or sepsis for 
triggers involving bacteremia, viremia, or mass tissue damage (e.g. electrocution, severe burns, 
etc.) (26-28). Current anti-TNF therapies being used in the clinical setting include: anti-TNF 
monoclonal antibodies (Infliximab, Adalimumab) and soluble TNF decoy receptors (29, 30). 
However, many disease processes do not respond to anti-TNF therapy. In fact some, as in the 
case of multiple sclerosis (31), are exacerbated with anti-TNF therapy; clearly demarcating the 
importance of understanding specific inflammomes before institution of a given therapy. As anti-
TNF treatment was the first biologic anti-cytokine therapy to be FDA approved (in 1998)(32), it 
is not surprising that this field is also the first to realize the need for a priori therapeutics, 
exemplified by the recent wave of NF-κB inhibitors currently in clinical trials (33-35), as well as 
TLR antagonists to prevent sepsis (36, 37).                      
B. INNATE (IFN DOMINANT) 
The innate IFN dominant inflammome is initiated in an analogous way as to the TNF dominant 
inflammome (i.e. PAMP-TLR interaction); however, the ligands recognized in these responses 
are generally nucleic acids from viruses, and to a lesser extent bacteria, or even endogenous 
DNA and RNA in the context of autoimmune diseases like systemic lupus erythematosus. The 
signaling mechanisms of type-I IFN generation are complex but are becoming well described. 
Briefly, these nucleic acid PAMPs are recognized by endosomal (TLR3, TLR7, TLR8) or 
cytoplasmic (RIG-I, MDA-5, STING) sensors, and converge downstream at the level of 
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interferon regulatory factor 3 (IRF3) and IRF7 phosphorylation (38, 39). IRF3 and IRF7 act to 
initiate the transcription of type-I IFNs (IFNα/β/δ/ε/ω) which, like TNF, can also enhance their 
own production via a positive feed-forward loop (40). Type-I IFNs can be made by most cell 
types, but plasmacytoid dendritic cells (pDCs) have been identified as professional IFNα 
producing cells in response to nucleic acid PAMPs (41). The importance of pDCs in type-I IFN 
production is exemplified by the fact that they have a cell-type specific alteration in their 
signaling machinery that permits IFNα production directly after stimulation with TLR7 and 
TLR9 ligands through a TRAF3-independent mechanism involving IKKα and IRF7 (42). Type-I 
IFNs, like TNF, also have pleiotropic effects at different levels of the immune system including 
activation of anti-viral response genes, the establishment of CXCR3-mediated chemokine 
gradients via CXCL9 and CXCL10, and the enhancement of IFNγ from Th1 and Tc1 T cells and 
NK cells (43, 44). They can also lead to STAT3 phosphorylation in macrophages and Tregs 
which can induce an anti-inflammatory response via up-regulation of IL-10 and PD-L1 (45, 46). 
Some diseases associated with altered type-I IFN production include SLE (47), psoriasis (48), 
multiple sclerosis (therapeutic) (49), insulin-dependent diabetes mellitus (50, 51), rheumatoid 
arthritis (52, 53), myasthenia gravis (54), and some hematologic malignancies (55). 
Therapeutically, anti-IFN treatments for diseases like SLE and polymyositis have shown promise 
is reducing symptom severity (56, 57), whereas recombinant IFNβ has been established as a 
treatment for relapsing-remitting multiple sclerosis (58).                  
C. INNATE (INFLAMMASOME DOMINANT) 
The third major inflammome driven by innate immune cells centers on activation of 
inflammasomes, which are pentameric or heptameric protein complexes that serve to couple 
PAMP and DAMP sensing with the proteolytic cleavage of pro-IL-1β and pro-IL-18 via caspase 
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1 (59). Several different inflammasomes exist and differ somewhat by structure, but each 
contains a PRR-like protein (i.e. NOD-like receptor (NLRs) or the interferon-inducible AIM2) 
which is connected to pro-caspase 1 by the adaptor protein ASC (60). These inflammasomes also 
have been reported to confer resistance to different kinds of pathogens based on the PRR that is 
affiliated with them. For example, the NLRP3 inflammasome responds to Staphylococcus spp., 
Listeria spp., and influenza viruses (61), the NLRC4 inflammasome is activated by intracellular 
pathogens bearing flagella (62), and the AIM2 inflammasome responds to dsDNA from 
Francisella tularensis, and herpes viruses (63). The exact nature of inflammasome activation and 
regulation are still active areas of investigation; however, several consensuses have been 
reached. First, inflammasomes usually require two signals in order to become fully responsive: 
1) substrates for the inflammasome (i.e. pro-IL-1β and pro-IL-18) are generated in response to 
signaling cascades downstream of other PRRs including NF-κB and Type-I IFN signaling, and 2) 
the inflammasome must have a second signal that allows for the activation of pro-caspase 1 into 
bioactive caspase 1, and subsequently the production of mature IL-1β and IL-18 (64). There are 
many theories as to what can supply signal 2 and those include: intracellular potassium efflux 
(65), extracellular ATP sensing (66), exposure to lysosomal enzymes like cathepsin B (67, 68), 
and reactive oxygen species (69). Inflammasome regulation is less well understood, but factors 
involved in chronic infections like prolonged IFNγ exposure can lead to inflammasome 
destabilization through nitric oxidize-mediated nitrosylation (70).  
The inflammasome dominant inflammome becomes medically relevant not only in response to 
bacterial and viral pathogens, but also in the context of situations involving “frustrated 
phagocytosis” which can result from chronic infections of Mycobacteria spp. or incidents of 
sterile inflammation such as exposure to particulate antigens (71). Diseases associated with the 
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inflammasome dominant inflammome include gout (uric acid crystals), asbestosis (asbestos 
fibrils), berylliosis (beryllium), silicosis (silica), sarcoidosis, and amyloidosis (proteins) (72). 
Each of these disease result lead to localized inflammation of the area where these particulates 
are deposited which is usually the lung (beryllium, silica, asbestos), joints (uric acid), or small 
blood vessels and soft tissue (amyloid). Inflammasomes are also implicated in both metabolic 
disease and atherosclerosis, and may be main player in the development of insulin resistance in 
type-2 diabetes mellitus (73-75). Antagonistic IL-1 therapies such as anakinra (receptor 
antagonist (76)), canakinumab (anti-IL-1 mAb (77)), and rilonacept (soluble decoy receptor (78)) 
have proved efficacious in these types of diseases, including gout (79, 80). Many of these 
therapies were initially developed for the treatment of rheumatoid arthritis; however, they have 
shown limited long-term efficacy in humans (81). This illustrates that the presence of a particular 
cytokine within the inflammatory milieu in a given disease, and thus an attempt to block it 
therapeutically, is not sufficient in most cases to effectively decrease symptom severity. 
However, a full understanding of the inflammome of a given disease can better guide clinicians 
to more rational interventions.     
D. ADAPTIVE (T CELL CENTRIC) 
T cells are perhaps the best studied of all immune cells, namely due to their importance of 
facilitating nearly every immune response in some way (82). T cells are activated after their T 
cell receptor (TCR) encounters peptide antigens in the context of the major histocompatibility 
complex (MHC) that have been processed and presented by APCs (83). Naïve T cells also 
require a second signal in the form of co-stimulatory molecules that drive their proliferation 
(clonal expansion) via the production of IL-2 (84). These are usually in the form of CD28 on the 
T cell and CD80/CD86 on the APC; however, ligation of other co-stimulatory molecules such as 
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ICOS, OX40, and 4-1BB can also provide this necessary signal (20). Finally, a third signal in the 
form of cytokines results in the differentiation of the activated T cell towards a specific effector 
subtype which has a specific cytokine potential. Thus, the T cell centric inflammome can take on 
different characteristics depending on the context in which it was induced (85). The major T cell 
subsets include Th1 (driven by IL-12, IL-18, IFNα/β), Th2 (IL-4, IL-33), Th17 (TGFβ & IL-1, 
IL-6, IL-21, IL-23), and T regulatory cells (TGFβ), but other, less well defined subsets also exist 
including cytotoxic T helper cells, Th9, Th22, Tfh, and Tr1 (86, 87). For the purpose of this 
review, we will focus on Th1, Th2, and Th17 subtypes as they have been the best studied in the 
context of mediating human disease.  
Th1 T cells are produced when activated in the context of IL-12, IL-18, and Type-I IFNs and 
inhibited in the presence of IL-4 (88). They are defined by the major transcription factor T-bet 
which is necessary for their ability to produce the effector cytokine IFNγ. Th1 T cells also 
provide help to CD8+ cytotoxic T lymphocytes (CTLs) that respond to cells infected with 
intracellular pathogens or altered self (cancerous cells), and kill them by production of several 
soluble effector molecules including IFNγ, granzymes, granulysin, and perforin (89). CTLs can 
also induce death through contact-mediated, caspase 8 dependent apoptosis by Fas-FasL (CD95-
CD95L) and TNF-related apoptosis-inducing ligand (TRAIL)-DR5 (90). Th1 cells have been 
implicated in the pathogenesis of numerous autoimmune diseases through inappropriate 
activation by self-antigens, and also the potentiation of innate immune responses through the 
positive feedback effects of IFNγ (91).  
Th17 T cells are produced in the context of TGFβ and other pro-inflammatory cytokines such as 
IL-6, IL-1β, IL-21, IL-23, and others (92). Their differentiation to Th17 can be enhanced through 
autocrine production of IL-21 (93), and also stabilized by subsequent IL-23 after the up-
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regulation of IL-23R after TCR activation (94). Th17 polarization is controlled by the master 
transcription factor RORγT, RORC2 in humans (95), which facilitates the production of IL-17A, 
IL-17F, IL-21, and IL-23 production from Th17 T cells (96).  A major known function of IL-17 
is to recruit neutrophils to the sites of infection by stimulating the production of IL-8, CCL2, 
CCL7, CXCL1, and CXCL5 (97). IL-17 can also promote synthesis of TNF, IL-6, and IL-1β 
from epithelial cells and macrophages. Th17 cells have been implicated as pathogenic in several 
mouse models of RA, IBD, psoriasis, and type-1 diabetes mellitus (98), as well as several 
diseases in humans: multiple sclerosis, RA (99), SLE (100), psoriasis (101), and IBD (102). 
These associations have been largely based on finding elevated IL-17 levels in either sera or 
tissue biopsies from afflicted patients or direct visualization of Th17 cells within diseased tissue 
biopsies (103). Several therapies exist to target the Th17 pathway including (104) (monoclonal 
antibody that targets the IL-12p40 subunit shared by IL-12 and IL-23) and several anti-IL17 
antibodies that are not yet FDA approved (brodalumab, ixekizumab, and secucinumab). 
Ustekinumab treatment has seen some success in treating patients with psoriasis, but that success 
has not translated to other Th17 implicated diseases to date (105, 106).  
The final T cell subset that can define the T cell centric inflammome are Th2 T cell which 
differentiate in the presence of IL-4 or IL-33 and the absence of IFNγ (107, 108). Th2 cells are 
potent promoters of IL-4, IL-5, and IL-13 production and are defined by their master 
transcription factor GATA3 (109). Th2 cells can also efficiently provide help to B cells through 
CD40-CD40L interactions. In the presence of IL-4, B cells secrete antibodies of the IgE isotype 
which are critical for protection against helminthic infection (110), but are also the main driving 
force of allergic responses in humans (111). The concomitant actions of IgE, by binding its 
receptor FcεRI, and Th2 cytokines potently induce granulocyte chemotaxis and degranulation of 
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mast cells, eosinophil, and basophils. This degranulation releases vasoactive amines (like 
histamine), serine proteases, and eicosanoids (such as prostaglandins and leukotrienes), all of 
which facilitate symptoms of allergy (erythema, pruritus, bronchoconstriction) (112). Once 
again, most therapies currently approved for treatment of allergic reactions are typically based on 
post hoc approaches. These interventions involve blockade of histamines and leukotrienes, or 
management of symptoms (e.g. bronchodilators) (113). Investigation into blocking these 
responses at the level of T cell (or B cell) initiation is an area that requires attention, as too few 
studies have been conducted to answer these questions.  
The T cell centric inflammome can assume very diverse outcomes, and be the driving force 
behind many different types of inflammatory diseases. However, because T cells undergo clonal 
expansion in response to activation, they are susceptible to many of the broadly 
immunosuppressive agents that aim to kill dividing cells (114, 115) . For example, 
corticosteroids block the production of IL-2, and immunophilins (such as tacrolimus, and 
cyclosporine) prevent calcineurin-mediated activation of NFAT, a transcription factor critical for 
T cell responses (116). Also, cyclostatic drugs (e.g. methotrexate, azathioprine, mercaptopurine) 
that block all cell proliferation, and are typically used in cancer therapy, are sometimes used to 
prevent T cell expansion in inflammatory diseases (117). All of these therapeutic options prevent 
pro-inflammatory cytokine production; however, they also suffer from lack of specificity. Future 
studies aimed at improving T cell based therapeutic interventions should seek to combine the a 
priori blockade of cytokine synthesis with the specificity of a biologic treatment in order to 
prevent such broad immunosuppression.                                                   
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E. ADAPTIVE (B CELL CENTRIC) 
The main effectors of the B cell centric inflammome are antibodies, which are generated after the 
integration signals from PRR triggering, B cell receptor ligation, T cell help, and sensing of the 
cytokine milieu (118). The effector functions of antibodies are well defined and include 
opsonization and neutralization of pathogens, initiation of the complement cascade, and 
activation of other effector cells as described above. Different antibody isotypes are generated by 
activation-induced cytodine deaminase (AICD) in response to sensing the cytokine milieu by B 
cells. For example, in humans the presence of IFNγ will trigger production of IgG1, IL-4 will 
give IgE, while TGFβ will yield IgA (119, 120). 
However, B cells can also be significant contributors to cytokine synthesis in their own right. B 
cells that are primed by Th1 cells and BCR ligation will begin to produce a “Th1-like” cytokine 
profile including synthesis of IFNγ and even IL-12, a cytokine not made explicitly by Th1 cells 
but key for Th1 differentiation (B effector type 1 or Be-1 cells). By analogy, those primed with 
Th2 cells will produce IL-2, IL-4, and IL-13 (Be-2) (121). Additionally, B cells can also produce 
regulatory cytokines, such as TGFβ and IL-10, in some circumstances (Bregs). Each of the B 
cell cytokine-producing subtypes have been identified in vivo (122, 123), and have documented 
functional significance, especially in the context of pathogen clearance and autoimmune diseases 
that result from the inappropriate production of autoantibodies like SLE (124). Nevertheless, 
much remains to be studied regarding their role in cytokine-based inflammation.        
F. REVERSE-PHASE IMMUNITY 
Recently, more evidence is coming to light that exemplifies the bi-directionality of the immune 
response, in that exposure to molecules that directly activate T cells, such as superantigens, can 
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lead to T-cell mediated activation of the innate immune system (125, 126). This concept outlines 
an emerging reverse-phase inflammome that relies on bystander activation of the innate immune 
response through cytokines produced by the adaptive arm of the immune system, rather than 
PAMP or DAMP exposure. The exact mechanism(s) by which this activation occurs is still an 
area of active investigation; however, production of IL-17 by TCR γδ T cells after cooperative 
activation by TCRαβ T cells has been implicated (127, 128). This novel route of innate immune 
system activation will generate an inflammatory-milieu that is largely similar to those generated 
by the innate inflammomes discussed previously. In cases such as Staphyloccal enterotoxin A 
(SEA) mediated acute lung injury or SIRS, a physician may see a clinical picture, based on 
cytokines, that heavily implicates the innate immune system as the main driving force in disease 
pathogenesis; however, when trying to treat such a disease process with therapeutics such as 
anti-TNF, they may encounter much difficulty because the actual pathogenic mechanism is 
directed by T cells and may be better treated by agents that affect IL-17 or IL-2 production. This 
illustrates that although a cytokine-based disease taxonomy allows for a better understanding of 
how to treat diseases that share related milieus, it may in some cases lead clinicians to incorrect 
assumptions that could be insignificant, or even deleterious to the patient.                  
III. RKIP: A NEW THERAPUETIC TARGET? 
Raf-1 kinase inhibitor protein (RKIP) is part of the highly evolutionarily conserved 
phosphatidylethanolamine-binding protein (PEBP) superfamily. This family of proteins has been 
found in species from bacteria to plants to humans (129, 130), and is ubiquitously expressed, to 
different degrees, in all tissues (131). RKIP (PEBP-1) was originally shown to interact with Raf-
1 by yeast-two hybrid screening in 1999 (132), which prevented the downstream 
phosphorylation of MEK and ERK (Figure 1-2). Since this time, RKIP has been implicated as a 
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regulator (both positive and negative) of important signaling pathways within cells. The 
functional significance of these interactions is poorly understood, and most likely varies between 
cell types. It has been shown to interact with upstream proteins involved in the NF-κB cascade, 
and may facilitate the assembly or stabilization of these complexes (133). The affinity for RKIP 
and its ligands can be altered based on post-translational modification events, the best example 
of which is its transition from Raf-1 inhibition to GRK-2 inhibition after phosphorylation of Ser 
(Thr)153. RKIP is also a positive regulator exemplified by its ability to enhance GSK-3β (134) 
through the prevention of an inhibitory (Thr390) phosphorylation and by enhancing production of 
the microRNA let-7 (135). RKIP has also been described as a suppressor of epithelial to 
mesenchymal transition, and subsequently, invasion and metastasis of cancerous cells (136) 
through a mechanism involving GSK-3β and its downstream target cyclin D1 (137).    
Despite these well-defined roles for RKIP in cancer cells, its function within primary cells and 
within the immune system is unknown. However, recent studies have suggested that RKIP may 
be linked to immune function and potentially cytokine production. First in 2006, studies 
implicated RKIP induction in successful macrophage and dendritic cell maturation in cell lines 
that included the up-regulation of the scavenger receptor CD36 and decreased nuclear 
localization of NF-κB (138).  In 2009, Reumer and colleagues found that RKIP overexpression 
in Drosophila melongaster (PEBP1 or CG18594) protected them from infection by pathogenic 
bacteria through the enhanced production and secretion of immunity-related proteins (139). Also 
in 2009, Ménoret et. al. demonstrated that RKIP was altered (either at the level of expression or 
post-translational modification) between primed OT-I T cells that were either resting or recalled 
with the cognate peptide SIINFEKL from ovalbumin (140). By blocking RKIP using the small 
molecule inhibitor locostatin, the production of IFNγ and TNF was attenuated through an 
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unknown mechanism. Taken together, these studies suggest that RKIP may have an 
immunological function that may result in altered cytokine responses. Also, the fact that RKIP 
can be inhibited exogenously allows for the possibility that it may provide a therapeutic target 
for modulating a priori cytokine production.                  
IV. CONCLUSIONS  
Inflammation is one of our body’s greatest assets as it is responsible for the defense against 
harmful pathogens and facilitates removal and repair of dead or dying cells. However, 
inflammation is also the pathogenic mechanism by which many diseases are manifest, leading to 
significant medical and financial burdens for patients. Our ability to therapeutically intervene in 
these pathophysiological processes is key to preventing undue morbidity and mortality in these 
patients. Before the 1990s, the standard of care for many auto-inflammatory diseases involved 
broad immunosuppression using corticosteroids or direct killing of proliferating cells, both of 
which lead to significant immunosuppression and the inability to ward off potential infections. 
With the advent of cytokine-specific biologics, clinicians and scientific investigators became 
much more interested in specific, targeted therapies that attenuated disease, while allowing for 
most of the immune response to continue unabated. This led many to consider a disease 
diagnostic schema that centered on a particular cytokine milieu. This has resulted in the 
development of successful therapeutic endeavors for some diseases (IBD, RA), but also to 
significant failures (anti-TNF in MS, anti-IL-1 in sepsis, and anti-IL-17 in Chron’s disease) (141-
143). These errors were due largely in part to the analysis of post hoc cytokine production rather 
than examination of the underlying inflammome that led to the generation of these cytokines in 
the first place. By understanding the inner workings of the body’s different inflammomes (Figure 
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1-1), even better therapies can be developed that stop altered cytokine production at the source, 
rather than after the fact.           
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Figure 1-1: An Inflammome-based Disease Taxonomy 
A schematic representation of the cytokine networks established by the host’s major 
inflammomes; the size of each circle pictorially represents the relative abundance of a given 
cytokine within its respective inflammome. Human diseases associated with each inflammome 
are listed in non-bold script.     
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Figure 1-2: RKIP: A regulator of kinase-mediated signaling cascades (A) Schematic diagram 
outlining previously described RKIP function. RKIP suppresses both the Raf-MEK-ERK and 
canonical NF-κB signaling cascades in the resting state; however, after stimulation RKIP is 
phosphorylated at Ser(Thr)153 by protein kinase C which allows is to dimerize and lose affinity 
for Raf-1 and IKK complex members while gaining affinity for GRK-2. This system allows for 
the coordinated activation of multiple pathways within the cell, theoretically leading to enhanced 
cytokine production, cell survival, proliferation, and locomotion. (B) A list of known RKIP 
binding partners and their functions;    
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Mice 
C57BL/6 mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). RKIP-/- mice 
were engineered by the Dr. Jan Kylsik Laboratory (Department of Neuroscience, Brown 
University, Providence, RI, USA) (144) and received from the laboratory of Dr. Kam Yeung 
(Department of Biochemistry and Cancer Biology, University of Toledo, Toledo, OH, USA). 
Once in-house, RKIP-/- mice were rederived by the Gene Targeting and Transgenic Facility 
(GTTF) at the University of Connecticut Health Center (UCHC) following a standard protocol 
(145). After successful rederivation, RKIP-/- were bred to C57BL/6J mice to obtain wild type 
littermate controls. All mice at UCHC were housed in specific pathogen-free conditions and 
handled in accordance with institutional and federal guidelines outlined by the National Institutes 
of Health.  
Immunizations and in vitro Stimulations 
For SIRS induction, staphylococcal enterotoxin A (SEA; Toxin Tech; Sarasota, FL, USA) was 
injected at 1μg per mouse diluted in 0.2ml of BSS intraperitoneally (i.p.). 48 h later a second i.p. 
injection of SEA was administered and tissues harvested at 48 or 72 h after the second injection 
(2°). For PAMP-TLR studies, 1μg SEA was i.p. injected followed by an i.p. injection of 10μg 
lipopolysaccharide (LPS) derived from Salmonella typhimurium (Sigma-Aldrich; St. Louis, MO, 
USA) 18 h after SEA and tissues were harvested 12 d after SEA administration. Doses for in 
vitro stimulations with TLR ligands are as follows unless otherwise indicated: LPS 50µg/ml, 
CpG-A 9µg/ml, CpG-B 9μg/ml, Poly I:C 50µg/ml, Pam3CSK4 50μg/ml (Invivogen; San Diego, 
CA, USA).          
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Tissue Processing 
Spleens were crushed through 100 μm nylon mesh strainers (Flacon/BD Biosciences; San Jose, 
CA, USA) and treated with ammonium chloride for 5 min at room temperature to lyse red blood 
cells (RBCs). Pooled peripheral lymph nodes (inguinal, axillary, and brachial) were crushed 
through nylon mesh strainers. Liver leukocytes were obtained as previously described (146). 
Briefly, livers were perfused using a solution of PBS and sodium heparin (Sigma-Aldrich) 
crushed through nylon mesh strainers, and separated by a 35% percoll gradient (Sigma-Aldrich). 
Blood was obtained from the tail veins of mice before and 1.5 h after 2° SEA administration. 
Blood was kept at room temperature for 30 min to allow for coagulation and then stored for 1 h 
at 4°C to shrink the absolute size of the clot. Samples subsequently underwent centrifugation at 
13,000 rpm at 4°C for 10 min, and the upper aqueous fraction (serum) was collected and stored 
at -80°C until analysis.  
Cell Purification and Sorting 
For studies involving purified cell populations, splenocytes were isolated from tissue as 
described above and were subjected to depletion using MicroBeads specific for CD8, CD4, and 
DX5 (Miltenyi Biotec; Gladbach, Germany) and MACS LD purification columns (Miltenyi 
Biotec) following the manufacturer’s protocol to obtain purified splenic APCs or subjected to 
positive selection using CD8 or CD4 MicoBeads and MACS LS purification columns (Miltenyi 
Biotec) to obtain purified CD8 and CD4 T cell populations. B cells were isolated using negative 
selection with the B cell isolation kit (Miltenyi Biotec). Purities for bead-isolated cell 
populations are routinely greater than 93% as assessed by flow cytometry.  
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Cell Culturing and Flow Cytometry 
For in vitro restimulations, 5 x 105 cells were cultured at 37°C and 5% CO2 in 0.2ml of complete 
tumor medium (CTM) which consists of minimal essential medium (MEM) supplemented with 
10% fetal bovine serum, dextrose, salts, amino acids, and antibiotics. As indicated, cells were 
restimulated with 0.1μg/well SEA, 50ng/ml phorbol 12-myristate 13-acetate (PMA) 
(Calbiochem; Gibbstown, NJ, USA) plus ionomycin (1μg/ml) (Invitrogen; Carlsbad, CA, USA). 
For studies involving locostatin (Calbiochem), 5µM solutions diluted in CTM were used as the 
effective dose with an equal volume by percent DMSO in CTM acting as the vehicle control. 
These reagents were used as indicated within the corresponding figure legends. Cultures 
analyzed for intracellular cytokine production by flow cytometry were stimulated in culture for 
4-5 h, while cultures being utilized to assess cytokine production by ELISA were stimulated 
overnight. The following mAbs were purchased from BD Biosciences: Phycoerythrin-conjugated 
TNFα, IL-10, Vβ3; Biotin-conjugated CD86; Allophycocyanin-conjugated CD44, Rat IgG2a, 
Rat IgG2b; FITC-conjugated Rat IgG2a, Hamster IgG; Alexa Fluor-700-conjugated CD3; 
PerCP-conjugated CD4, B220, Rat IgG2a; and Pacific Blue-conjugated CD8. The following 
mABs were purchased from eBioscience (Sand Diego, CA, USA): PE-conjugated CD11b, 
CD25, CD80, Rat IgG1, Rat IgG2b, Hamster IgG; Biotin-conjugated Rat IgG2a; Alexa Fluor 
700-conjugated MHC-II, Rat IgG2b; APC-conjugated IFNγ, B220, Rat IgG1, Rat IgG2b; FITC-
conjugated Foxp3, CD11c; PE-Cy7-conjugated Streptavidin; and PerCP-conjugated Rat IgG2a. 
FITC-conjugated Annexin V was purchased from BD Biosciences.   
Surface and intracellular staining was performed as previously outlined (147). Briefly, cells were 
suspended in a wash buffer containing BSS, 3% FBS, and 0.1% sodium azide. Blockade of 
nonspecific binding (Fc Block) was performed by treating cells for 10 min prior to initial 
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extracellular antibody staining with a solution containing mouse serum, human IgG, and anti-Fc 
mAb 2.4G2 (148). Surface staining of approximately 1 x 106 cells/well was performed with the 
aforementioned antibodies at concentrations determined by individual titration studies, ranging 
from 1:50 to 1:200, for 30 min at 4°C in the dark. After incubation, cells were washed twice with 
wash buffer to remove any non-bound antibody and were subsequently fixed with 2% 
paraformaldehyde. For intracellular staining, the cells were additionally permeabilized with wash 
buffer containing 0.25% saponin (Sigma-Aldrich) and stained with antibodies against 
intracellular antigens overnight at 4°C in the dark. The following day cells were washed twice to 
remove any non-bound antibody. For analysis of Foxp3 containing cells, a commercially 
available staining buffer set from eBioscience was used. Flow cytometric analysis was conducted 
in the UCHC flow cytometry core on a Becton Dickinson (Franklin Lakes, NJ, USA) LSR II 
flow cytometer and data was analyzed using FlowJo 9.5.2 software (Tree Star; Ashland, OR, 
USA).          
Enzyme-linked Immunosorbent Assay (ELISA) 
IFNγ, IL-10, CCL2, IL-1β, and IL-2 OptEIA ELISA kits were purchased from BD Biosciences. 
ELISA kits for CCL3, CXCL10, and CCL5 were purchased from R&D Systems (Minneapolis, 
MN, USA), and IFNα and IFNβ ELISA kits were purchased from PBL Interferon Source 
(Piscataway, NJ, USA). All ELISAs were performed according to the manufacturer’s 
instructions. Briefly, capture antibody (1:250 dilution) was coated overnight on MaxiSorp 96-
well plates (Thermo Scientific; Rochester, NY, USA) in coating buffer (0.1 M sodium carbonate 
or 0.1M sodium phosphate). The following day, the plates were washed with PBS+0.05% 
Tween-20 and blocked with PBS+10% FBS for 1 h at room temperature. Next, the plates were 
washed again and incubated with supernatants from overnight cultures or from mouse sera for 2 
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h at room temperature. Following, the plates were washed again and incubated with a 1:250 
dilution of capture antibody plus streptavidin-HRP conjugate solution for 1 h at room 
temperature. Finally, the plates were washed and incubated with substrate solution 
(tetramethylbenzidine-TMB; BD Biosciences) for 30 min in the dark and stopped with 1M 
phosphoric acid. Absorbance was read on a Bio-Rad iMark microplate reader (Bio-Rad; 
Hercules, CA, USA) and concentrations were calculated using a standard curve line of best fit on 
Microplate Manager Software (Bio-Rad). Mouse SAA ELISA kit was purchased from 
Immunology Consultants Laboratory Inc. (Portland, OR, USA) and used according to the 
manufacturer’s protocol. All reagents, including an antibody pre-coated plate were contained 
within the kit. For assessment of serum LDH activity, sera were diluted 1:10 in a 96-well 
microtiter plate (100 µl) in tandem with a 1:2 serial dilution (11600-1.33 U/ml) of native bovine 
LDH standard (Cell Sciences, Canton, MA, USA). Next, 100 µl of a 1:50 mix of two 
colorimetric reagents from a commercially available LDH assay kit (Clontech, Mountain View, 
CA, USA) was added to the sera samples. Absorbance was measured every 10 min for 30 min at 
490 nm (600 nm reference) and converted into activity units (U/ml) based on the prepared 
standard curve. Because LDH can be released from disrupted RBCs, any serum samples that 
showed visible signs of hemolysis were excluded from the study.    
Multiplex Cytokine Analysis 
Sera samples and culture supernatants were subjected to multiplex cytokine analysis using the 
32-analyte Miliplex MAP kit (Millipore; Billerica, MA, USA) according to the manufacturer’s 
instructions. This kit measures the following cytokines between 3.2 and 10,000 pg/ml and is 
standardized by internal quality controls: G-CSF, GM-CSF, IFNγ, IL-1α, IL-1β, IL-2, IL-3, IL-4, 
IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, CXCL10, CXCL1, 
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LIF, LIX, CCL2, M-CSF, CXCL9, CCL3, CCL4, CXCL2, CCL5, TNFα, and VEGF. The 
Miliplex MAP kits were run using the Bio-Plex reader and software package (Bio-Rad).  
Immunofluorescence Microscopy 
Cells were isolated (~2 x 105) in PBS and affixed to 1” x 3” frosted poly-lysine coated slides 
(BD Falcon) using the Cytospin 4 (Thermo Shandon; Pittsburgh, PA, USA). Cells were fixed 
using 4% PFA in PBS at 4°C for 30 min. After fixation, the cells were washed three times in 
PBS and then permeabilized with 0.3% Triton X-100 in PBS for 20 min at room temperature. 
Next, the cells were washed again as before and then blocked using 10% naïve goat serum and 
0.2% BSA in PBS for 10 min at room temperature. After blocking, the cells were incubated in 
the dark overnight at 4°C in a humidified chamber using a FITC-conjugated anti-RKIP antibody 
(Biorbyt; Cambridge, UK) or FITC-conjugated rabbit-anti mouse isotype control at several 
concentrations. The next day, the cells were washed again as before and then mounted using 
Vectasheild mounting medium (Vector Labs; Burlingame, CA, USA) containing DAPI. Slides 
were visualized using the Axioplan 2 inverted fluorescence microscope (Carl Zeiss; Thornwood, 
NY, USA).    
Quantitative Real-Time Polymerase Chain Reaction 
Total RNA was isolated from cells (~3 x 106) using the Qiagen RNeasy Mini kit (Qiagen Inc: 
Valencia, CA, USA) according to the manufacturer’s instructions. Total RNA was quantified 
using the NanoDrop 2000 (Thermo Scientific) spectrophotometer and then 250ng-1μg RNA was 
reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad). Next, transcript levels for 
IRF3 (fwd. GAGAGCCGAACGAGGTTCAG, rev. CTTCCAGGTTGACACGTCCG), IRF5 
(fwd. GGTCAACGGGGAAAAGAAACT, rev. CATCCACCCCTTCAGTGTACT), IRF7 (fwd. 
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GAGACTGGCTATTGGGGGAG, rev. GACCGAAATGCTTCCAGGG), TRAF3 (fwd. 
CAGCCTAACCCACCCCTAAAG, rev. TCTTCCACCGTCTTCACAAAC), MDA-5 (fwd. 
AGATCAACACCTGTGGTAACACC, rev. CTCTAGGGCCTCCACGAACA), TBK1 (fwd. 
ACTGGTGATCTCTATGCTGTCA, rev. TTCTGGAAGTCCATACGCATTG), IKKε (fwd. 
ACCACTAACTACCTGTGGCAT, rev. CCTCCCCGGATTTCTTGTTTC), IFNAR1 (fwd. 
AGCCACGGAGAGTCAATGG, rev. GCTCTGACACGAAACTGTGTTTT), IFNα (fwd. 
CCTGATGGTCTTGGTGGTGAT, rev. CAGTTCCTTCATCCCGACCAG), IFNβ (fwd. 
AGCTCCAGCTCCAAGAAAGGACGAACAT, rev. GCCCTGTAGGTGAGGTTGATCT), and 
actin (fwd. GTGGGCCGCTCTAGGCACCA, rev. CTCTTTGATGTCACGCACGA) were 
determined from cDNA using the SYBR Green PCR Master Mix kit (Life Technologies; Grand 
Island, NY, USA) on an ABI 7300 Real-Time PCR system (Applied Biosystems by Life 
Technologies). The primer sequences were chosen from those previously validated in 
PrimerBank (149) (Center for Computational and Integrative Biology, Harvard Medical School, 
Cambridge, MA, USA) and were purchased from Integrated DNA Technologies (Coralville, IA, 
USA). Relative fold changes between experimental and control groups were determined using 
the ∆∆CT method.    
RNA Sequencing and Pathway Analyses 
Total RNA was isolated as before and sent to Otogenetics Crp. (Atlanta, GA, USA) for next 
generation RNA-sequencing. RNA was sequenced using the HiSeq 2000 platform (Illumina inc., 
San Diego, CA, USA) at a depth of 20 million reads and analyzed using both proprietary 
software capable of handling Illumina based scripts, and differential expression of FPKM 
(fragments per kilobase mapped) normalized data was determined using the public domain 
software: Cufflinks (UC Berkeley, Johns Hopkins University, Cal Tech). Genes of interest were 
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identified by taking all genes that were found to be statistically significantly different between 
experimental groups and had a relative fold change of  > ±1.2. These genes of interest were next 
subjected to functional pathway analysis using the IPA knowledge database (Ingenuity Systems; 
Redwood City, CA, USA). IPA cross-references a user’s list of genes of interest to known 
canonical signaling pathways and determines the level of enrichment of a given pathway using 
the user’s gene list and fold changes. IPA then calculates a P value based on this enrichment 
using Fisher’s exact test. Functional pathway analysis by IPA was also confirmed using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) (Laboratory of 
Immunopathogenesis and Bioinformatics, Frederick, MD, USA) (150).      
Oxygen Consumption Rate (OCR) Measurements 
Cells were seeded at a concentration 3x105/well in an XF96 tissue culture plate (Seahorse 
Bioscience; North Billerica, MA) that had been coated with BD Cell-TAK (BD Biosciences) 
overnight to improve adherence of non-adherent cells. Cells were cultured in DMEM 
supplemented with 25mM glucose, 2 mM glutamine, and 1mM pyruvate. Basal, maximum and 
reserve OCR was measured using the Seahorse XF 96 extracellular flux analyzed (Seahorse 
Biosciences), and mitochondrial function was tested using the following reagents: oligomycin 
(1μM), FCCP (2μM), rotenone (1μM) and antimycin (1μM).     
Immunoblot  
Whole cell lysates were generated using a solution consisting of 50mM Tris-HCl, 150mM NaCl, 
5mM EDTA, 5mM EGTA, 10mM NaF, 0.5% Triton X-100, and 0.5% n-ocytl-β-D-
glucopyranoside. To prevent nucleic acid contamination, the whole cell lysis buffer was 
supplemented with DNAse (0.67μg/μl) and RNAse (0.33μg/μl). Additionally the phosphatase 
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inhibitor sodium orthovanadate (1mM) was added to prevent loss of phosphorylated proteins. 
Cell lysates were centrifuged at 25,000 x g for 10 min at 4°C. Subsequently, lysates were 
resolved on 4-15% SDS-PAGE (Bio-Rad) at 100V for 60 min and the transferred to 0.2μm 
nitrocellulose membranes (Bio-Rad) by semi-dry transfer at 25 V for 60 min at 4°C. Membranes 
were blotted with antibodies for the following antigens: RKIP, p44/p42 ERK, ERK-1 (Cell 
Signaling Technologies, Danvers, MA, USA), and Actin (Sigma-Aldrich) at 1:1000 in blocking 
grade milk solution overnight at 4°C. Next, membranes were washed thrice with PBS + 0.1% 
Tween-20 and blotted with goat anti-rabbit conjugated to horseradish peroxidase (Santa Cruz 
Biotechnologies, Santa Cruz, CA, USA) at 1:1000 in blocking grade milk solution at room 
temperature for 2-4 h. Finally, membranes were washed again as before and visualized using 
ECL chemiluminescence (GE Healthcare Biosciences; Piscataway, NJ, USA). For subcellular 
fractionation studies, nuclear and cytoplasmic lysates were generated using the NE-PER reagent 
kit (Thermo Scientific, Waltham, MA, USA) following the manufacturer’s instructions. 
Densitometric quantification of immunoblots was conducted using GeneTools software 
(Syngene; Federick, MD, USA).       
PF 2D Proteomics 
PF 2D lystaes were generated by lysing ~ 50 x 106 purified splenic B cells using a lysis buffer 
consisting of: 7.5 M urea, 2.5 M thiourea, 12.5% glycerol, 62.5 mM Tris-HCl, 2.5% n-octyl β-D-
glucopyranoside, 6.25 mM TCEP, 1.25 mM protease inhibitor mixture (Sigma-Aldrich) and 
centrifuged at 25,000 × g for 1 h at 18°C. Subsequently, the buffer used for cell lysis was 
exchanged using PD-10 columns (GE Healthcare Biosciences) equilibrated with PF 2D start 
buffer (6M Urea, 25 mM Bis-Tris, 0.2% n-ocytl- β-D-glucopyranoside). Next, the complex 
protein sample was quantified by bicinchoninic acid (BCA) Protein Assay Kit (Thermo 
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Scientific; Rockford, IL, USA). Proteomic samples (2 mg) were injected into the Beckman 
Coulter ProteomeLab PF 2D platform (Beckman Coulter; Brea, CA, USA) and subjected to two-
dimensional protein fractionation. First, the complex protein mixture was fractionated over a 
ProteoSep HPCF column (Eprogen; Downers Grove, IL, USA) by isoelectric focusing with a 
linear gradient between pH 8.0 and 4.0. Before first dimension fractions were purified further, 
the fraction collector/injector (FC/I) apparatus was cleaned with a series of washes: 1) 100% 
H2O, 2) 50% NH4OH, 3) 100% H2O, 4) 50% methanol, 5) 100% H2O, and 6) 100% start buffer. 
This allows for an increased level of quality control prior to second dimension fractionation. 
Next, each of these corresponding fractions was further purified over a ProteoSep HPRP column 
(Eprogen) with a 0-100% acetonitrile + 0.8% trifluoroacetic acid gradient at 50°C that separates 
proteins based on their hydrophobicity. Protein spectra were generated with UV light measured 
at 214 nm and fractions were collected in 0.5 min intervals into 96-deep well plates and stored at 
−80°C. Proteomic maps for each sample were created using ProteoView software (Beckman 
Coulter) and maps between groups were analyzed for regions of similarity (signatures) and 
dissimilarity (fingerprints) using the DeltaView/MultiView software package (Beckman 
Coulter). It is projected that fractions of interest will be boiled at 100°C for 10 min and further 
resolved by 4-15% SDS-PAGE and stained using Oriole fluorescent protein stain (Bio-Rad). 
Any bands correlating to proteomic differences between groups will be excised from the gel and 
sent for subsequent analysis and identification by matrix-assisted laser desorption/ionization time 
of flight (MALDI-TOF) and liquid chromatography-tandem mass spectrometry (LC/MS/MS).      
Statistical Analysis 
Unpaired, two-tailed Student’s t tests were performed with P < 0.05 representing statistical 
significance in all figures except Figure 3-1B (paired, two-tailed Student’s t test). For tests 
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involving unequal standard deviations between groups, Welch’s correction was used. 
Homogeneity of variance was determined by F test, with F > 0.05 as a threshold for equal 
variance. F-tests were performed using Microsoft Excel 2010 software (Microsoft; Redmond, 
WA, USA) and P values were determined using GraphPad Prism 6.01 (GraphPad Software; 
LaJolla, CA, USA).       
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CHAPTER 3 
 
RKIP CONTRIBUTES TO IFNγ SYNTHESIS BY CD8+ T CELLS AFTER SERIAL TCR 
TRIGGERING IN SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 
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ABSTRACT 
Systemic inflammatory response syndrome (SIRS) is associated with the development of severe 
medical complications including progression to multiple organ dysfunction syndrome and even 
death. To date, only marginal improvements in terms of therapeutic options have been 
established for patients affected by SIRS. Raf kinase inhibitor protein (RKIP) is a regulator of 
MAPK and NF-κB signaling cascades which are both critical for production of the 
proinflammatory cytokines responsible for SIRS initiation. By testing a T cell dependent mouse 
model of SIRS which utilizes staphylococcal enterotoxin A (SEA) specific for Vβ3+ T cells, we 
show that RKIP is necessary for the exaggerated production of IFNγ from SIRS splenocytes. 
This effect was not due to differences in T cell expansion, IL-10 production, or APC priming, 
but rather a cell intrinsic defect lying downstream of the T cell receptor in SEA-specific CD8+ T 
cells. Importantly, mice lacking RKIP were still able to proliferate, survive, and contribute to 
cytokine production in response to PAMP-TLR mediated stimuli, despite the TCR-dependent 
defects seen in our SIRS model. Finally, by blocking RKIP in wild type SIRS splenocytes, the 
IFNγ response by CD8+ Vβ3+ T cells was significantly diminished. These data suggest that 
RKIP may be a potential therapeutic target in SIRS by curbing effector cytokine production from 
CD8+ T cells during serial TCR triggering.  
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INTRODUCTION 
Systemic inflammatory response syndrome (SIRS) results from the general release of large 
quantities of proinflammatory cytokines into circulation. This cytokine storm has the potential to 
lead to many clinical complications for patients including respiratory failure from acute 
respiratory distress syndrome, gastrointestinal bleeding, anemia, deep vein thrombosis, metabolic 
abnormalities, hypotension, disseminated intravascular coagulopathy, multiple organ dysfunction 
syndrome, and many times death (26, 151, 152). SIRS can be prompted from many initiators 
including infectious and non-infectious etiologies. These triggers range from uncontrolled 
bacterial, viral, and fungal infections to pathogenic toxin exposure, organ ischemia, trauma, 
autoimmune disorders, pancreatitis, hemorrhage, and substance abuse. Several studies have 
shown that between 30-60% of all hospital admissions meet the clinical diagnostic criteria for 
SIRS (27, 153). Even though not all patients that meet these criteria progress to severe sequelae, 
SIRS remarkably carries a baseline mortality rate of ~7%, which climbs to >40% if the patient 
develops symptoms of shock (27). Taken together, it is no surprise that SIRS is a both a 
widespread and costly problem for health care systems nationally and globally (154). 
Despite affecting a large number of patients, few therapeutics exist for SIRS. Clinical trials 
attempting to inhibit inflammatory factors such as TNFα and IL-1β failed to show significant 
efficacy (155, 156). A current therapeutic regimen typically involves an antimicrobial agent, if 
an infection is present, medications to restore cardiac and respiratory abnormalities if needed, 
and a broadly immunosuppressive corticosteroid (157, 158). Using drugs that inhibit beneficial 
inflammatory responses in patients that have either concomitant infections or increased 
susceptibility due to hospitalization is likely to be counterproductive.  
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SIRS is very difficult to study in humans because the onset and progression is rapid, and it is 
likely challenging to enroll patients that are acutely ill into clinical studies. Also, because of its 
heterogeneity of origins, no unified mouse model of SIRS exists. We sought to utilize a model 
system that was clinically relevant to human disease, which contained a known trigger of human 
SIRS that followed the natural history of the disease in terms of its acute onset and patterns of 
systemic cytokine release. One model incorporating these important facets of human SIRS is 
exposure to staphylococcal enterotoxin A (SEA). SEA is produced by the human pathogen 
Staphylococcus aureus, and other S. aureus enterotoxins, like toxic shock syndrome toxin-1 
(TSST-1), induce rapid release of proinflammatory cytokines into the systemic circulation in 
significant quantities and importantly, can cause SIRS in humans (159, 160). This robust 
cytokine storm is mediated by the rapid expansion and activation of T cells that specifically bear 
the Vβ3 chain of the T cell receptor (161). In addition, exposure to these superantigens has 
explicitly illustrated many other aspects of SIRS pathology including the induction of acute lung 
injury after vascular damage  (140, 162, 163) as well as transient immunosuppression similar to 
the compensatory anti-inflammatory response syndrome (CARS) seen in a number of SIRS 
patients (152, 164, 165).  
The major cytokine network in SIRS involves production of proinflammatory factors, such as IL-
6, IFNγ, and TNFα, which are dependent on the NF-κB and the MAPK signaling pathways (166, 
167). It is critical to discover ways to modulate these cascades in order to control SIRS without 
affecting immunocompentence. Raf kinase inhibitor protein (RKIP) negatively regulates these 
pathways by binding and inhibiting the kinase activities of several important signaling factors 
including Raf, MEK, ERK, TRAF6, TAK1, NIK, and IKKα/β (132, 133, 168, 169). RKIP has 
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also been associated with metastatic disease in many human cancers including prostate (170) and 
breast (171), but its role in the immune system is undefined. 
Here we report that serial triggering of the T cell receptor with SEA models many aspects of 
human SIRS and identifies IFNγ as a potential intersection between the damage associated with 
SIRS and the diminished inflammation seen in CARS. This is illustrated by the fact that wild 
type T cells continue to make IFNγ in SIRS even if they fail to make IL-2, and thus retain the 
capability to potentiate disease. Importantly, RKIP is shown to be a critical player in these 
processes because genetic loss of this protein prevents the ability of specific T cells to make 
exorbitant amounts of IFNγ while only moderately affecting the anti-inflammatory cytokine, 
Interleukin-10. In addition, by inhibiting RKIP using the small molecule inhibitor locostatin 
(172), IFNγ production was blocked in wild type SIRS T cells. The data herein suggest that 
RKIP may be a key therapeutic target for dampening the robust inflammation seen in SIRS while 
preserving the CARS response. 
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RESULTS 
RKIP drives IFNγ production in mice undergoing SIRS  
Systemic Inflammatory Response Syndrome is associated with significant morbidity and 
mortality in patients, and results from the exorbitant release of inflammatory factors from 
immune cells (152). To study and model human SIRS in mice, we used a regimen involving 
multiple administrations of Staphylococcal enterotoxin A (SEA) that induces potent T cell 
expansion by 48 h (173) and systemic proinflammatory cytokine production (Fig. 3-1A). To 
verify that we had indeed prompted systemic inflammation, serum from mice 90 min after the 
secondary administration of SEA was used to measure IFNγ, IL-6, SAA, and LDH. These 
cytokines were chosen since they are considered prognostic markers for SIRS in human patients 
(174-177). As expected, significantly increased levels of IFNγ, IL-6, SAA, and LDH were 
detected in sera after SEA (Fig. 3-1B).  
To determine if RKIP played a role in a SIRS response, we compared the cytokine output of 
SIRS and naïve splenocytes restimulated in vitro with SEA from RKIP-/-, wild type littermates, 
and C57BL/6J mice at the height of the SIRS response. Splenocytes from all mice stimulated 
with SEA in vivo produced decreased levels of IL-2 when compared to naïve controls, signifying 
that the T cells in these cultures were anergic or immunosuppressed similar to CARS T cells. 
However, the production of the effector cytokine IFNγ was increased dramatically in wild type 
mice relative to naïve, but maintained or reduced in mice lacking RKIP, suggesting that RKIP 
may play a role in the optimal production of IFNγ during a SIRS response (Fig. 3-1C). Figure 3-
1D shows that in each individual experiment the C57BL/6 splenocytes, from now on referred to 
as wild type unless otherwise specified, produced substantially more IFNγ in SIRS mice versus 
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naïve. The RKIP-/- SIRS splenocytes did not make increased IFNγ levels over their naïve 
counterparts in this overnight culture.   
To investigate the reason for reduced IFNγ production seen in Figure 3-1C/D, we phenotyped 
primary and secondary lymphoid organs from naïve RKIP-/- mice and determined that there were 
no underlying deficits in T cell, B cell, NK cell, or CD11b+ antigen presenting cell (APC) 
populations (Fig. 3-2A), as well as important thymic subsets (Fig. 3-3A). Also, we found that 
there were no deficiencies in baseline cytokine production potential of IFNγ in a multitude of 
lymphoid organs (Fig. 3-2B). Next, we hypothesized that the reduced IFNγ production could be 
due to a reduction in the expansion of SEA-specific (Vβ3+) T cells. No difference in either SEA-
specific CD8+ or CD4+ splenic T cells by percentage or total number after SIRS induction was 
detected (Fig. 3-4A/B). Based on these results we hypothesized that reduction in IFNγ 
production might be T cell intrinsic.        
SEA-specific CD8+ T cells are responsible for suboptimal IFNγ production in RKIP-/- mice  
To test our hypothesis suggesting that if the lower levels of IFNγ were due to a defect in a 
specific cell type or if it was generalized amongst all splenocytes, we harvested splenocytes from 
naïve and SIRS induced RKIP-/- and wild type mice and examined IFNγ production in specific 
cell populations by flow cytometry after a short-term (4 h) in vitro restimulation with SEA (Fig. 
3-5A). After SIRS induction there was a marked decrease in the percentage of IFNγ producing 
CD8+ Vβ3+ T cells from RKIP-/- mice compared to wild type (Fig. 3-5B). Furthermore, of the 
CD8+ Vβ3+ T cells producing IFNγ, RKIP-/- cells produced lower amounts compared to wild 
type cells when using mean fluorescence intensity as a measurement (Fig. 3-5C). This defect in 
IFNγ production was not observed in SEA-specific CD4+ T cells (Fig. 3-5B/C), bystander T 
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cells, or in splenic non-T cell populations (data not shown). Importantly, naïve T cells did not 
produce IFNγ in these short-term cultures, as opposed to the overnight stimulation in Figure 1. 
Perhaps this is due to the IFNγ gene locus not having sufficient time to open and translate IFNγ 
mRNA into protein in 4 h. These data suggest that the suboptimal IFNγ production seen in RKIP-
/- SIRS splenocytes is due to a cell intrinsic defect specifically in CD8+ Vβ3+ T cells.  
Because of the reduced IFNγ production by CD8+ Vβ3+  T cells, we tested if higher levels of the 
anti-inflammatory cytokine Interleukin-10 (IL-10) could explain this result, since there is a 
known reciprocity between these cytokines (178). IL-10 can be induced by S. aureus 
enterotoxins (179) and T regulatory cells (Tregs) proficiently synthesize this suppressive 
cytokine (180), thus they were examined during SIRS in our model. Tregs from SIRS-induced 
RKIP-/- mice had a decreased propensity to synthesize IL-10 during stimulation with PMA + 
ionomycin when compared to wild type controls (Fig. 3-6A, left panel). This was not due to a 
difference in the percentage of Tregs between groups (Fig. 3-6A, right panel) or a baseline 
alteration in IL-10 production potential from naïve Tregs (Fig. 3-6B). Interestingly, when whole 
splenocytes from RKIP-/- and wild type mice were restimulated with SEA and compared for IL-
10 induction, a slight, but not statistically significant, reduction was seen in the RKIP-/- group 
(Fig. 3-6C). This implies that other cell types within the spleen have the ability to compensate, to 
a degree, for the loss of IL-10 production in Tregs during SIRS associated inflammation.  
SIRS CD8+ RKIP-/- T cells have an intrinsic signaling defect that lies downstream of the T 
cell receptor  
In order to better localize the lesion that was responsible for suboptimal IFNγ production from 
RKIP-/- CD8+ Vβ3+ T cells after TCR-triggering, we wanted to determine if these cells ever had 
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the potential to make IFNγ or not. Therefore, we tested RKIP-/- and wild type splenocytes after 
initiation of SIRS with PMA + ionomycin restimulation as opposed to SEA. The defect in IFNγ 
production by RKIP-/- SIRS CD8+ Vβ3+ T cells was no longer apparent (Fig. 3-7A, upper panel). 
Furthermore, there was also no longer a difference in the release or secretion of IFNγ between 
RKIP-/- and wild type splenocytes after PMA + ionomycin stimulation (Fig. 3-7B). Hence, the 
signaling defect seen in RKIP-/- SIRS CD8+, but not SIRS CD4+, T cells most likely lies 
downstream of TCR engagement, but upstream of the factors induced by Ca2+ influx and phorbol 
esters.  
Blockade of RKIP using the small molecule inhibitor locostatin greatly diminishes IFNγ 
production from wild type CD8+ T cells in SIRS 
In order to test the therapeutic potential of RKIP blockade in SIRS, we restimulated 48 h post-
SIRS induction splenocytes from wild type mice overnight with SEA or PMA + ionomycin in 
the presence of locostatin or vehicle control. The optimal effective dose of locostatin was chosen 
based on titration studies which elicited a dose that showed both a biological effect while leaving 
the vast majority of T cells viable, even after overnight stimulation (Fig. 3-8A/B). As in RKIP-/- 
SIRS splenocytes, inhibition of RKIP function with locostatin significantly decreased IFNγ 
production after TCR re-triggering with SEA, but not after PMA + ionomycin restimulation, 
suggesting once again that RKIP is playing a role downstream of the TCR (Fig. 3-7C).  
Because SEA crosslinks T cells with APCs, we investigated whether the loss of IFNγ production 
was due to poor APC presentation. First, we assessed expression of MHC II and the 
costimulatory molecules CD80/CD86 on splenic APC populations and found no difference 
between RKIP-/- and wild type littermate controls (Fig. 3-9A/B). Additionally, we isolated APCs 
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and CD8+ T cells from the spleens of RKIP-/- and wild type littermate mice 48 h after SIRS 
induction. We then restimulated cultures of RKIP-/- APCs and wild type (or RKIP-/-) CD8+ T 
cells overnight with SEA and unlike stimulation of the intact splenocyte population (Fig. 3-1) we 
observed no difference in IFNγ production (data not shown). Thus, in order to rule out any 
unappreciated developmental defect that may have confounded these results, we isolated APCs 
and CD8+ T cells from spleens of C57BL/6 mice 48 h after SIRS induction and treated them 
separately with either locostatin or vehicle in vitro for 1 h. Cells were washed twice to remove 
residual locostatin or vehicle, untreated APCs or CD8+ T cells were added, and restimulated 
overnight with SEA. We observed that by pre-treating wild type CD8+ SIRS T cells with 
locostatin, IFNγ production was diminished to 30% of untreated or vehicle treated controls (Fig. 
3-7D). However, blocking RKIP in APCs before restimulation had little effect of IFNγ output, 
once again suggesting that RKIP is playing a role at the level of the T cell and can be 
therapeutically targeted to diminish IFNγ responses from CD8+ T cells during SIRS.     
RKIP-/- T cells retain the ability to mount an effective response to PAMP-TLR mediated 
stimuli 
Because RKIP-/- SIRS CD8+ T cells have an intrinsic defect downstream of TCR triggering, we 
hypothesized that RKIP-/- cells may also have difficulty with proliferation, survival, and cytokine 
production during a vaccination response. In order to address this question, we replaced the 
second in vivo administration of SEA in our SIRS induction model with the vaccine adjuvant 
lipopolysaccharide (LPS) (Fig. 3-10A). This model mimics a standard vaccination protocol 
which results in the expansion and survival of SEA-specific T cells, which become Th1-like cells 
(147). We found no difference in the survival of CD4+ Vβ3+ or CD8+ Vβ3+ T cells between 
RKIP-/- and wild type in terms of percentage or total number at day 12 after SEA-LPS 
44 
 
immunization. This was seen in both spleen (Fig. 3-10B, Table 3-1) and liver (Fig. 3-10D, Table 
3-1), as well as in pooled peripheral lymph nodes (Table 3-1). Also, there were no observable 
differences in contraction of SEA-specific cells after SEA immunization alone (Table 3-1). 
These data are consistent with the lack of changes in clonal expansion during the SIRS model 
seen in Figure 3-4. Unexpectedly, when cells were harvested from the spleen and liver at day 12 
post immunization and restimulated in vitro with SEA overnight, RKIP-/- cells now made equal 
or greater amounts of IFNγ (Fig. 3-10C/E). These results were also recapitulated when cells were 
restimulated with plate-bound anti-CD3 acting as the TCR-trigger instead of SEA, although a 
slight reduction in IL-2 production was seen in this instance (Fig. 3-3B). Importantly these data 
suggest that, although RKIP-/- CD8+ T cells have a defect in effector cytokine production during 
SIRS mediated inflammation, they can still expand, survive, and contribute to effector cytokine 
production in response to PAMP-TLR mediated reactions.  
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DISCUSSION 
SIRS is an extensive and profound burden on the U.S. healthcare system (153). One well known 
cause of SIRS induction is exposure to superantigens, most famously TSST-1 enterotoxin from 
Staphylococcus aureus which was directly responsible for many cases of toxic shock syndrome 
in the 1980s. TSST-1 and SEA bypass canonical antigen processing and activate a large 
percentage of the T cell repertoire by cross-linking β-chain variable regions, specifically Vβ3, of 
the T cell receptor (TCR) to constant domains of the major histocompatibility complex on APCs 
(126). T cells are critically important for mediating SIRS because they can directly release 
proinflammatory factors themselves and potentiate the inflammatory and destructive effects of 
innate immune cells (160). In fact IFNγ, an important T cell effector cytokine, has been shown to 
be necessary for certain clinical sequelae of SIRS including acute lung injury (ALI) (163). By 
utilizing a T cell-dependent model of SIRS we sought to identify proteins that could alter 
cytokine production in T cells, thus lessening the inflammatory response at several different 
levels. We show that RKIP represents a new, and potentially valuable, therapeutic target since its 
inhibition curbs IFNγ synthesis without shutting down responses to PAMPs. From a mechanistic 
perspective, we demonstrate that CD8+ T cells may be a spring for cytokine production during a 
SIRS response, and have demonstrated that RKIP is coupled to continued IFNγ potential in 
anergic or immunosuppressed CD8+ T cells.  
However, like all animal models, SEA exposure does not recapitulate all aspects of human SIRS 
perfectly. As with many inflammatory mouse models, especially ones on the C57BL/6 genetic 
background, most are resistant to the typical symptomology seen in human SIRS patients (i.e. 
fever, lethargy, malaise, hypovolemia, organ dysfunction, death). This may be due to 
inflammatory reactions in humans and mice eliciting different genetic responses to burns, 
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trauma, or endotoxemia, all of which trigger SIRS (181). Nevertheless, we feel that this model 
provides at least a reasonable starting point to analyze potential molecular targets that can 
modify systemic inflammatory responses.    
The NF-κB and MAPK pathways are both critical for the production of proinflammatory 
cytokines (166, 167) and RKIP has been previously shown to be a negative regulator of these 
pathways. RKIP imparts control by interfering with the kinase activities of several signaling 
factors in these cascades. Little is known regarding the in vivo effects of RKIP, especially within 
the immune system. Based on the findings of these previous studies, we anticipated that mice 
lacking RKIP would be more prone to exaggerated cytokine production during T cell activation, 
but contrary to our hypothesis we found that RKIP was actually important for enhancing IFNγ 
production in CD8+ SIRS T cells after serial triggering of the TCR with SEA (Figs. 3-1,3-5). 
This is critical because SEA induces a SIRS response in mice that results in T cells that are 
anergic (characterized by their failure to produce IL-2 (182), but can continue to perpetuate 
inflammation due to their ability to make IFNγ in large quantities. On a molecular level we 
showed that RKIP is playing a role in the signaling machinery downstream of the TCR, as 
evidenced by the fact that the diminished IFNγ production from CD8+ T cells lacking RKIP was 
rescued if the TCR is bypassed using PMA and ionomycin (Fig. 3-7). Interestingly, expansion of 
these T cells, which is another critical process mediated by MAPK signaling, was unaltered in 
our model of SIRS (Fig. 3-4). This implies that RKIP’s role within effector T cells may be more 
critical for cytokine output rather than proliferation.  
Currently, no choice drug exists for the treatment of SIRS. Therapy focuses on treating specific 
infections, if one is present, in combination with therapies that stabilize the respiratory and 
cardiovascular systems if a patient has signs of shock (157). Clinical trials centered on 
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antagonizing the function of TNFα and IL-1β failed to show efficacy (28); however, our data 
suggests that perhaps inhibiting the effects of IFNγ may be a better therapeutic strategy. The only 
treatment to target the robust inflammation of SIRS that has shown marginally better outcomes is 
the usage of low-dose steroids like hydrocortisone (183). This therapeutic approach is broadly 
immunosuppressive, thereby minimizing inflammatory reactions that are advantageous to the 
host, such as productive responses to vaccines or pathogens. This is critical for a patient pool that 
might be afflicted with established bacterial, viral, or fungal infections. Nevertheless, this is in 
contrast to patients suffering from autoimmunity where steroid-mediated suppression of the 
immune system would provide beneficial effects with a diminished risk of infection compared to 
SIRS. However, an ideal therapeutic for either scenario would be one which dampens the 
inflammatory effects of T cells that are being chronically stimulated through the TCR (e.g. 
enterotoxins in SIRS or self-antigen in autoimmunity) while leaving advantageous immune 
responses, such as to a vaccine or new infection, largely intact. 
 RKIP may be one potential molecule that, if targeted, could possibly achieve these optimal 
therapeutic goals. For example, when RKIP is absent from the immune system, or when 
therapeutically targeted, effector T cells, serially triggered through their TCR, produce 
significantly less IFNγ than wild type while impinging only marginally on overall IL-10 
production (Fig. 3-6). In addition, when the TCR is engaged only once in vivo and adjuvanted 
with TLR stimulation from LPS, splenocytes synthesize normal levels of IFNγ (Fig. 3-10). Thus, 
it is possible that blockade of RKIP could diminish IFNγ production from effector T cells during 
SIRS while permitting a relatively unabated response to PAMPs. Although, it remains to be 
determined what would occur in a complex response where both serial TCR triggering and 
PAMP-TLR mediated stimuli both exist simultaneously or what the exact role, if any, that RKIP 
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plays in these responses. Finally, therapeutically targeting RKIP may provide a substantial 
benefit over direct inhibition of IFNγ because it allows for the alleviation of IFNγ effects at the 
level of synthesis rather than receptor binding. This may be especially important in acute SIRS 
where it could be too late to impact disease outcomes once IFNγ has been produced.  
Although our data suggests that a loss of RKIP leads to a T cell intrinsic defect in optimal IFNγ 
production, it still does not exclude the possibility of potential T cell extrinsic effects as well. In 
fact in 2006, Schuierer and colleagues showed that RKIP expression may play a role in 
appropriate macrophage and dendritic cell differentiation (138). Since APCs are critical for the 
activation of T cells in response to classically presented antigens, as well as superantigens, any 
deficit in APC function could also impart effects onto cytokine production from T cells. We 
show that RKIP is playing a role at the level of the CD8+ T cell in responses to superantigens 
because inhibition of RKIP in APCs specifically had no effect on IFNγ production, but inhibition 
in CD8+ T cells did (Fig. 3-7D). Also, if T cell extrinsic effects such as this were playing a large 
role in our model systems, we would have expected to see little or no response in our SEA-LPS 
studies, which was not the case. However, this does not explicitly rule out a potential extrinsic 
defect in response to MHC-restricted peptide antigens that must undergo canonical processing 
and presentation within APCs.   
Another facet that makes RKIP a unique therapeutic target is that it is a druggable protein. A 
small molecule inhibitor of RKIP, locostatin, is available (184). Locostatin exerts its inhibitory 
effects on RKIP by alkylating a conserved histidine residue (His86) within its ligand-binding 
pocket (172). Modification of this residue prevents RKIP from binding to its aforementioned 
ligands, thus preventing their inhibition. In addition to abating IFNγ production from wild type 
cells during SIRS (Fig. 3-7C), locostatin also potently blocks IFNγ and TNFα production upon 
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triggering mouse OT-I or human antigen-specific T cells against influenza with cognate peptide 
and human PBMCs treated with LPS (140). However, the specificity of this inhibitor is still 
being investigated as it has several potential off target effects (184). Furthermore, the target 
analyses for locostatin have largely been conducted in immortalized cell lines (185), and thus, 
the exact mechanism of how it mediates its inhibitory effects within an in vivo immunological 
system remains unclear. This allows significant room for improvement in developing better 
target-specific inhibitors of RKIP before use in a clinical setting. Nevertheless, our new data pin 
points a locostatin effect on CD8+ T cells, but not APCs, in response to the pathogenic 
enterotoxin SEA (Fig. 3-7D). In sum, our data suggests that RKIP represents a potentially new 
therapeutic target for reducing the effects of IFNγ from CD8+ effector T cells during the serial 
TCR triggering events in SIRS. 
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Figure 3-1: RKIP is necessary for optimal production of IFNγ by splenocytes during SIRS. 
(A) Schematic of SIRS induction protocol. (B) Serum was isolated from C57BL/6 mice before 
1° SEA and 90 min post 2° SEA treatment, and then quantified for IL-6, IFNγ, SAA, and LDH 
by ELISA. Data are from 3 independent experiments, N=5-8/group. (C) Splenocytes from 
C57BL/6J, WT littermate, and RKIP-/- mice were harvested 72 h after 2° SEA as depicted in 
Figure 1A. 5 x 105 cells/well were stimulated overnight with 0.1μg SEA, supernatants were 
collected and analyzed for IFNγ and IL-2 by ELISA. Data are from 5 independent experiments, 
N=10-13/group, are expressed as a percent change from naïve splenocytes cultured and 
stimulated similarly. (D) Absolute values of IFNγ for C57BL/6J and RKIP-/- from each 
independent experiment in Figure 1C with Standard Error of the Mean (SEM). P values were 
determined by unpaired t test between groups in Figure 3-1C/D and by paired t test in Figure 3-
1B *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. 
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Figure 3-2: RKIP-/- mice show no overt developmental deficits in important immunological 
cell populations. (A) Cells from spleen, inguinal lymph node (ILN), axillary lymph node 
(ALN),and mesenteric lymph node (MLN) were isolated from 4 week and 11 week old RKIP-/- 
and wild type littermate mice. Cells populations were phenotyped by flow cytometric analysis. 
Data are from 3 independent experiments, N=8 mice/group. Error bars represent SEM. *P<0.05.  
RKIP-/- mice show no overt defects in baseline cytokine production potential. (B) Cells 
from in Figure 3-2A were stimulated in vitro with PMA + Ionomycin including Brefeldin A for 4 
h. After stimulation, cells were analyzed by intracellular cytokine staining. Data are from 3 
independent experiments, N=8 mice/group. Error bars represent SEM. *P<0.05, **P<0.01. 
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Figure 3-3: RKIP-/- mice show no loss of Thymic T cell populations. (A) Thymocytes from 
Figure 3-2 mice were isolated and stained directly ex vivo for CD3, CD4, CD8, CD25, and 
CD44 to determine important thymocyte populations by flow cytometric analysis. Error bars 
represent SEM. P values determined by unpaired t test between groups. Plate bound anti-CD3 
restimulation as a substitute TCR-trigger during SEA-LPS vaccination shows IFNγ 
production is unaltered in RKIP-/- splenocytes. (B) Cells from spleen and liver in Figure 3-10 
were harvested, treated, and analyzed as in Figure 3-10C and Figure 3-10E respectively. Error 
bars represent SEM. P values determined by unpaired t test between groups *P<0.05. 
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Figure 3-4: Reduced IFNγ production in RKIP-/- mice during SIRS is not due to reduced 
expansion of SEA-specific Vβ3+ T cells. (A) Splenocytes from C57BL/6J and RKIP-/- mice 
were harvested 72 h after 2° SEA as depicted in Figure 3-1A, stained directly ex vivo with 
antibodies against CD3, CD4, CD8, and Vβ3, and CD3+ CD8+ or CD3+ CD4+ T cells were gated 
to determine the percent Vβ3+ T cells in spleen. (B) Total cell numbers of Vβ3+ T cells from 
spleen. Data in Figure 3-4A-B are from 5 independent experiments, N=15-16/group. Error bars 
represent SEM and P values were determined by unpaired t test between groups. 
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Figure 3-5: SEA-specific CD8+ effector T cells are responsible for suboptimal IFNγ 
production in RKIP-/- mice. (A) Gating strategy for flow cytometric analysis utilized in Figure 
3B-C. (B) Splenocytes were harvested as described in Figure 3-1A and restimulated in vitro with 
0.1μg of SEA/well + Brefeldin A for 4 h. After restimulation, cells were analyzed by 
intracellular cytokine staining for IFNγ production. Data are plots from a representative 
experiment displaying median values. (C) The left panels show the mean +/- SEM of IFNγ-
producing T cells and (right panels) display Mean Fluorescence Intensity (MFI) of IFNγ+  T cells. 
Data are from 3 independent experiments, N=8 mice/group. Error bars represent SEM and P 
values were determined by unpaired t test between groups *P<0.05. 
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Figure 3-6: Tregs from RKIP-/- mice during SIRS show reduced IL-10 production. (A) 
Splenocytes were harvested as outline in Figure 3-1A and restimulated in vitro with PMA + 
ionomycin including Brefeldin A for 4 h. After restimulation, cells were surfaced phenotyped 
with antibodies against CD3, CD4, and Foxp3, stained intracellularly for IL-10 production, and 
cells were then analyzed by flow cytometry. Data are from 2 independent experiments, N=5-
6/group. (B) Splenocytes were harvested from 4 week and 11 week old naïve RKIP-/- mice or 
wild type littermates (see Fig. 3-2). 5 x 105 cells/well were stimulated in vitro with PMA + 
ionomycin including Brefeldin A for 4 h then surface phenotyped with antibodies specific to 
CD3, CD4, and Foxp3, and stained intracellularly for IL-10 production. Data are from 3 
independent experiments, N=10/group. (C) Supernatants from Figure 3-1 were analyzed for IL-
10 production by ELISA. Data are expressed as a percentage change from naïve splenocytes 
cultured and stimulated similarly. As in Figure 3-1, data are from 5 independent experiments, 
N=10-13/group. Error bars represent SEM and P values determined by unpaired t test between 
groups *P<0.05. 
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Figure 3-7: SEA-specific CD8+ effector T cells lacking RKIP have an intrinsic signaling 
defect that lies downstream of the T cell receptor. (A) Splenocytes from Figure 3-5 were 
restimulated in vitro for 4 h with PMA + ionomycin including brefeldin A and then stained with 
antibodies against CD3, CD4, CD8, Vβ3, and IFNγ, followed by flow cytometric analysis. Data 
are from 3 independent experiments, N=8/group. (B) Splenocytes were harvested as in Figure 3-
7A and cultured overnight (5 x 105/well) with PMA + ionomycin. Subsequently, supernatants 
were collected and analyzed for IFNγ production by ELISA. Data are from 2 independent 
experiments, N=6/group. (C) 48 hr post-SIRS induction splenocytes from C57BL/6J mice were 
isolated and restimulated overnight with SEA or PMA + ionomycin in the presence of medium 
alone, vehicle alone (DMSO), or 5µM locostatin. The supernatants from these cultures were then 
analyzed for IFNγ production by ELISA. The grey dotted line represents SEA (or PMA + 
ionomycin) restimulation without locostatin or vehicle. Data are from 3 independent 
experiments, N=9/group. (D) Isolated and magnetic bead purified APC and CD8+ T cell 
populations from C57BL/6J mice 48 hr after SIRS induction were treated separately with either 
5μM locostatin or vehicle for 1 hr. Subsequently, cells were washed twice with medium to 
remove any residual locostatin or vehicle present, and then untreated APCs or CD8+ T cells (in a 
1:1 ratio) were added to these cultures and restimulated overnight with 0.1μg SEA. As controls, 
cultures of untreated APCs and CD8+ T cells containing locostatin or vehicle for the entire 
duration were stimulated in parallel. The supernatants of these overnight cultures were then 
assessed for IFNγ production by ELISA. The grey dotted line represents untreated APCs and 
CD8+ T cells stimulated with SEA alone. Data are from 3 independent experiments, N=10-
11/group. Error bars represent SEM and P values determined by unpaired t test between groups. 
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Figure 3-8: Blockade of RKIP with the small molecule inhibitor locostatin abates IFNγ 
production from SEA restimulated wild type SIRS splenocytes. (A) 48 h post-SIRS induction 
splenocytes from C57BL/6J mice were harvested as described in Figure 3-1A and restimulated 
them overnight with SEA or PMA + ionomycin in the presence of medium alone, vehicle alone 
(DMSO), or a titration of locostatin (0.5 - 50μM). The supernatants from these cultures were 
then analyzed for IFNγ production by ELISA. Low dose locostatin (5μM) shows both a 
biological effect on IFNγ production while leaving the bulk of T cells viable, even after 
overnight stimulation. (B) Splenocytes from cultures in Figure 3-8A were stained for CD3 and 
Annexin V in order to assess viability by flow cytometry. 
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Figure 3-9: RKIP-/- SIRS mice have no quantitative differences in splenic APC populations 
compared to wild type. (A) 48 h post-SIRS induction splenocytes were harvested from RKIP-/- 
and wild type littermates and stained for B cells (B220) and different macrophages and dendritic 
cells (CD11b, CD11c) populations. Error bars represent SEM (N=7-11, 3 independent 
experiments). RKIP-/- splenic APC populations exhibit no differences in MHC-II 
expression, or the costimulatory molecules CD80/86 compared to wild type. (B) APC 
populations from Figure 3-9A were stained and analyzed by flow cytometry for MHC-II 
(AF700), CD80 (PE), and CD86 (Biotin-PECy7) surface expression. Error bars represent SEM 
(N=7-11, 3 independent experiments). 
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Figure 3-10: RKIP-/- T cells can expand, survive, and contribute to cytokine production in 
response to PAMP-TLR mediated stimuli. (A) Schematic representation of immunization 
protocol. (B) Splenocytes were harvested at 12 d post immunization with LPS as outlined in 
Figure 3-10A and stained directly ex vivo for SEA-specific (Vβ3+) T cells as outlined in Figure 
3-5A. Data are from 3 independent experiments, N=11-14/group. (C) Splenocytes were 
harvested as in Figure 3-10A and cultured (5 x 105/well) overnight with 0.1μg SEA. The next 
day, IFNγ and IL-2 levels in supernatants were measured by ELISA. Data are from 3 
independent experiments, N=11-14/group. (D) Liver leukocytes were harvested, treated, and 
analyzed as in Figure 3-10B. (E) Liver leukocytes were harvested, treated, and analyzed as in 
Figure 3-10C. Error bars represent SEM and P values determined by unpaired t test between 
groups. 
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TABLE I: Normal clonal expansion, contraction, and survival in RKIP-/- mice after SEA-
LPS Immunization 
  
pLN 
 
Spleen 
 
Liver 
   CD8* CD4*   CD8 CD4   CD8 CD4 
  
  
 
  
 
  
Naïve 
Wild Type  2.61 ± 0.20 4.30 ± 0.31 
 
2.99 ± 0.46 4.07 ± 0.18 
 
2.44 ± 0.44 1.76 ± 0.57 
RKIP-/-   2.32 ± 0.13 4.26 ± 0.12 
 
2.80 ± 0.27 5.69 ± 0.93 
 
2.38 ± 1.19 1.69 ± 0.46 
  
  
 
  
 
  
LPS 
Wild Type  2.70 ± 0.20 4.25 ± 0.13 
 
3.20 ± 0.82 4.98 ± 0.72 
 
2.17 ± 0.28 1.90 ± 0.88 
RKIP-/-  2.29 ± 0.09 3.98 ± 0.60 
 
3.27 ± 0.61 5.48 ± 0.52 
 
2.25 ± 0.94 1.53 ± 0.13 
  
  
 
  
 
  
SEA 
Wild Type  1.14 ± 0.19 2.03 ± 0.13 
 
2.78 ± 0.92 3.43 ± 0.25 
 
1.59 ± 0.27 0.96 ± 0.15 
RKIP-/-  1.44 ± 0.19 2.20 ± 0.17 
 
2.03 ± 0.15 3.61 ± 0.31 
 
1.75 ± 0.26 1.67 ± 0.29 
  
  
 
  
 
  
SEA+LPS 
Wild Type  5.36 ± 1.02 7.57 ± 1.04 
 
9.00 ± 1.57 13.04 ± 1.86 
 
14.18 ± 2.31 7.95 ± 1.55 
RKIP-/-  5.87 ± 0.68 8.73 ± 0.78 
 
9.13 ± 1.31 14.96 ± 1.23 
 
12.37 ± 1.49 10.82 ± 1.55 
                    
* Percent of Vβ3+ T cells in various tissues on day 12 after no treatment, LPS, SEA, or Both 
 
Data is a pooled analysis of all experiments in Figure 6. 3 independent experiments, N=11-
14/group.    
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CHAPTER 4 
 
RKIP IS INVOLVED IN DOWNSTREAM SIGNALING AFTER PATTERN 
RECOGNITION RECEPTOR ENGAGEMEMENT, IMPACTING CYTOKINE 
PRODUCTION  
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ABSTRACT 
The ability to sense pathogen-associated molecular patterns (PAMPs) through pattern 
recognition receptors (PRRs) is a critical first step in our body’s defense against pathogenic 
infection. Although much of the signaling mediators downstream of PRR ligation have been well 
established, new molecules continue to be discovered. Previous data from our laboratory and 
others suggest that one such molecule, Raf-1 kinase inhibitor protein (RKIP), which has been 
proposed to interact with several important signaling proteins in pathways typically activated 
after PRR ligation, may play an important role in PRR signaling events. However, RKIP’s 
function within primary immune cells and specifically how RKIP effects normal PRR signaling 
is currently unknown. Herein, we suggest that RKIP may play a role in PAMP sensing by PRRs, 
specifically in Toll-like receptor (TLR) signaling, by forming an ordered signaling complex after 
TLR ligation. The functional significance of this phenomenon is a marked loss in pro-
inflammatory cytokine production after PAMP sensing in the absence or blockade of RKIP, 
signifying that RKIP is necessary for the proper production of cytokines after TLR ligation. 
These data also mark RKIP as a potential druggable target in cytokine-based therapies for 
diseases related to pathogenic cytokine release.         
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INTRODUCTION 
Our body’s ability to detect foreign pathogens quickly and efficiently is key in mounting an 
effective immune response against them. PRRs are largely responsible for coupling PAMP 
sensing to the generation of pro-inflammatory cytokines, activation and maturation of antigen 
presenting cells, and subsequently effective adaptive responses of T and B cells. The importance 
of PRRs and host defense has been demonstrated in both mice and humans with defective PRR 
responses leading to an increased susceptibility to bacterial, viral, and fungal infections (13). 
Moreover, PRR responses that are excessively robust can lead to or potentiate inflammatory 
diseases including systemic inflammatory response syndrome (SIRS), inflammatory bowel 
disease (IBD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), atherosclerosis, 
and others (36). On the other hand, because of their ability to induce potent inflammatory 
responses, PRR agonists are also promising molecules for raising the adjuvanticity of certain 
vaccine-based therapies (186).  
The most widely studied, and best understood, family of PRRs are the TLRs, which are 
responsible for sensing many structural components of pathogens including nucleic acids, 
proteins, and lipoproteins. Once these patterns are sensed by TLR bearing cells, they transduce a 
pro-inflammatory genetic program to the nucleus through the utilization of either the MyD88 (all 
TLRs except TLR3) or TRIF (TLR3 & 4) adaptor molecules. Despite having exponentially 
increased our understanding of TLR function over the past 20 years, important signaling 
molecules within these pathways that modulate, potentiate, or regulate the TLR response are 
continuously being discovered. In 2010, Tang and colleagues showed that RKIP interacted with 
proteins downstream of MyD88 signaling in cancer cells including TRAF6, TAK-1, and IKKα/β 
(169). Additionally, our laboratory has shown that RKIP blockade, using the small molecule 
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inhibitor locostatin, decreased TNFα and IFNγ production from human peripheral blood 
mononuclear cells (PBMCs) stimulated with the TLR4 ligand LPS (140), and that administration 
of LPS helps RKIP-/- T cells overcome a deficit in IFNγ production in a mouse model of SIRS 
(Fig. 3-10). These data suggest that RKIP may be a potentially important player in TLR 
signaling dynamics; however, the exact nature of RKIP’s role within these responses in 
unknown, especially in primary immune cells.  
Through the following studies, we present data that demonstrate that RKIP is an active 
participant in the early signaling events of several TLRs. Our data are consistent with the 
working hypothesis that RKIP’s role is most likely to facilitate the generation and stabilization of 
a membrane-associated protein complex involved with TLR signaling. The functional 
importance of these interactions is demonstrated by evidence that loss of RKIP through targeted-
deletion or through exogenous blockade lead to a diminished cytokine profile. Thus, this study is 
the first to suggest that RKIP is not only involved in the ability of PRRs to transduce 
inflammatory signals properly after PAMP sensing, but also points to RKIP as a potential target 
for treating inflammatory diseases linked to inappropriate TLR responses or bolstering the 
adjuvanticity of vaccines that utilize TLR agonists.        
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RESULTS 
Currently, exceptionally little is known regarding RKIP’s role during PAMP sensing by immune 
cells. The data in Figure 3-10 show that in the context of T cell mediated inflammation, exposure 
to a PAMP after TCR ligation with SEA did not result in the same defect in IFNγ production 
seen after serial TCR triggering in CD8+ T cells. Additionally, our laboratory has previously 
demonstrated that exposing human PBMCs to LPS during RKIP blockade with locostatin 
decreases TNFα and IFNγ production from these cells (140), although this effect was very dose 
dependent with low doses elevating IFNγ and higher locostatin inhibiting. Taken together, these 
data suggest that RKIP may or may not play a role in TLR signaling, and that this role may be 
fundamentally different than its established effect in IFNγ production from serially triggered 
CD8+ T cells.  
Stimulation of wild type splenocytes with LPS leads to a time and dose dependent 
disappearance of RKIP protein 
In order to test the hypothesis that RKIP is indeed involved in TLR signaling, we first tested the 
response of bulk splenocytes from wild type C57BL/6J mice to the TLR4 agonist LPS and 
measured RKIP protein levels by immunoblot over time. This heterogeneous mixture of cells, 
which has been consistently characterized by many laboratories (14), contains a number of 
populations capable of sensing a wide complement of PAMPs and thus provided a very 
important tool for determining any generalizable effect on TLR ligation. We found that after 
stimulation of these splenocytes with LPS, RKIP became very difficult to detect by immunoblot 
as rapidly as 10 minutes after exposure (Fig. 4-1A/B). This effect was transient, and began 
around 5 minutes after stimulation, peaked between 10-30 minutes (data not shown), and was 
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nearly completely abrogated by 60-90 minutes (Fig. 4-1B and Fig. 4-2). This effect was highly 
reproducible over many experiments despite being conducted with different culture medium and 
varying doses of LPS. Additionally, treatment of bulk splenocytes with locostatin also impeded 
the detection of RKIP by immunoblot (Fig. 4-1A) and seemed to provide an additive effect in 
conjunction with LPS exposure. However, this phenomenon may be explained by masking of the 
epitope that the RKIP antibody used in these studies recognizes through steric hindrance or 
blockade. Unfortunately, this hypothesis cannot be tested until better site specific antibodies 
corresponding to regions outside of the locostatin binding area are commercially available and 
validated.         
RKIP was originally characterized by its binding to, and functional inhibition of, Raf-1 kinase 
which subsequently resulted in a decrease in downstream MAPK phosphorylation of MEK and 
ERK (132). In order to validate that our decrease in RKIP detectability shown in Figures 4-1A/B 
impinged upon its previously characterized function, we stimulated bulk splenocytes again with 
a titration of LPS and measured both RKIP and phosphorylated-ERK protein levels 10 minutes 
after exposure. Consistent with these previously published results, we found an inverse 
relationship between RKIP protein detectability and ERK phosphorylation that was dose-
dependent (Fig. 4-1C and Fig. 4-1D). Taken together, these data suggest that RKIP is involved in 
the early signaling events located downstream of TLR4 ligation in splenocytes, and that RKIP’s 
previously characterized function (i.e. suppression of the Raf-MEK-ERK axis) may need to be 
transiently prohibited in order to allow for proper ERK phosphorylation to occur during PAMP 
sensing.  
The inability to detect RKIP protein after PAMP stimulation is generalizable to multiple 
TLR ligands 
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Next, we wanted to determine if the disappearance of RKIP on immunoblot after TLR4 
triggering was generalizable to multiple TLR ligands or whether it was an effect specific to LPS 
sensing by splenocytes. To test this question, we stimulated bulk splenocytes with titrations of 
several TLR ligands including: Pam3Cys (TLR1/2), Poly I:C (TLR3), LPS (TLR4), CpG type A 
(TLR9), and CpG type B (TLR9), and then measured RKIP by immunoblot at 10 minutes, 30 
minutes (data not shown), and 90 minutes after TLR ligation. These agonists were chosen in 
order to stimulate both of the different signaling pathways downstream of TLRs (i.e. MyD88 and 
TRIF) independently (e.g. TLR3 vs. TLR9) or cooperatively (TLR4). We found that each of the 
TLR ligands tested exhibited the same phenomenon observed in Figure 4-1; however, each did 
so with varying potencies and kinetics (Fig. 4-2A). Poly I:C and CpG-A seemed to have the most 
profound effect on RKIP detectability, with LPS and CpG-B affecting RKIP less robustly. 
Interestingly, TLR2 ligation with Pam3Cys also led to a decrease in RKIP, but the effect was 
delayed until 30-90 minutes after stimulation. The stimuli also differed in the duration that RKIP 
remained less detectable. CpG-A and LPS affected RKIP at 10 minutes post stimulation but by 
90 minutes the effect had ceased, whereas Poly I:C and CpG-B seemed to still have an effect on 
RKIP up to 90 minutes after TLR ligation (Fig. 4-1B). These data suggest that although RKIP 
may be involved in the signaling machinery of all TLRs tested here, the degree to which it is 
utilized, and the timing of its utilization, may vary depending on the nature of the stimulus.             
Proteosomal degradation and de novo translation impart only minor contributions to the 
disappearance of RKIP 
Next, we wanted to better understand the molecular mechanism of RKIP’s disappearance after 
PAMP sensing in splenocytes. Based on our previous findings, two hypotheses emerged as 
potential possibilities to explain RKIP’s disappearance: 1) proteosomal degradation with 
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subsequent de novo translation of RKIP protein and 2) sequestration of RKIP into a signaling 
complex, and/or altered subcellular localization, which rendered it insoluble during lysate 
generation. In order to test the former hypothesis, we cultured splenocytes again with LPS or 
medium alone in the presence of the translational inhibitor cyclohexamide. Also, based on the 
transient nature of LPS’s effect on RKIP detectability, we suspected that the presence of pre-
synthesized RKIP mRNA was highly likely given that de novo transcription and subsequent 
translation of new protein can take much longer than the 90 minutes it took for RKIP to reappear. 
Because of this, we also repeated our stimulation in the presence of the transcriptional inhibitor 
actinomycin D to determine whether or not de novo transcription was necessary for detection of 
RKIP at 90 minutes post TLR ligation. We found that after stimulating splenocytes with LPS in 
the presence of actinomycin D, there was no effect on the RKIP’s disappearance at 10 minutes 
post TLR ligation and reappearance at 90 minutes, confirming our suspicion that de novo 
transcription of RKIP was likely not involved with this phenomenon (Figs. 4-3A/C). 
Additionally, stimulating in the presence of cyclohexamide only had minimal effects are 
preventing the re-detectability of RKIP at 90 minutes in one of two experiments, suggesting that 
de novo translation of RKIP protein also plays little to no role (Figs. 4-3A/C). Finally, we wanted 
to determine if degradation via the proteasome played a role in the rapid loss of RKIP detection. 
In order to test this, we repeated our LPS stimulation in splenocytes after a 10 minute pre-
treatment with the pan-proteasome inhibitor lactacystin. Due to the rapidity of RKIP’s 
disappearance, pre-treatment was required in order to assure that the majority of cellular 
proteasomes were blocked before stimulation commenced. The active β-lactone intermediate 
responsible for proteosomal inhibition has been shown to peak at 10 minutes and decay shortly 
thereafter with a half-life around 30 minutes (187). When comparing the amount of detectable 
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RKIP at 10 minutes after TLR4 ligation between splenocytes pre-treated or not with lactacystin, 
we found only a small increase in the amount of RKIP in the pre-treated group (Fig. 4-3B). 
There still remains a possibility that RKIP may be degraded by a non-proteosomal mechanism, 
such as cleavage via cellular caspases; however, after assessing RKIP’s primary amino-acid 
sequence using the bioinformatics tool ExPASy Peptide Cutter, no cleavage sites for any non-
proteosomal peptidases were found (Table II).  Nevertheless, taken together these data suggest 
that the transient loss of RKIP detection after PAMP sensing may be impacted by proteosomal 
degradation and de novo protein synthesis.  
The disappearance of RKIP protein after PAMP stimulation may be due to insoluble 
complex formation or altered subcellular localization 
In order to test our second hypothesis regarding the disappearance of RKIP, we first looked at 
RKIP’s cellular distribution in splenocytes after LPS stimulation by immunofluorescent 
microscopy. Interestingly, we observed that after TLR4 ligation with LPS, RKIP’s pattern of 
staining changed drastically. Splenocytes cultured in medium alone had an RKIP staining pattern 
that was diffusely spread across the cytoplasm with a small increase in intensity at the cell 
membrane, but after LPS stimulation, this RKIP staining pattern became much more punctate in 
nature and seemed to be localized into a very small, clustered region within each cell that was in 
or near the nucleus (Fig. 4-4A). This finding gave credence to the idea that RKIP may be a 
member of a distinct signaling complex that forms after TLR ligation. To look at this further, we 
repeated our LPS stimulation and separated our lysates into “cytoplasmic” and “nuclear” 
fractions using a commercially available kit. After TLR4 ligation, RKIP could be seen within the 
“nuclear” fraction, but was absent in splenocytes that were cultured in medium alone (Fig. 4-4B). 
This nuclear RKIP band was much less intense, but still present at 90 minutes post LPS 
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stimulation. Also of note, the molecular weight of the nuclear RKIP band was slightly higher 
than that found within the cytoplasm, suggesting that the form of RKIP found within this fraction 
may very well be post-translationally modified in some way. There are numerous putative post 
translational modification sites contained within RKIP that could explain this shift; however, 
most of these sites still need validation (Table II). Finally, even though we were able to confirm 
that our commercial subcellular fractionation kit was able to prevent cytoplasmic protein 
contamination into our “nuclear” fractions (confirmed by the exclusivity of Hsp90, a purely 
cytoplasmic protein, within our cytoplasmic fractions), we still cannot rule out the possibility 
that RKIP may also be tethered to the cytoplasmic membrane or endoplasmic reticulum (ER) 
within these punctate regions of staining seen in Figure 4-4A, given that many studies have 
highlighted the problem of membrane and ER-associated protein contamination into “nuclear” 
fractions in commercial kits that utilize RIPA buffer (188). Nevertheless, these data suggest that 
after PAMP sensing in splenocytes, RKIP does not undergo substantial degradation, and its 
disappearance on immunoblot analysis is more consistent with its re-direction into an ordered 
signaling complex that becomes insoluble during our normal lysate generation, most likely due 
to its tethering to insoluble material such as membrane-associated lipid rafts.    
Loss of RKIP by genetic knockout or exogenous blockade leads to altered cytokine and 
chemokine responses after TLR stimulation      
In order to determine if loss of RKIP had any significant downstream functional effects after 
TLR ligation, we stimulated bulk mesenteric lymph node (MLN) cells from RKIP-/- mice and 
wild type littermates with the TLR9 ligand CpG-A overnight. The supernatants from these 
cultures were then subjected to multiplex cytokine analysis that measured the output of 32 
distinct cytokines and chemokines from these cells. Many cytokines were found to be lower than 
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the lowest limit of assay detection in both RKIP-/- and wild type littermate bulk MLN cells after 
TLR9 ligation: G-CSF, IL-1β, IL-2, IL-3, IL-4, IL-7, IL-10, IL-15, IL-17A, CCL2, LIF, M-CSF, 
VEGF, and Eotaxin (data not shown). Of the cytokines and chemokines that were induced by 
CpG, the vast majority were generated in much smaller quantities in RKIP-/- MLN cells 
compared to wild type littermate: TNFα, GM-CSF, IL-5, IL-6, IL-9, IL-12, CXCL1, CXCL2, 
CXCL5, CCL3, CCL4, and CCL5 (Fig. 4-5A). This suggests that RKIP may be necessary for 
adequate production of some cytokines and chemokines following triggering of the MyD88 
pathway. Also, consistent with our previous findings that SEA-LPS vaccination led to slightly 
higher IFNγ output in RKIP-/- mice (Fig. 3-10C) and previous data showing that low doses of 
locostatin increased IFNγ after LPS stimulation of human PBMCs (140), we also observed 
increased levels of IFNγ, as well as the interferon-stimulated genes CXCL9, and CXCL10 after 
CpG stimulation of RKIP-/- MLN cells (Fig. 4-5A). In order to validate the observation that loss 
of RKIP results in decreased cytokine output after TLR ligation, we treated wild type 
splenocytes with either LPS or CpG-A overnight in the presence of exogenous RKIP blockade 
using the small molecule inhibitor locostatin and measured IL-6 and TNFα production in the 
culture supernatants. Consistent with our findings in Figure 4-5A, splenocytes treated with 
locostatin had markedly lower production of both cytokines measured (Fig. 4-5B), once again 
suggesting that functional RKIP is necessary for appropriate cytokine production during TLR 
signaling in splenocytes.                            
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DISCUSSION 
Charles Janeway first hypothesized the existence of a group of receptors important for 
recognizing foreign pathogens and providing the initiating events in host defense in Approaching 
the Asymptote? Evolution and Revolution in Immunology during a Cold Spring Harbor symposia 
in 1989 (189). Since that time, a voluminous literature base has been developed supporting 
Janeway’s theory, and currently we understand, in moderate detail, the existence, specificity, 
function, and importance of PRRs in host immunity and disease. After initially being discovered 
in plants in 1995 (190), groups shortly thereafter described their function in Drosophila 
melongaster (191), Mus musculus (192), and Homo sapiens (193). The first family of PRRs to be 
functionally described was the Toll-like receptors, named after their homology to a known 
Drosophila protein involved in embryonic polarity, Toll, initially discovered in 1985 (194). 
TLRs were found to recognize a number of different structural molecules found in bacteria, 
viruses, and fungi, including: LPS and lipopeptides, single and double-stranded RNA and DNA, 
flagellin, a protein involved in bacterial motility, and unmethylated CpG sites in DNA. 
Currently, it is known that many more families of PRRs exist in mice and humans including: C-
type lectin receptors (CLRs) which respond to glycoproteins and glycolipids, NOD-like receptors 
(NLRs) which recognize structural components of peptidoglycan and are responsible for 
coupling other PRRs to the inflammasome, and RIG-I-like receptors (RLRs) which respond to 
intracellular nucleic acids.  
Despite the immense collection of PAMPs that PRRs can recognize, the vast majority of 
signaling events after PRR ligation are restricted to two well-defined pathways named for the 
adapter molecule that initiates them: myeloid differentiation primary response gene 88 (MyD88) 
and TIR-domain-containing adapter-inducing interferon-β (TRIF)(195). All TLRs except for 
84 
 
TLR3 signal through MyD88 (196-198), while TLR3 and TLR4 can signal through TRIF (199, 
200). MyD88 signaling leads to the induction of NF-κB through the canonical pathway, and 
subsequently, the production of many pro-inflammatory cytokines (through AP-1), as well as co-
stimulatory molecules important for providing “signal 2” to T cells during activation (201). On 
the other hand, TRIF activation leads to a type I interferon dominated response (through IRF3/7) 
which is important for anti-viral immunity (202). Despite having some differences in upstream 
signaling molecules, ligation of CLRs, NLRs, and RLRs also lead to the activation of these 
downstream signaling molecules. Even though the MyD88 and TRIF pathways have been well 
defined, molecules that are important for proper transduction through these pathways are still 
being discovered on a regular basis, as exemplified by the recent discovery of STING as an 
alternative means of type I interferon generation (203). 
Previously, our lab and others have suggested that RKIP may be another such molecule 
important for PRR signaling. This hypothesis was based on several lines of evidence including: 
the fact that RKIP binds several molecules upstream of NF-κB activation (TRAF6, IKKα/β and 
TAK1; (133)), that blockade of RKIP with low dose locostatin in human PBMCs leads to 
decreased TNFα production after LPS stimulation (140), and administration of LPS helps RKIP-/- 
T cells overcome a deficit in IFNγ production (204). Nevertheless, the exact nature of RKIP’s 
role in primary cells remains unknown, and provides an important area for investigation.  
Through our studies, we demonstrate that RKIP is markedly affected after stimulation of bulk 
splenocytes with the TLR4 ligand LPS. This is evidenced by the fact that RKIP becomes 
exceedingly difficult to detect by immunoblot shortly, but transiently, after TLR ligation (Fig. 4-
1A/B), the mechanism of which we still do not understand completely. This “disappearance” 
begins as early as 5 minutes after stimulation, peaks at 10-30 minutes, and is almost completely 
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resolved 60-90 min later. Importantly, this phenomenon was generalizable to stimulation through 
TLRs that activate My88 alone, TRIF alone, or both together, suggesting that RKIP probably 
plays a role in both pathways (Fig. 4-2), albeit with different potency and kinetics. Although, the 
relative impact of RKIP on each pathway individually, and whether or not this is an effect of a 
specific lesion that lessens heterologous pathway activation, requires additional study. 
Interestingly, in these experiments it became clear that the RKIP inhibitor locostatin also leads to 
an inability to detect RKIP using this method (Fig. 4-1C/D). This finding could be due to several 
factors including epitope masking by steric hindrance of locostatin when bound within RKIP’s 
ligand binding pocket, or increased proteosomal degradation when RKIP is pulled away from 
potential binding partners by locostatin.   
Next, we sought to better understand RKIP function after PRR triggering. Based on previous 
work demonstrating the RKIP can act as a negative regulator of MAPK signaling in vitro, and 
given the rapidity of RKIP’s “disappearance” seen in Figure 4-1, we hypothesized that perhaps it 
was essential for RKIP to be degraded in order to provide the release of inhibition necessary for 
TLR signaling to proceed. Additionally, because of the transient nature of this effect, we also 
hypothesized that pre-synthesized RKIP mRNA must be present within the cell in order to 
bypass de novo transcription, a process which typically requires at least several hours to generate 
a biologically observable effect (205). Our data show that RKIP’s disappearance on immunoblot 
is not robustly affected by pre-treatment with the pan-proteosomal inhibitor lactacystin (Fig 4-
3B). This does not rule out the possibility of another form of protein degradation with an 
endogenous peptidase; however, a bioinformatic analysis using ExPASy-peptide cutter 
exemplifies that RKIP lacks putative cleavage sites for caspases 1 through 10, factor Xa, 
thrombin, and granzyme B (Table II). RKIP detectability was also not robustly affected by pre-
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treatment with either the transcriptional inhibitor actinomycin D or the translational inhibitor 
cyclohexamide (Fig. 4-3A) after TLR ligation. Additionally, we tested if RKIP was secreted after 
TLR ligation in splenocytes by immunoblotting for RKIP in the supernatants from these cultures 
and found that they were devoid of detectable RKIP (data not shown). Based on these data, we 
concluded that intracellular levels of RKIP were most likely staying relatively constant after 
PRR triggering. Given this, we next determined that it was necessary to investigate RKIP by 
utilizing immunofluorescence which would provide us the opportunity to visualize RKIP over 
the time of our stimulation, and could potentially corroborate our immunoblot findings. It is 
shown by immunofluorescence not only that RKIP was still observable after TLR4 ligation, but 
also that the staining pattern became very punctate in nature instead of cytoplasmically diffuse 
(Fig. 4-4A). This observation suggests that RKIP is more likely being recruited to a signaling 
complex after stimulation, rather than being degraded and resynthesized. Because RKIP has only 
been previously described as a negative signaling regulator, these data also imply a dual role for 
RKIP in that it may additionally act in a positive manner to promote signal transduction, perhaps 
as a scaffold protein. Furthermore, after utilizing a subcellular fractionation method in place of 
traditional whole cell lysis, we were able to find RKIP within “nuclear” fractions after LPS 
stimulation (Fig. 4-4B). As aforementioned, these fractions are highly contaminated by proteins 
that are associated with cytoplasmic and organelle membranes, especially proteins contained in 
lipid rafts. This type of signaling architecture is exceptionally common for MAPK transduction, 
which recruits signaling complexes to the plasma membrane by KSR (206), endosomes via MP1 
(207) and β-arrestin (208), endoplasmic reticulum by ERi1 (209), and to the golgi apparatus via 
Sef (210). This is especially significant given that RKIP also contains a pleckstrin homology 
domain, which is necessary for recruitment and binding to lipids (Table II). It is difficult to 
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determine at this time with absolute confidence whether RKIP is located within the nucleus or in 
one of these membrane-associated signaling complexes, given the fact that RKIP also has a 
putative nuclear localization sequence (Table II). Further studies using better imaging 
approaches such as confocal or two-photon microscopy are required to co-localize RKIP with 
proteins of known location and function.                       
RKIP has been previously described as a negative regulator of MAPK activation through the 
interaction with Raf-1, MEK, and ERK. This pathway is critical for generating pro-inflammatory 
cytokines through the induction of Elk-1 and the transcription of Fos which, when combined 
with the protein Jun, form the transcription factor AP-1 (211). By measuring phosphorylated-
ERK (active) in our studies, we were able to demonstrate that RKIP and p-ERK are indeed 
inversely proportional to one another, giving weight to these prior studies (Fig. 4-1C/D). 
Surprisingly, even though pERK levels increase as RKIP decreases, a genetic deletion of RKIP 
or exogenous blockade did not translate into increased cytokine levels (Fig. 4-6). RKIP has 
previously been shown to modulate its substrate affinity after phosphorylation by PKC from Raf-
1 to GRK2, thus allowing for the transduction of both the Raf-MEK-ERK axis and G-protein 
coupled receptors through disinhibition (212). Given this, it is possible that after TLR 
stimulation, RKIP also switches affinity away from Raf-MEK-ERK and to another 
(MyD88/TRIF) pathway allowing both to proceed simultaneously and cooperatively with 
subsequent cytokine production. However, if RKIP is lost completely or is prevented from 
functioning properly, this could result in an effect that only allows one of two pathways (ERK) 
to transduce a signal without the cooperation of the other. This could effectively override the 
high levels of p-ERK and lead to poor cytokine responses. In other words, it may “take two to 
tango” in regards to cytokine production, with the possibility that RKIP is utilized to assist in 
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pathway cooperativity. A bioinformatic analysis of putative post-translational modification sites 
revealed that RKIP has 2 glycosylation sites and at least 32 phosphorylation sites, 13 of which 
have higher predictability scores than the validated PKC Ser153 phosphorylation site (Table II). 
This suggests that there are numerous possibilities in terms of altered RKIP substrate affinity that 
have yet to be described. Another alternative explanation for the p-ERK-cytokine disconnect 
would be that exceedingly high levels of p-ERK transmits a negative, instead of a positive, signal 
to the cell through a negative feedback loop. This hypothesis is less likely because it would 
require the strength of this suppressive signal mediated by p-ERK to shut down normal pro-
inflammatory cytokine production through MyD88 and TRIF signaling which prototypically 
does not involve the Raf-MEK-ERK axis, but rather the JNK and p38 MAPKs.    
TLRs have been implicated in the pathogenesis of several human inflammatory diseases 
including: SIRS/sepsis (213), atherosclerosis (214), inflammatory bowel disease (215), 
rheumatoid arthritis (216), asthma (217), systemic lupus erythematosus (36), and 
ischemia/reperfusion injury (218). To this end, therapeutic agents have been developed to 
decrease the inflammation seen after TLR stimulation by exogenous or endogenous ligands, and 
several have been examined in human clinical trials. These include the TLR4-TIRAP small 
molecule inhibitor TAK-242 (resartorvid) for sepsis and SIRS (219, 220) and chaperonin-10 
(Cpn-10) for RA (221) and SLE (currently recruiting). Many other pharmaceutical companies, 
such as Coley, Dynavax, and VentiRx, currently have TLR antagonists in their respective pre-
clinical study pipelines as well (222). RKIP may represent a potential novel therapeutic target 
option for these diseases, given that its targeted inhibition using an already commercially 
available small molecule inhibitor leads to decreased cytokine responses are TLR stimulation. 
However, a more thorough understanding of RKIP’s exact molecular mechanism for facilitating 
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PRR responses is needed in order to provide the amount of evidence necessary to proceed into 
human disease trials.                                    
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Figure 4-1: Stimulation of wild type splenocytes with LPS leads to a time and dose 
dependent disappearance of RKIP protein. (A) Representative immunoblots of bulk 
splenocyte lysates from wild type C57BL/6J mice kept either on ice in balanced salt solution 
(BSS) or cultured in BSS at 37°C & 5% CO2 for 10 min. or 60 min. (data not shown) in the 
presence or absence of 10μg/ml LPS, 50μM of the RKIP inhibitor locostatin, or both. Dimethyl 
sulfoxide (DMSO) at the same percent (v/v) as locostatin (~0.1%) was utilized as a vehicle 
control. (B) Densitometric quantification of RKIP expression from 4 independent experiments 
conducted similarly to Figure 4-1A. RKIP expression was normalized to the loading control 
(Actin) to generate an RKIP/Actin ratio, and then the relative quantity of RKIP protein was 
determined by setting the ratio of each medium control to 100. Error bars represent SEM and P 
values determined by unpaired t test between groups *P<0.05. (C) Immunoblots for RKIP and 
phosphorylated ERK-1/2 from lysates of wild type bulk splenocytes that were cultured as in 
Figure 4-1A for 10 min. in the presence of various quantities of LPS (range: 1.56-50μg/ml) or 
medium alone. (D) Densitometric quantification of RKIP and p-ERK expression from 
immunoblot in Figure 4-1C. Data are represented as relative abundance between pERK and 
RKIP protein levels.  
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Figure 4-2: The inability to detect RKIP protein after PAMP stimulation is generalizable to 
multiple TLR ligands. (A) Representative immunoblots of RKIP and Actin protein from lysates 
of wild type splenocytes stimulated for 10 min. or 90 min. with titrations of the following TLR 
ligands: TLR9- CpG type A (0.33-27μg/ml), TLR9- CpG type B (0.33-27μg/ml), TLR3- Poly 
I:C (0.33-81μg/ml), TLR4- LPS (0.33-81μg/ml), and TLR1/2- Pam3CSK4 (0.33-81μg/ml). 
Medium controls (M) were utilized for Poly I:C, LPS, and Pam3CSK4 stimulations, and ODNs 
containing GpC dinucleotides (**) were used as negative controls for CpG-A, and CpG-B 
stimulations. (B) Densitometric quantification of RKIP protein levels from 10 min. (closed 
circles) and 90 min. (open circles) stimulations in Figure 4-2A. Data are presented as relative 
RKIP expression normalized to actin as described in Figure 4-1B.         
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Figure 4-3: Proteosomal degradation and de novo translation impart only minor 
contributions to the disappearance of RKIP. (A) Representative immunoblots of wild type 
bulk splenocytes stimulated with LPS (50μg/ml) or medium alone for 10 min. or 90 min. in the 
presence of the transcriptional inhibitor actinomycin D (100ng/ml) or the translational inhibitor 
cyclohexamide (10μg/ml).  (B) Immunoblot of bulk wild type splenocytes treated similarly to 
Figure 4-3A in the presence or absence of the proteosomal inhibitor lactacystin (2μM). (C) 
Densitometric quantification of RKIP protein levels from experiments outlined in Figures 4-
3A/B. Data are presented as relative RKIP expression normalized to actin as described in Figure 
4-1B.   
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Figure 4-4: The disappearance of RKIP protein after PAMP stimulation may be due to 
insoluble complex formation or altered subcellular localization. (A) Immunofluorescent 
images of RKIP (green) from wild type bulk splenocytes cultured with either medium or LPS 
(50μg/ml) for 10 min. Data are from 2 independent experiments. (B) Wild Type bulk splenocytes 
were stimulated for 10 min. or 90 min. in the presence or absence of LPS (25μg/ml). Lysates 
from these cultures were generated using the NE-PER subcellular fractionation kit (Thermo 
Pierce) which separates cellular protein content into “cytoplasmic” and “nuclear” fractions. 
These lysates were immunoblotted for RKIP protein or Hsp90 as a cytoplasmic protein control. 
Data are representative images of 5 independent experiments.       
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Figure 4-5: Loss of RKIP by genetic knockout or exogenous blockade leads to altered 
cytokine and chemokine responses after TLR stimulation. (A) Multiplex cytokine analysis of 
bulk mesenteric lymph node (MLN) cells from RKIP-/- or wild type littermate mice stimulated 
with CpG-A (9μg/ml) overnight in vitro. Data are represented as relative abundance with the 
value of each analyte in wild type littermate stimulations being normalized to 100. (B) ELISA 
for IL-6 and TNFα protein in culture supernatants from wild type bulk splenocytes treated 
overnight with medium, LPS (50μg/ml), or CpG-A (9μg/ml) in the presence of vehicle (DMSO) 
or locostatin (50μM). Error bars represent SEM and P values determined by unpaired t test 
between groups using Welch’s correction for variable standard deviations *P<0.05, **P<0.01. 
Data are from 2 independent experiments; N=4/group total.      
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TABLE II: Bioinformatic Analysis of RKIP in Mus musculus 
 
Prediction 
 
Sequence (Site) 
 
Score 
 
Algorithm 
 
Reference  
PBP Family Sig. YTLVLTDPSRKDPKFREWHH (64) N.A. Predict Protein 
Rost et. al. Nucleic 
Acids Research. 
W321-326 (2004) 
Localization Cytoplasmic N.A. LOCkey 
Nuclear 
Localization 
Sequence 
RGKFKVETFRKK N.A. PredictNLS 
Nair. et al. EMBO 
Reports. 1(5): 411-
415 (2000)  
Peptidase 
Cleavage  
No Caspase (1-10), 
Factor Xa, Thrombin, or 
GzB sites found 
N.A. ExPASy-Peptide Cutter 
Gasteiger et. al. The 
Proteomics 
Protocols Handbook, 
Humana Press. 
(2005) 
Asn (N)-
Glycosylation NKSG (140) 
0.6721 
(>0.5 confidence 
threshold) 
NetNGlyc v1.0 
Gupta et. al. Pacific 
Symposium on 
Biocomputing 
7:310-322 (2002) 
O-Glycosylation None N.A. NetOGlyc v3.1 
Steentoft et. al. 
EMBO 32(10):1478-
88 (2013). 
PKCα/β/γ 
Phosphorylation 
RGKVETFRKKYNL* 
(153) 
0.114% 
(<0.2% high 
confidence) 
Scansite v2.0 
Motif Scan 
John et. al. Nucleic 
Acid Res. 
31(13):3656-3641 
(2003). 
PKCζ 
Phosphorylation 
RGKVETFRKKYNL* 
(153) 
0.003% 
(<0.2% high 
confidence) 
PIP3-binding 
domain (PH) 
GKFKVETFRKKYNL 
(154) 
0.112% 
(<0.2% high 
confidence) 
Serine 
Phosphorylation** 
MNRPSSISW (51) 0.849 
NetPhos v2.0 
Blom et. al. J. Mol. 
Biol. 294(5):1351-
1362 (1999) 
NRPSSISWD (52) 0.995 
PSSISWDGL (54) 0.984 
PDAPSRKDP (75) 0.998 
SGPPSGTGL (113) 0.891 
EQPLSCDEP (132) 0.780 
EPILSNKSG (139) 0.958 
LSNKSGDNR (142) 0.734 
YEQLSGK (185) 0.813 
 (>0.5 confidence threshold) 
Threonine 
Phosphorylation† 
YAGVTVDEL (33) 0.846 
GKVLTPTQV (42) 0.702 
FKVETFRKK (153)* 0.724 
PVAGTCYQA (167) 0.515 
 (>0.5 confidence threshold) 
Tyrosine 
Phosphorylation‡ 
VLSDYVGSG (106) 0.624 
EWDDYVPKL (176) 0.979 
 (>0.5 confidence threshold) 
  
* Thr (Ser) 153 phosphorylation site validated in: Lorenz et. al. Nature 426, 574-579 (2003). 
** 14 Predicted p-Ser sites; (9/14 have higher predictability than Thr/Ser153) 
† 9 Predicted p-Thr sites; (2/9 have higher predictability than Thr/Ser153) 
‡ 9 Predicted p-Tyr sites; (2/9 have higher predictability than Thr/Ser153) 
N.A. = not acquired 
  
101 
 
 
 
 
 
 
CHAPTER 5 
 
RKIP IS NECESSARY FOR THE GENERATION OF OPTIMAL TYPE I INTERFERON 
RESPONSES DURING B CELL ACTIVATION BY TLR LIGANDS     
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ABSTRACT 
The activation of APCs by TLR ligands is critical for the host’s initial response to pathogenic 
invasion, and the robust inflammatory response generated by these interactions has been 
harnessed as a means to enhance the adjuvanticity and effectiveness of vaccine-based therapies. 
However, if these responses are directed against endogenous ligands, such as host nucleic acid, 
autoimmunity can result, leading to significant morbidity in patients. B lymphocytes play an 
underappreciated role in facilitating both advantageous adjuvant responses and deleterious 
autoimmunity through the production of protective or destructive antibodies. Interventions that 
can affect the response of B cells to TLR ligands could provide a useful therapeutic tool for 
autoimmune diseases, or provide valuable insight into B cell adjuvant reactions. Previous data 
from our laboratory suggest that RKIP may play an important role in the generation of cytokines 
after TLR ligation in splenocytes; nevertheless, RKIP’s functional impact on B cell responses to 
PAMPs has not been studied. Here we demonstrate that loss of RKIP results in an attenuated 
TRIF-type I IFN transcriptome signature in steady state B cells. This leads to a deficiency in the 
generation of IFNα and the interferon-stimulated chemokine CXCL10 in response to TLR3 
stimulation with Poly I:C, despite the normalization of many transcripts after TLR-triggering. 
Additionally, by blocking RKIP with the small molecule inhibitor locostatin, type-I interferon 
responses could also be significantly diminished in wild type B cells, providing evidence that 
RKIP may prove to be a valuable therapeutic target for inflammatory diseases potentiated by B 
cells and type-I IFNs.       
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INTRODUCTION 
The largest constituency capable of acting as APCs within the spleen are B lymphocytes. B cells 
are responsible for the production of antibodies that help to protect the host eliminate invading 
pathogens, but if directed against inappropriate self or innocuous targets, these autoantibodies 
can initiate both systemic and localized inflammatory reactions through antibody-dependent 
cellular cytotoxicity or immune complex deposition (223). B cell antibody production is also 
critical for prophylactic vaccination against many viral and bacterial pathogens (224), and more 
recently even parasitic infections and certain cancers (225, 226). Besides the generation of both 
protective and destructive adaptive antibody responses, B cells are also important in pathogen 
recognition through innate PRRs, antigen presentation and activation of cognate T cells, and 
even the production of many pro-inflammatory cytokines and chemokines (IL-6, TNF, Type I 
IFNs, CCL2,3,4,5, CXCL10, etc.) that bolster immune responses (227). Thus B cells intersect 
adaptive and innate immune pathways.  
Because of the pleiotropic effects that B lymphocytes exert on the overall immune response, 
having the ability to therapeutically target RKIP in B cells and decrease cytokine production 
during auto-inflammatory diseases may provide a useful alternative to direct B cell ablation with 
traditional anti-CD20 therapies like rituximab (228). This therapeutic approach can lead to 
significantly adverse events including tumor lysis syndrome, cardiac arrest, renal failure, and 
progressive multifocal leukoencephalopathy (229). Previous data from our laboratory 
demonstrate that RKIP may play an important role in the generation of cytokines during serial 
TCR engagement in T cells and after TLR ligation in splenocytes; however, RKIP’s functional 
impact on B cell responses, and specifically to PAMPs, is currently unknown.   
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It is shown that RKIP is utilized downstream of TLR signaling in B cells, and that it is necessary 
for the maintenance of TRIF-Type-I IFN transcriptomic gene signature. Specifically, through 
genetic disruption of the RKIP gene in B cells, and through its exogenous inhibition using the 
small molecule inhibitor locostatin, we demonstrate that the proper function of RKIP is 
necessary for optimal production of IFNα and the interferon stimulated chemokine CXCL10 
after exposure to the nucleic acid adjuvant Poly I:C. Due to the critical nature of Type-I IFN 
responses in anti-viral immunity, augmentation of Th1 and CTL reactions, contextual immune 
suppression, and enhancement of B cell function after PAMP sensing, the ability to 
therapeutically inhibit these responses affords a unique opportunity to help control inappropriate 
immune reactions that lead to human disease. Finally, these studies provide new insight into the 
basic mechanisms of nucleic acid adjuvant usage by B cells, and how RKIP may be important 
for the maintenance of these responses during vaccination.   
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RESULTS 
Since RKIP was involved in the TLR4 response (chapter 4), we hypothesized that after TLR 
ligation, RKIP is transiently recruited to a membrane-associated signaling complex. The 
functional significance of this interaction was decreased cytokine output after loss of RKIP 
through genetic interruption or by therapeutic blockade. In light of these findings, we next sought 
to determine the specific nature of the lesion that exists in the absence of RKIP in the context of 
TLR ligation. Clinically, this is a very important question given RKIP’s impact on cytokine 
production during PRR ligation because it could potentially open the door to both a novel 
therapeutic strategy for inflammatory diseases and could shed light on the importance of RKIP 
during vaccine-adjuvant based interventions.  
Loss of B cells abrogates the disappearance of RKIP after LPS stimulation  
In order to choose a model to best study the effects of RKIP loss during TLR responses, we 
established four major criteria: 1) select a cell population that played an important and 
established role in human inflammatory diseases, 2) test cells that were important for vaccine-
adjuvant based therapies, 3) study a population that feasibly allowed testing of enough cells to 
undertake a systems approach to examine the role of RKIP, and 4) the cells chosen must also 
exhibit the same phenomenon of RKIP disappearance after TLR ligation seen in the chapter 4 
data set. B lymphocytes were best suited to satisfy these criteria because they are known to be 
critical players in many auto-inflammatory conditions such as RA and SLE, they are critical for 
the production of protective antibodies during vaccine-based therapies by responding to 
adjuvants like monophosphoryl lipid A (MPL), and they make up 40-50% of the splenocytes cell 
mass thus providing a feasible number of cells for various experimental techniques (230-235). 
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Finally, we stimulated bulk splenocytes from wild type, TCR-βδ-/- (no T cells), and RAG-1-/- 
mice (no B or T cells) and found that the RKIP disappearance after TLR4 ligation with LPS was 
greatly diminished when B cells were absent (RAG-/-) but was retained when only T cells were 
depleted (βδ-/-), suggesting that B cells were a major contributor to the phenomena outlined in 
chapter 4 (Figure 5-1A; compare 0 to 50μg LPS). 
RKIP-/- B cells have higher basal levels of phosphorylated-ERK and TLR4/TLR9 
engagement leads to transient disappearance of RKIP protein and reciprocal increases in 
p-ERK in B cell enriched populations 
In order to test the role that RKIP plays in TLR responses in B cells, we began by purifying 
naïve “untouched” steady state splenic B cells by magnetic bead negative selection against CD4, 
CD43, and Ter119 (B cell isolation kit, Miltenyi Biotec). This method results in a highly 
enriched B cell population (~95 ± 2% by CD19 and CD45R expression) that is largely devoid of 
NK cells (data not shown), CD8 and CD4 T cells, CD11b+ monocytes (Figure 5-1B). After 
purification, approximately 1-2% of the remaining cells are CD11c+, so we cannot rule out the 
possibility that some plasmacytoid and other dendritic cell populations may still be contributing 
to any effect seen, but they are massively outnumbered by B cells. Using this B cell enriched 
population we determined whether p-ERK aberrations existed when RKIP was knocked out. We 
examined B cells directly ex vivo from wild type or RKIP-/- mice and found that there were 
higher amounts of basal p-ERK levels in B cells devoid of RKIP by immunoblot (Figure 5-2A). 
Next, we wanted to determine if this B cell enriched population behaved similarly to bulk 
splenocytes in response to TLR ligation. To test this, we treated wild type B cells with 9μg/ml 
CpG-B, 50μg/ml LPS, or vehicle alone and harvested cells 10 min, 1 h, 2 h, 4 h, or overnight 
after stimulation. We observed that B cells, after stimulation with CpG-B, a TLR ligand with a 
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penchant for B cells, begin to have significant amounts of p-ERK after about 1 h and these levels 
increase to a maximum at 4 h post stimulation (Figure 5-2B). This maximum p-ERK is preceded 
by a moderate decrease in RKIP at 2 h post stimulation, which is consistent with the data in 
Figure 4-2A/B. After TLR4 ligation with LPS, however, p-ERK is maximally induced at 1 h 
after stimulation and decreased thereafter. Consistent with our findings in bulk splenocytes 
presented in chapter 4, this high p-ERK is preceded by a transient disappearance of RKIP 10 min 
after TLR4 ligation (Figure 5-2C). Taken together, these data show these splenic B cell enriched 
populations perform similarly to bulk splenocytes in the context of RKIP’s behavior after TLR 
ligation.    
LPS and CpG-B drive divergent B cell cytokine programs partially controlled by RKIP 
Next, we wanted to test whether RKIP was necessary for cytokine production in response to LPS 
and CpG-B in our enriched B cell population. Therefore, we treated wild type and RKIP-/- B cells 
with medium (data not shown), LPS, or CpG-B overnight, and subjected the supernatants from 
these cultures to multiplex cytokine array analysis. The vast majority of cytokines were made 
similarly between wild type and RKIP-/- (Figure 5-3A), and some were not produced in response 
to either CpG-B or LPS including: IL-3, IL-4, IL-5, IL-7, IL-12, IL-13, IL-17, IFNγ, M-CSF, 
Eotaxin, CXCL5, and LIF (data not shown). Of the cytokines that were different, most were 
decreased in RKIP-/- B cells compared to wild type, except for CCL5 in response to CpG-B, and 
IL-2 in response to LPS (Figure 5-3B). Also, we observed that the cytokine programs that were 
generated in response to LPS and CpG-B varied from one another. For example, CpG-B, which 
has previously been described as a strong stimulator of B cell responses (236), was much more 
potent at inducing pro-inflammatory cytokines such as: IL-1α/β, IL-6, TNFα, GM-CSF, and IL-
9. Also, CpG-B induced high quantities of CCL2, CCL3, and CCL4 chemokines compared to 
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LPS (Figure 5-3C). In contrast, LPS was able to potently stimulate CXCL10 and CCL5 
chemokines more than CpG-B, which implies that these chemokines are more likely to be 
associated with TRIF stimulation rather than MyD88. Given the vastly different cytokine profiles 
in response to stimulation through MyD88 alone or in conjunction with TRIF, we next tried to 
validate these findings by conventional ELISA by testing Poly I:C in order to examine TRIF 
stimulation. We stimulated our naïve splenic B cell enriched populations with medium, LPS, 
Poly I:C, or CpG-B overnight and measured IL-1β, CCL2, CCL3, CCL5, and  CXCL10 in the 
culture supernatants. We also measured the type I interferons IFNα, and IFNβ, given that our 
multiplex array suggested a potential effect in the TRIF pathway. We found that several 
cytokines were lower than the lowest limit of detection by conventional ELISA after TLR 
ligation including IL-1β, CCL2, and IFNβ (data not shown). CCL3, which had no genotype 
effect in our multiplex array, also showed no difference by ELISA (Figure 5-3D). When testing 
for CCL5, CXCL10, and IFNα, we found that RKIP-/- B cells made less of these cytokines 
compared to wild type (Figure 5-3D & Figure 5-8B), but only when the TRIF signaling pathway 
was driven alone with Poly I:C. Taken together, these data suggest that RKIP may be necessary 
for TRIF-dependent cytokine production. 
Naïve RKIP-/- B cells have an attenuate transcriptome which normalizes rapidly after TLR 
ligation with LPS or CpG-B      
In order to better understand the altered cytokine responses in B cells devoid of RKIP, we 
isolated total mRNA from wild type and RKIP-/- B cells that were naïve or stimulated for 1 h in 
vitro with either LPS or CpG-B for RNA sequencing. Interestingly we found that in naïve B 
cells, 884 genes (3.7% of total) were significantly different in RKIP-/- compared to wild type 
(Figure 5-4C). Of these 884 genes that were significantly different, 870 were reduced in the 
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RKIP-/- B cells compared to wild type, suggesting that in the absence of RKIP, these cells have a 
transcriptome that is attenuated at baseline (Figure 5-4A). However, when RKIP-/- B cells were 
stimulated with either LPS or CpG for just 1 h, their transcriptomes became largely normalized 
compared to wild type (Figure 5-4B). LPS seems to have a slightly stronger effect on 
transcriptome normalization compared to CpG-B, most likely because of its ability to trigger 
both the MyD88 and TRIF pathways simultaneously. In fact, after stimulation, the majority of 
significantly altered genes in RKIP-/- B cells were increased rather than decreased, suggesting 
that even though RKIP-/- B cells may start at a disadvantage at the mRNA level, the 
transcriptome can be rapidly normalized, or even exhibit slightly higher induction of some genes 
after TLR ligation (Figure 5-4C).  
Pathway analysis of altered genes in RKIP-/- B cells reveals an enrichment of pathways 
involved in mitochondrial function, TLR signaling, and cytokine responses 
Next, we wanted to determine whether the genes that were significantly different in untouched 
RKIP-/- B cells were restricted to specific pathway alterations, or if the transcriptome attenuation 
was a global effect on all pathways. In order to test this, we subjected all of the genes that were 
statistically significantly different between wild type and RKIP-/- and had a log2 (fold change) 
greater than ± 1.2 (absolute fold change greater than ± 2.3) to pathway analysis using the 
Ingenuity Pathway Analysis (IPA) software algorithm. IPA identified 371 pathways that 
contained at least one of our genes of interest, of those 371, 98 had enrichment not due to chance 
(Table III).  The most significantly enriched pathways in RKIP-/- B cells were those that were 
important for mitochondrial function, TLR signaling, and cytokine responses (Figure 5-5A). 
Additionally, pathways important for proliferation, apoptosis, and co-stimulation were also 
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enriched, but to a lesser degree. Most of these canonical pathways share important genes 
between them, which could explain why they showed similar enrichment. 
RKIP-/- B cells do not have significantly altered basal or maximal mitochondrial respiration 
before or after stimulation with TLR ligands     
Our IPA analysis determined that the most significantly enriched pathway in RKIP-/- B cells was 
composed of 22 different genes important for mitochondrial function. These genes were 
comprised of components of each of the major complexes involved in the electron transport 
chain, as well as, several associated kinases known to modulate their function (Table IV). 
Because all of the identified genes were decreased in B cells devoid of RKIP, we hypothesized 
that oxidative phosphorylation may also be diminished, and may be a contributing factor to 
decreased cytokine output. Also, given recent evidence that metabolic products can post-
transcriptionally regulate cytokine translation (237), we thought it necessary to test the 
mitochondrial function of RKIP-/- B cells. In order to determine if loss of RKIP played a role in 
oxidative phosphorylation, we stimulated B cells from wild type (C57BL/6J), RKIP-/-, RKIP+/-, 
and RKIP+/+ mice with LPS, CpG-B, Poly I:C, PMA + ionomycin, or medium alone for 1 h, and 
then analyzed their rate of oxygen consumption (OCR) on the Seahorse XF96 extracellular flux 
analyzer which measures several parameters of mitochondrial function (Figure 5-6A). We 
observed no significant differences in either the basal OCR (Figure 5-6B) or maximum OCR 
(Figure 5-6C) between groups regardless of stimulation. Thus, 1 h after TLR stimulation no 
difference was seen but it is possible that during the stimulation metabolic differences occurred, 
but this was not tested. It remains open that early during stimulation, metabolic changes may 
occur, but if so, this did not last past 1 h. 
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Steady state RKIP-/- B cells have an attenuated TRIF-Type I Interferon transcriptome 
signature        
After demonstrating that mitochondrial function was relatively normal in RKIP-/- B cells, we 
next re-examined the RNA sequencing data and IPA pathway analysis to assess the TLR 
signaling pathways. We observed by RNAseq that untouched naïve RKIP-/- B cells exhibited a 
decreased TRIF-type I interferon gene signature that included significant reductions in upstream 
mediators of type I interferon generation including: Ticam1 (TRIF), Traf3, Irf3, Irf5, Irf7, Ikbke 
(IKKε), as well as a subunit of the type I interferon receptor (Ifnar1). Other pathway members 
including: Tmem173 (STING), Tram, Tank, Tbk1, and Mavs (IPS-1) were also reduced, but not 
significantly so (Figure 5-7A, left panel). Naïve B cells devoid of RKIP also had significant 
reductions in Tlr3 and Tlr9 transcript levels, but the rest of their PRRs were, for the most part, 
intact (Figure 5-7A, right panel). Additionally, the MyD88 and NF-κB signaling pathways were 
also somewhat decreased, but this was less robust compared to the TRIF-type I interferon 
pathway (Table V). Importantly, after stimulation with either LPS or CpG-B for 1 h, we 
discovered that the vast majority of gene transcripts that were affected at baseline had 
normalized to wild type levels, with the exception of Irf7 after CpG-B stimulation (Table VI). To 
avoid the complication of using disadvantaged RKIP-/- B cells, we employed locostatin to test 
RKIP inhibition in wild type cells. We found that after 2 h of Poly I:C stimulation in wild type B 
cells, in the presence of absence of the RKIP inhibitor locostatin, there was no significant 
difference in the transcript levels of Irf3, Irf5, Irf7, Traf3, Tbk1, Ikbke, or Ifnar1 between B cells 
with RKIP inhibition or none (Figure 5-7B). Nevertheless, RKIP inhibition had an effect on Ifna 
transcription when wild type B cells were pretreated with locostatin prior to Poly I:C stimulation. 
The amount of Ifna mRNA was significantly reduced 1-2 h after stimulation compared to vehicle 
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pre-treated B cells (Figure 5-7C). However, after approximately 6 h post stimulation, the 
transcript levels of Ifna were indistinguishable between groups. Taken together these data 
suggest that RKIP may be important for the early induction of Ifna, but there are mechanisms in 
place that allow the transcript levels of this gene to approximate normal with a sustained 
stimulus.  
RKIP optimizes IFNα synthesis and the Type I IFN stimulated chemokine CXCL10 
following TLR3 ligation   
In order to determine whether the perturbations in TRIF-type I interferon seen in RKIP-/- B cells, 
or RKIP blockade, had any functional consequences, we tested cytokine output from these 
pathways. First, enriched B cells populations from wild type and RKIP-/- mice were stimulated 
with Poly I:C with or without RKIP blockade for 6 h (data not shown) or overnight and CXCL10 
and CCL5 were measured in the culture supernatants. Consistent with findings in Figure 5-7, we 
found a severely diminished (~30% of wild type) amount of the interferon-stimulated chemokine 
CXCL10 in RKIP-/- B cells after stimulation (Figure 5-8A). In contrast, CCL5, a chemokine only 
partially dependent upon TRIF signaling, was slightly decreased (~70% of wild type). 
Importantly, RKIP blockade in wild type B cells mirrored CXCL10 output from RKIP-/- B cells. 
Nevertheless, locostatin had little to no effect on RKIP-/- B cells, suggesting a moderate degree of 
specificity (Figure 5-8A).  
To test the therapeutic relevance of these findings, we repeated the experiment described in 
Figure 5-8A in wild type B cells alone in the context of type I interferon receptor blockade (anti-
IFNAR1) or isotype control. First, RKIP blockade potently inhibited IFNα production at 6 h in 
culture and during its feed-forward enhancement after overnight (Figure 5-8B). In fact, the 
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reduction IFNα was even greater after overnight culture, suggesting the RKIP may play a role in 
both the initial production of type I interferons, but also in their ability to enhance their own 
production through a feed-forward loop. Consistent with our findings in Figure 5-8A, we also 
found a significant decrease in CXCL10 production from wild type B cells after RKIP inhibition, 
and to a lesser degree CCL5 (Figure 5-8B). Importantly, in the presence of type-I interferon 
receptor blockade CXCL10 production was abolished, demonstrating its dependence on type-I 
interferon signaling. In contrast, CCL5 production was independent of IFNAR blockade. Taken 
together, these data suggest that RKIP may be a valuable therapeutic target to inhibit the 
production of type I interferons and their associated downstream effectors during TLR responses 
in APCs.   
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DISCUSSION 
B cells are well known to impact vaccine development due to their antibody producing capacity, 
they are nevertheless understudied cytokine producing cells that may contribute to vaccine 
adjuvanticity and the potentiation of autoimmune diseases (238-241). One way B cells can 
contribute to adjuvant responses is by producing cytokines in response to PAMPs (121, 238, 242, 
243). Through these interactions, B cells can be significant producers of both cytokines and 
chemokines which contribute to the establishment of the inflammatory milieu and chemotactic 
locomotor gradients (244, 245). Recently, there have been renewed efforts to better utilize B cell 
responses to nucleic acid adjuvants to foster vaccine development for HIV, malaria, intracellular 
pathogens, and other emerging infections (238, 246, 247). A successful application of this 
strategy has been the mechanistic reexamination of the YF-17D vaccine against yellow fever 
causing Flaviviridae which provides protection through TLR7 ligation and Type-I IFN 
production (248-250).  Analogously, B cell depleting agents such as Rituximab (anti-CD20 
mAb) have been utilized as a successful treatment modality for autoimmune diseases such as 
rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and many others (233, 
251). What both of these reactions have in common is the necessity of B cells to respond to 
initial triggering through their PRRs in order to produce productive reactions in vitro and in vivo 
(252). 
Previous data from our laboratory implicated RKIP as an important molecule for productive 
cytokine responses after TLR signaling in splenocytes, yet the role that RKIP plays in these 
critical initiating events of PRR ligation in B cells is unknown and provides a fertile area of 
study. We initially observed that depleting B cells from our bulk splenocyte populations using 
RAG-/- mice abrogated our central finding in chapter 4 (i.e. the “disappearance” of RKIP shortly 
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after TLR ligation), while losing only T cells (βδ-/- mice) kept this phenomenon intact (Fig. 5-
1A). The fact that B cells exhibited similar responses to bulk splenocytes, in terms of RKIP after 
LPS and CpG stimulation and high basal p-ERK levels when lacking RKIP, verified that this cell 
population was at least a significant contributor to our findings in chapter 4 (Fig. 5-2A-C). 
However, because our method to enrich naïve splenic B cell populations does not robustly 
deplete CD11c+ cells (Fig. 5-1B), it prevents us from ruling out the possibility that conventional 
and plasmacytoid dendritic cells might also play a role in our studies. Although the likelihood of 
pDC effects may be marginal given that they do not express TLR3 (253) and that TLR9 ligation 
leads to IFNα production through IKKα and IRF7 (42), which was not seen in our studies (Fig. 
5-3D).                   
Upon investigation of the cytokine milieu driven by either LPS or CpG-B in B cells, we 
observed vastly divergent outputs depending on the nature of the ligand. CpG-B was much more 
potent than LPS in inducing pro-inflammatory cytokine production including IL-1, IL-6, TNF, 
GM-CSF, and others. However, LPS stimulated B cells were more efficiently able to produce 
factors normally associated with TRIF, namely CXCL10 and CCL5 (Fig. 5-3C). Interestingly, 
RKIP seemed to be more important for the cytokine output in response to CpG-B, rather than 
LPS, in B cells (Fig. 5-3B). This could be due to several factors including the ability of LPS to 
signal through both MyD88 and TRIF, potentially giving this stimulus a way to circumvent small 
signaling lesions due to heterologous pathway activation. Consistent with this hypothesis, when 
inducing the TRIF pathway alone with the dsRNA Poly I:C, we observed attenuated production 
of several TRIF-associated cytokines including IFNα, CXCL10, and CCL5, but not CCL3 which 
is made indiscriminately in response to NF-κB activation (Fig 5-3D). Nevertheless, consistent 
with Figure 4-5A, RKIP-/- cells were altered in their output of some cytokines but not others. 
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Because the generation of many cytokines is dependent on the cooperative nature of several 
pathways, it becomes very difficult to pinpoint the exact location of RKIP function.     
In order to better understand the molecular mechanisms of these differential adjuvant responses, 
as well as to garner new insights into how RKIP affects cytokine production from B cells, we 
utilized total transcriptome RNA sequencing of naïve, LPS, and CpG-B stimulated B cells from 
wild type and RKIP-/- mice. This approach has, to our knowledge, not been previously utilized to 
interrogate the RKIP pathway during TLR signaling. Through RNAseq, we discovered that the 
vast majority (~96.2%) of mRNAs were unaffected in RKIP-/- B cells. However, there were 884 
mRNAs that had significantly different expression levels in naïve RKIP-/- B cells compared to 
wild type, and interestingly, of these mRNAs, 870 (98.4%) were decreased in RKIP deficient 
cells (Fig. 5-4A). Importantly, we also observed that within 1 hour of TLR ligation with either 
LPS or CpG-B many of these transcripts normalize to wild type levels, or in some cases, are 
induced even higher than wild type (Fig. 5-4B/C). This suggests that RKIP-/- B cells, may start 
off at a signaling disadvantage due to their partially attenuated transcriptome, but may catch up, 
at least at the level of transcription, over time. This is an excellent example of why it is difficult 
to compare a knockout mouse to wild type due to a disadvantage in the steady state, even though 
there is no obvious phenotypic defect. 
In order to determine if the affected transcripts from our RNA sequencing analysis were 
evidence of specific pathway alterations or stochastic changes within the transcriptome, we used 
Ingenuity’s pathway analysis (IPA) in conjunction with the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) to mine for enrichment of particular pathways 
based on our list of altered genes. We discovered that although many canonical signaling 
pathways were affected, there was a significant enrichment in pathways involved in 
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mitochondrial function, TLR signaling, cytokine responses, co-stimulation, and survival (Fig. 5-
5A, Table III). 
Recent findings from Dr. Pearce’s laboratory and others have implicated products involved in 
cellular metabolism as regulators of cytokine production post-transcriptionally (237), as well as, 
from an energetics standpoint (254). Because genes involved in mitochondrial function were the 
most highly enriched pathway within RKIP-/- B cells, we tested the capacity of these cells to 
properly undergo oxidative phosphorylation ex vivo and after stimulation with TLR ligands. 
Despite the fact that loss of RKIP led to a number of decreased transcripts involved in the 
oxidative phosphorylation machinery (Table IV), RKIP-/- B cells had no significant difference in 
their oxygen consumption rates, and thus their ability to undergo oxidative phosphorylation, 
before or after stimulation with LPS, CpG-B, or Poly I:C compared to wild type (Fig. 5-6A/B).  
With mitochondrial dysfunction providing little evidence to explain the aberrations in cytokine 
production, we next turned our attention to evaluating mRNAs involved in TLR signaling. Upon 
examination, we observed that naïve RKIP-/- B cells had a greatly attenuated “Type-I IFN gene 
signature”, previously described by others (255), that included significantly decreased levels of 
Ticam1, Traf3, Irf3, Irf5, Irf7, Ifnar1, Ikbke, and others (Fig. 5-7A). RKIP-/- B cells also had 
lower expression levels of some genes involved MyD88 and NF-κB signaling as well, but to a 
lesser degree (Table V). Interestingly, these cells also had lower basal expression of Cd40, which 
could suggest that in addition to having an attenuated TLR signaling apparatus, these B cells may 
have trouble accepting help from cognate T helper cells through CD40L-CD40 interaction. 
Because it is still unknown exactly how B cells integrate the initial activation events of PRR 
ligation with recognition of antigen through the BCR and T cell help via CD40L, it is unclear 
exactly how large of a disadvantage diminution of two critical signaling events would place 
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RKIP-/- B cells at. Future studies looking at CD40L-mediated help, as well as BCR crosslinking 
effects in the context of these attenuated pathways in RKIP-/- mice should be conducted before 
conclusions can be made regarding effects on the entirety of the B cell response.  
However, as with the broad overview of transcriptomic changes between naïve and TLR 
triggered B cells, most of these deficits in transcript levels are normalized after stimulation, with 
the exception of Irf7 after TLR9 ligation (Table VI). This normalization was confirmed 
independently of RNA seq by qPCR analysis of several genes associated with the Type-I IFN 
signature after Poly I:C stimulation with or without RKIP blockade (Fig 5-7B). Nevertheless, 
despite the correction of genes involved in the Type-I IFN generating signaling machinery, 
transcript levels of Ifna were still decreased until about 6 hours post TLR3 ligation with Poly I:C 
in the presence of RKIP blockade in wild type B cells (Fig. 5-7C). The functional effect of this 
was a significant reduction in both IFNα protein and the interferon-dependent chemokine 
CXCL10 (Fig. 5-8B). The abatement of these two important molecules was also confirmed in 
RKIP-/- B cells (Fig. 5-8A, Fig 5-3D). Additionally, we have observed that after adoptive transfer 
of wild type TCR transgenic T cells into RKIP deficient hosts, these T cells have a decreased 
migratory capacity to peripheral tissues, especially to the liver (data not shown). This migration 
into the hepatic circulation has been shown to be dependent on the generation of chemotactic 
gradients involving CXCL9 and CXCL10 and their interaction with the CXCR3 receptor on 
circulating T cells (256), and thus is consistent with the notion that RKIP-/- mice have deficits in 
the production of these cytokines. Finally, CCL5 was also decreased in the presence of RKIP 
blockade; however, unlike CXCL10, CCL5 is not dependent on type-I IFN signaling and is only 
partially dependent on downstream TRIF signaling (Fig.5-8B). Currently, it is still unclear 
whether or not the role that RKIP plays in the generation of IFNα and its sequelae and the 
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production of CCL5 are one in the same. Given that the MyD88 and NF-κB signaling pathways 
also were affected in RKIP-/- B cells, and that they also contribute to the production of CCL5, it 
is conceivable that RKIP’s role in CCL5 generation may be independent of its effects on the 
TRIF-Type-I IFN pathway.  
Previous work from other laboratories have established that productive B cell responses to 
nucleic acid PRR ligands are dependent upon the fidelity of the Type-I IFN positive feed forward 
loop (257). This is due in part to the up-regulation of TLR3 and TLR7 expression which provide 
more robust reactions to occur following initial activation (258), and the increase production of 
B cell survival factors, such as BAFF (259). This feed-forward loop is exemplified by the 
increase in IFNα production between 6 hours after Poly I:C stimulation and overnight (Fig. 5-8B, 
left panel). Interestingly, RKIP blockade reduced both the initial production of IFNα (6 h) and its 
enhanced feed-forward production (O/N), perhaps even to a larger extent. These data suggest 
that RKIP may play a role in facilitating the Type-I IFN response both before and after the 
generation of IFNα per se. The mechanism by which RKIP mediates these effects requires more 
study, however we hypothesize that RKIP may act by stabilizing signaling complexes upstream 
of Type-I IFN production (most likely at the level of TRAF3, TBK-1, and IKKε) and/or coupling 
the Type-I IFN receptor to its downstream machinery which would facilitate proper feed-forward 
signaling. This hypothesis will be expanded upon in chapter 6. 
Irrespective of the exact molecular role that RKIP plays in generation of Type-I IFNs, the fact 
that its functional blockade is druggable and can essentially attenuate production of IFNα, and its 
related effectors, provides a novel target for therapeutic intervention in auto-inflammatory 
diseases that are predominated or potentiated by Type-I IFNs, such as SLE.        
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Figure 5-1: Loss of B cells abrogates the disappearance of RKIP after LPS stimulation  
(A) Representative immunoblot of RKIP in bulk splenocyte lysates from wild type C57BL/6J 
mice, T cell deficient TCR-βδ-/- mice, or T and B cell deficient RAG-1-/- mice stimulated for 10 
min with either 10μg/ml or 50μg/ml of LPS. Balanced slat solution (BSS) was used as the 
vehicle control (0μg/ml LPS). N.A. = not acquired. (B) Representative flow cytometry plots 
illustrating the gating strategy for B cell enrichment before and after magnetic bead purification. 
Naïve “untouched” B cells were isolated by negative selection after incubation with anti-CD4, 
anti-Ter119 (expressed on all leukocytes except B cells) (260), and anti-CD43 (expressed on all 
T and B cells that have previously been activated) (261) antibody-magnetic bead complexes. The 
average purity of B cell enriched populations is 95 ± 2% (N>50 mice).  
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Figure 5-2: RKIP-/- B cells have higher basal levels of phosphorylated-ERK (A) 
phosphorylated-ERK/ERK-1 ratios determined by densitometric analysis of lysates from 
unstimulated splenic B cell enriched populations. TLR4 and TLR9 ligation leads to transient 
disappearance of RKIP protein and reciprocal increases in p-ERK in B cell enriched 
populations (B) Immunoblots of RKIP, pERK-1/2, and ERK-1 in splenic B cell enriched 
populations from wild type mice stimulated with either media, 50μg/ml LPS, or 9μg/ml CpG-B 
for 10 min, 1 h, 2 h, 4 h, or overnight. Data are representative of 3 independent experiments.  
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Figure 5-3: LPS and CpG-B drive divergent B cell cytokine programs partially controlled 
by RKIP (A-C) Multiplex cytokine array of naïve splenic B cells stimulated with either medium 
(data not shown), 50μg/ml LPS, or 9μg/ml CpG-B overnight. Data are presented as RKIP-/- 
quantities or each cytokine normalized to wild type (set to 100). Error bars represent mean ± 
SEM, and data are from 3 independent experiments; N=6/group. P values determined using t 
tests between 2 groups, using Welch’s correction where necessary; *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. (D) Naïve splenic B cells stimulated as in Figure 5-3A with the 
addition of 50μg/ml Poly I:C overnight. Supernatants from these cultures were used to determine 
quantities of CCL5, CXCL10, CCL3, and IFNα by ELISA. Error bars represent mean ± SEM, 
and data are from 3 independent experiments; N=6-9/group. P values determined using t tests 
between 2 groups, using Welch’s correction where necessary; *p<0.05, **p<0.01.  
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Figure 5-4: Naïve RKIP-/- B cells have an attenuated transcriptome which normalizes 
rapidly after TLR ligation with LPS or CpG-B (A) Heat map representing the expression of 
the top 400 altered genes between wild type and RKIP-/- naïve B cell transcriptomes. Color 
intensity represents relative expression of gene transcripts (0 = min, 100 = max). Total mRNA 
sent for RNA sequencing was pooled from 3 individual mice in each group. (B) Volcano plots 
showing significantly increased and decreased genes from naïve splenic B cell enriched 
populations, or after 1 h stimulation with 50μg/ml LPS or 9μg/ml CpG-B. Numbers represent 
percentages of all genes analyzed (23,235). (C) Table showing the number of genes that were 
statistically significantly up-regulated or down-regulated between naïve, LPS stimulated, or 
CPG-B stimulated wild type and RKIP-/- B cells.  
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Figure 5-5: Pathway analysis of altered genes in RKIP-/- B cells reveals an enrichment of 
pathways involved in mitochondrial function, TLR signaling, and cytokine responses (A) 
Top 30 most enriched pathways in naïve RKIP-/- B cells graphically represented as –log10(p-
value). Briefly, genes of interest were identified by taking all genes that were found to be 
statistically significantly different between experimental groups and had a relative fold change of  
> ±1.2, and subjected to functional pathway analysis using the IPA knowledge database 
(Ingenuity Systems; Redwood City, CA, USA). IPA cross-references a user’s list of genes of 
interest to known canonical signaling pathways and determines the level of enrichment of a 
given pathway using the user’s gene list and fold changes. IPA then calculates a P value based 
on this enrichment using Fisher’s exact test. 
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Figure 5-6: RKIP-/- B cells do not have significantly altered basal or maximal mitochondrial 
respiration before or after stimulation with TLR ligands (A) Technical diagram showing 
normal oxygen consumption rate curves and different measurable parameters by Seahorse 
extracellular flux analysis. Oligomycin is used to inhibit ATP synthase and inhibit mitochondrial 
respiration, FCCP uncouples the electron transport chain (ETC) allowing for maximal respiration 
capacity, and antimycin A/rotenone disrupt the ETC preventing oxygen utilization. (B-C) 
Splenic B cell enriched populations from C57BL/6J, RKIP-/-, RKIP+/-, and wild type littermates 
were cultured for 1 h with medium, 50μg/ml LPS, 50μg/ml Poly I:C, 9μg/ml CpG-B, or PMA + 
ionomycin and subsequently mitochondrial function was assessed by measuring oxygen 
consumption rates (OCR) expressed as pMoles/min. Basal mitochondrial rates (B) were 
determined by averaging OCRs at 0, 6, and 12 min (before oligomycin administration) for each 
mouse. Maximal mitochondrial rates (C) were determined by averaging OCRs at 33 and 40 min 
(4 min after FCCP administration). N=9 for C57BL6J and RKIP-/- groups from 3 independent 
experiments, and N=3 for RKIP+/- and RKIP+/+ groups from 1 experiment.  
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Figure 5-7: Steady state RKIP-/- B cells have an attenuated TRIF-Type I Interferon 
transcriptome signature (A) Comparison of genes important for TRIF-type I interferon 
signaling (left panel) and pattern recognition receptor genes (right panel) in naïve wild type and 
RKIP-/- B cells from RNA sequencing data in Figure 5-4. Data are represented as relative 
abundance normalized to wild type quantities of each gene (set to 100).  P-values calculated by 
Otogenetics normalized to FPKM using cufflinks software; *p<0.05, **p<0.01, ***p<0.001. (B) 
qPCR analysis of important TRIF-type I interferon genes from wild type and RKIP-/- B cells 
stimulated in vitro with 50μg/ml Poly I:C and 5μM locostatin or vehicle control (DMSO at same 
(v/v) percent) for 2 h. Data are expressed as fold change (2-∆∆Ct), error bars represent mean ± 
SEM, data are from 1 experiment, N=3/group. (C) qPCR analysis of IFNα transcript levels from 
wild type B cells stimulated with 50μg/ml Poly I:C and 5μM locostatin or vehicle control 
(DMSO at same (v/v) percent) for 1, 2, 4, or 8 h. In 2 of 3 experiments, locostatin was given 
concomitantly with Poly I:C, and in 1 of 3 experiments, locostatin was given 10 min prior to 
Poly I:C stimulation. Error bars represent mean ± SEM, data are from 3 independent experiments 
N=3 (1 h), 9 (2 h, 4 h), or 6 (8 h); **p<0.01.   
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Figure 5-8: RKIP optimizes IFNα synthesis and the Type I IFN stimulated chemokine 
CXCL10 following TLR3 ligation (A) ELISA for CXCL10 and CCL5 from culture 
supernatants of wild type and RKIP-/- B cells stimulated in vitro with 50μg/ml Poly I:C and 5μM 
locostatin or vehicle control (DMSO at same (v/v) percent) overnight. Error bars represent mean 
± SEM, data are from 1 experiment, N=3/group; **p<0.01, ****p<0.0001. (B) ELISA for 
CXCL10, CCL5, and IFNα from culture supernatants treated similarly as described in Figure 5-
8A for 6h or overnight in the presence of anti-IFNAR1 blocking antibody (10μg/well) or isotype 
control (10μg/well). Error bars represent mean ± SEM data are from 3 independent experiments, 
N=6/group (6 h) and N=9/group (O/N); *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.          
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TABLE III: Ingenuity Analysis of Pathways Enriched in RKIP-/- B Cells 
Pathway p-value -log (p-value) 
Mitochondrial Dysfunction 1.28825E-06 5.89 
Induction of Apoptosis by HIV1 4.36516E-05 4.36 
CD28 Signaling in T Helper Cells 5.7544E-05 4.24 
CD40 Signaling 0.000134896 3.87 
TNFR1 Signaling 0.000223872 3.65 
TNFR2 Signaling 0.000223872 3.65 
iCOS-iCOSL Signaling in T Helper Cells 0.000251189 3.6 
April Mediated Signaling 0.000295121 3.53 
B Cell Activating Factor Signaling 0.00042658 3.37 
TWEAK Signaling 0.000549541 3.26 
Activation of IRF by Cytosolic Pattern Recognition Receptors 0.00057544 3.24 
Lymphotoxin β Receptor Signaling 0.000676083 3.17 
Toll-like Receptor Signaling 0.000676083 3.17 
PKCθ Signaling in T Lymphocytes 0.000676083 3.17 
PI3K Signaling in B Lymphocytes 0.000676083 3.17 
B Cell Receptor Signaling 0.000812831 3.09 
Dendritic Cell Maturation 0.001 3 
Role of NFAT in Regulation of the Immune Response 0.001230269 2.91 
mTOR Signaling 0.001380384 2.86 
T Cell Receptor Signaling 0.001584893 2.8 
RANK Signaling in Osteoclasts 0.002041738 2.69 
Apoptosis Signaling 0.002041738 2.69 
4-1BB Signaling in T Lymphocytes 0.002238721 2.65 
EGF Signaling 0.004073803 2.39 
Huntington's Disease Signaling 0.004466836 2.35 
Oxidative Ethanol Degradation III 0.005370318 2.27 
Tryptophan Degradation X (Mammalian, via Tryptamine) 0.00676083 2.17 
Gαq Signaling 0.007079458 2.15 
CD27 Signaling in Lymphocytes 0.007943282 2.1 
IL-1 Signaling 0.008128305 2.09 
Type I Diabetes Mellitus Signaling 0.008128305 2.09 
Ethanol Degradation IV 0.008317638 2.08 
Ethanol Degradation II 0.00851138 2.07 
Antigen Presentation Pathway 0.00851138 2.07 
Ceramide Signaling 0.009120108 2.04 
CCR5 Signaling in Macrophages 0.009120108 2.04 
SAPK/JNK Signaling 0.009332543 2.03 
Regulation of IL-2 Expression in Activated and Anergic T Lymphocytes 0.01 2.00 
Interferon Signaling 0.01 2.00 
IL-10 Signaling 0.01 2.00 
Non-Small Cell Lung Cancer Signaling 0.01 2.00 
Androgen Signaling 0.01 2.00 
NGF Signaling 0.01 2.00 
Regulation of eIF4 and p70S6K Signaling 0.010715193 1.97 
FcγRIIB Signaling in B Lymphocytes 0.010964782 1.96 
CREB Signaling in Neurons 0.010964782 1.96 
EIF2 Signaling 0.011481536 1.94 
Phenylethylamine Degradation I 0.012022644 1.92 
α-tocopherol Degradation 0.012022644 1.92 
Estrogen Receptor Signaling 0.012589254 1.9 
CTLA4 Signaling in Cytotoxic T Lymphocytes 0.013489629 1.87 
Role of NFAT in Cardiac Hypertrophy 0.014125375 1.85 
α-Adrenergic Signaling 0.014454398 1.84 
Caveolar-mediated Endocytosis Signaling 0.015488166 1.81 
Small Cell Lung Cancer Signaling 0.015488166 1.81 
Calcium-induced T Lymphocyte Apoptosis 0.015848932 1.8 
IL-4 Signaling 0.016595869 1.78 
Role of RIG1-like Receptors in Antiviral Innate Immunity 0.016982437 1.77 
14-3-3-mediated Signaling 0.017782794 1.75 
IL-12 Signaling and Production in Macrophages 0.019054607 1.72 
Systemic Lupus Erythematosus Signaling 0.019498446 1.71 
Histamine Degradation 0.019952623 1.7 
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TABLE III: Ingenuity Analysis of Pathways Enriched in RKIP-/- B Cells (cont.) 
Pathway p-value -log (p-value) 
Tumoricidal Function of Hepatic Natural Killer Cells 0.019952623 1.7 
IL-17A Signaling in Gastric Cells 0.019952623 1.7 
Fc Epsilon RI Signaling 0.023988329 1.62 
Fatty Acid α-oxidation 0.024547089 1.61 
Renin-Angiotensin Signaling 0.025118864 1.6 
PDGF Signaling 0.025703958 1.59 
Chronic Myeloid Leukemia Signaling 0.026915348 1.57 
GNRH Signaling 0.029512092 1.53 
NF-κB Signaling 0.029512092 1.53 
Granzyme B Signaling 0.029512092 1.53 
CDP-diacylglycerol Biosynthesis I 0.029512092 1.53 
NRF2-mediated Oxidative Stress Response 0.030902954 1.51 
Protein Kinase A Signaling 0.031622777 1.5 
Role of PI3K/AKT Signaling in the Pathogenesis of Influenza 0.032359366 1.49 
UVB-Induced MAPK Signaling 0.032359366 1.49 
Role of PKR in Interferon Induction and Antiviral Response 0.033113112 1.48 
Altered T Cell and B Cell Signaling in Rheumatoid Arthritis 0.033884416 1.47 
TREM1 Signaling 0.035481339 1.45 
Integrin Signaling 0.035481339 1.45 
Putrescine Degradation III 0.035481339 1.45 
IL-8 Signaling 0.036307805 1.44 
Superpathway of Inositol Phosphate Compounds 0.036307805 1.44 
GDNF Family Ligand-Receptor Interactions 0.03801894 1.42 
Death Receptor Signaling 0.040738028 1.39 
Phosphatidylglycerol Biosynthesis II (Non-plastidic) 0.041686938 1.38 
Noradrenaline and Adrenaline Degradation 0.043651583 1.36 
Aryl Hydrocarbon Receptor Signaling 0.044668359 1.35 
Virus Entry via Endocytic Pathways 0.045708819 1.34 
FAK Signaling 0.045708819 1.34 
UVA-Induced MAPK Signaling 0.045708819 1.34 
Glucocorticoid Receptor Signaling 0.046773514 1.33 
Acetyl-CoA Biosynthesis III (from Citrate) 0.046773514 1.33 
Gap Junction Signaling 0.046773514 1.33 
iNOS Signaling 0.047863009 1.32 
Myc Mediated Apoptosis Signaling 0.047863009 1.32 
D-myo-inositol (1,4,5)-trisphosphate Degradation 0.047863009 1.32 
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TABLE IV: Altered Genes Important for Mitochondrial Function in RKIP-/- B Cells 
 Relative Expression  
Gene Wild Type RKIP-/- Function 
Map2k4 6.02709 2.18678 JNK-K 
Ndufv1 49.028 18.897 NADH dehydrogenase (Complex I) subunit 
Atp5d 79.958 32.0431 ATP Synthase Delta (Complex V) subunit 
Cox6a1 101.328 39.5858 Cytochrome C Oxidase (Complex IV) subunit  
Ndufs7 183.742 55.3997 NADH dehydrogenase (Complex I) subunit 
Cox8a 89.4472 25.6215 Cytochrome C Oxidase (Complex IV)subunit  
Ndufa7 389.806 175.586 NADH dehydrogenase (Complex I) subunit 
Ndufb8 333.707 120.657 NADH dehydrogenase (Complex I) subunit 
Dhodh 6.02206 1.70485 Quinone dehydrogenase (Complex II) subunit 
Ndufa1 207.983 65.7994 NADH dehydrogenase (Complex I) subunit 
Ndufa2 628.054 215.532 NADH dehydrogenase (Complex I) subunit 
Ndufa13 105.126 36.7641 NADH dehydrogenase (Complex I) subunit 
Ndufb10 360.958 143.939 NADH dehydrogenase (Complex I) subunit 
Fis1 142.321 60.9672 Mitochondrial fission 1 protein 
Ndufs8 221.571 94.443 NADH dehydrogenase (Complex I) subunit 
Txn2 113.475 39.5416 Thioredoxin-2 
Ndufb7 89.5458 36.1698 NADH dehydrogenase (Complex I) subunit 
Cyc1 15.5698 4.84798 Cytochrome C1 
Cyb5r3 10.2153 2.45583 Cytochrome B5R3 
Uqcrc1 84.7091 33.7325 Cytochrome b-c1 complex subunit 1 
Uqcrq 185.161 79.4686 Cytochrome b-c1 complex subunit 1 
Pink1 5.79479 1.79302 Ser/Thr kinase (Mito. Clearance-Autophagy) 
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells 
 Relative Expression  
Gene Location Wild Type RKIP-/- log2 (Fold Change) p-value 
Pattern Recognition Receptors    
Tlr1 Chr. 5  16.27 9.27 -0.811 0.0514 
Tlr2 Chr. 3 1.16 1.00 -0.022 0.7594 
Tlr3 Chr. 8 0.80 0.25 -1.691 0.0478* 
Tlr4 Chr. 4 1.70 1.33 -0.355 0.5374 
Tlr5 Chr. 1 0 0.02 N.A. 0.2244 
Tlr6 Chr. 5 1.29 0.85 -0.595 0.4243 
Tlr7 Chr. X 3.61 2.69 -0.423 0.3728 
Tlr8 Chr. X 0.63 0.21 -1.597 0.1165 
Tlr9 Chr. 9 0.82 0.13 -2.71 0.0121* 
Tlr11 Chr. 14 0.28 0.09 -1.597 0.2275 
Tlr12 Chr. 4 1.04 0.69 -0.597 0.4232 
Tlr13 Chr. X 0.11 0.05 -1.013 0.5050 
Ddx58 (RIG-I) Chr. 4 7.50 4.66 -0.685 0.1002 
Ifih1 (MDA-5) Chr. 2 1.16 0.85 -0.453 0.4220 
      
Type I IFN Generation     
Mavs (IPS-1) Chr. 2 13.95 8.81 -0.663 0.1293 
Tmem173 (STING) Chr. 18 52.65 32.02 -0.714 0.0771 
Ticam1 (TRIF) Chr. 17 7.68 2.49 -1.626 0.0009*** 
Tram Chr. 1 21.09 15.14 -0.478 0.2392 
Tank Chr. 2 28.27 18.77 -0.591 0.2103 
Ikbke (IKKε) Chr. 1 1.64 0.48 -1.789 0.0180* 
Traf3 Chr. 12 2.29 0.78 -1.562 0.0026** 
Tbk1 Chr. 10 9.40 5.45 -0.787 0.0675 
Irf3 Chr. 7 5.27 1.45 -1.862 0.0027** 
Irf7 Chr. 6 7.48 1.96 -1.925 0.0018** 
      
Type I IFN Signaling    
Ifnar1 Chr. 16 5.86 2.46 -1.256 0.0030** 
Ifnar2 Chr. 16 3.78 2.03 -0.899 0.2210 
Stat1 Chr. 1 35.29 33.29 -0.084 0.8486 
Stat2 Chr. 10 3.99 3.16 -0.338 0.4458 
Stat3 Chr. 11 10.97 6.52 -0.751 0.1160 
Irf9 Chr. 14 24.59 20.98 -0.229 0.5877 
Cxcl9 Chr. 5 0.69 1.71 1.321 0.0669 
Cxcl10 Chr. 5 0.23 1.21 2.419 0.2228 
Cxcl11 Chr. 5 0.30 0 N.A. 0.1349 
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells 
  Relative Expression   
Gene Location Wild Type RKIP-/- log2 (Fold Change) p-value 
Type I Interferons    
Ifna4 Chr. 4 0 0.22 N.A. 0.1421 
Ifna5 Chr. 4 0.53 0.18 -1.556 0.4870 
Ifna13 Chr. 4 0.45 0.61 0.436 0.7858 
Ifna14 Chr. 4 0.53 0.18 -1.556 0.4870 
 
† Ifna1,2,6,7,9,11,12 Ifnb, Ifne, Ifnk, Ifnz – Not Detectable  
      
MyD88 & NF-κB  Signaling    
Myd88 Chr. 9 10.39 4.39 -1.237 0.0100** 
Cd14 Chr.18 0.63 0.58 -0.130 0.9053 
Ly96 (MD-2) Chr. 1 9.34 3.67 -1.349 0.0813 
Tollip Chr. 7 6.72 3.50 -0.939 0.0330* 
Tirap Chr. 9 1.99 1.24 -0.685 0.2038 
Irak1 Chr. X 9.55 4.81 -0.989 0.0268* 
Irak4 Chr. 15 8.32 4.52 -0.881 0.0479* 
Irak3 (IRAK-M) Chr. 10 2.75 1.40 -0.978 0.0956 
Traf2 Chr. 2 31.54 14.50 -1.122 0.0058** 
Traf6 Chr. 2 3.41 1.55 -1.135 0.0104* 
Map3k7 (TAK-1) Chr. 4 2.08 0.98 -1.095 0.0507* 
Ripk1 (Rip1) Chr. 13 3.32 1.84 -0.874 0.0742 
Map3k8 (Tpl2) Chr. 18 16.42 7.41 -1.147 0.0067** 
Irf5 Chr. 6 78.11 32.38 -1.27 0.0017** 
Chuk (IKKα) Chr. 19 4.95 2.81 -0.814 0.1571 
Ikbkb (IKKβ) Chr. 8 21.97 8.03 -1.453 0.0011** 
Ikbkg (IKKγ) Chr. X 6.96 2.27 -1.615 0.0057** 
Nfkbia (IκBα) Chr. 12 73.79 38.71 -0.931 0.0217* 
Rela Chr. 9 25.45 8.12 -1.648 7.37x10-5**** 
Relb Chr. 7 9.15 2.35 -1.961 0.0002*** 
Nfkb1  (p105) Chr. 3 19.88 12.63 -0.931 0.0217* 
Mapk11 (p38) Chr. 15 19.37 7.72 -1.327 0.0017** 
Mapk8 (JNK) Chr. 14 0.74 0.95 0.345 0.5689 
Mapk1 (ERK) Chr. 16 8.99 7.15 -0.329 0.4998 
      
TLR Signaling Effector Molecules    
Tnf Chr. 17 1.73 1.16 -0.652 0.8053 
Il1b Chr. 2 0.72 0.30 -1.265 0.354 
Il6 Chr. 5 0 0.46 N.A. 0.0649 
Il18 Chr. 9 4.24 2.74 -0.629 0.4125 
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TABLE V: Altered Genes Important for TLR-Type I IFN Signaling in Naïve RKIP-/- B Cells 
  Relative Expression   
Gene Location Wild Type RKIP-/- log2 (Fold Change) p-value 
TLR Signaling Effector Molecules (cont.)    
Ccl3 Chr. 11 0.34 0 N.A 0.1110 
Ccl4 Chr. 11 4.76 1.76 -1.439 0.1234 
Ccl5 Chr. 11 40.88 32.54 -0.329 0.4760 
Cd40 Chr. 2 101.90 41.72 -1.29 0.0032** 
Cd80 Chr. 16 0 0.14 N.A. 0.1122 
Cd86 Chr. 16 12.41 8.89 -0.482 0.2510 
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†Relative expression of gene of interest in RKIP-/- B cells vs. Wild Type (WT = 1)    
 
 
 
 
 
TABLE VI: Normalization of TLR-Type I IFN Genes after TLR Stimulation in RKIP-/- B Cells 
 Naïve  LPS CpG-B 
Gene Relative Expression† p-value 
Relative 
Expression p-value 
Relative 
Expression p-value 
TLR-Type I IFN Signaling Genes     
Ticam1 (TRIF) 0.3242 0.0009*** 1.2291 0.4559 0.9894 0.9506 
Traf3 0.3406 0.0026** 1.9121 0.0646 1.5892 0.02292* 
Irf3 0.2751 0.0027** 1.1941 0.6824 0.8029 0.4315 
Irf5 0.4145 0.0017** 1.7642 0.0020** 0.8705 0.3145 
Irf7 0.2620 0.0018** 1.3720 0.4717 0.2994 3.15x10-6**** 
Ifnar1 0.4198 0.0030** 1.3177 0.1425 0.9030 0.4149 
Myd88 0.4225 0.0100** 1.7144 0.0497* 0.9104 0.5036 
Irak1 0.5037 0.0268* 1.3225 0.1372 1.1498 0.3525 
Irak4 0.5434 0.0479* 1.0666 0.7417 1.0336 0.8596 
Tollip 0.5208 0.0330* 1.2484 0.3048 1.2885 0.0491* 
Traf6 0.4545 0.0104* 0.9545 0.8360 1.0706 0.6418 
       
Pattern Recognition Receptors     
Tlr1 0.5699 0.0514 1.2171 0.3111 0.9046 0.5155 
Tlr2 0.9848 0.7594 0.6973 0.4475 0.7145 0.3626 
Tlr3 0.3097 0.0478* 0.4643 0.2138 1.0053 0.2777 
Tlr4 0.7818 0.5374 1.9635 0.1049 0.6574 0.4839 
Tlr6 0.6620 0.4243 1.9506 0.3076 0.7490 0.3350 
Tlr7 0.7458 0.3728 1.2270 0.5047 1.0651 0.7718 
Tlr8 0.3305 0.1165 0.5362 0.2191 0.6558 0.7780 
Tlr9 0.1528 0.0121* 0.2140 0.2839 1.3147 0.6933 
Tlr11 0.3305 0.2275 1.1618 0.8494 2.3016 0.3307 
Tlr12 0.6611 0.4232 0.4879 0.2162 1.0521 0.9385 
Tlr13 0.4955 0.505 0.1019 0.9291 0.3042 0.2380 
Ddx58 (RIG-I) 0.6220 0.1002 1.0943 0.6178 0.5187 0.1972 
Ifih1 (MDA-5) 0.7305 0.422 0.7829 0.3916 0.8742 0.6581 
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CHAPTER 6 
 
DISCUSSION: RKIP IS AN IMPORTANT, CO-EVOLVED REGULATOR OF 
INTERFERON RESPONSES AND MAY PROVIDE A NOVEL TARGET FOR 
INTERVENTIONAL CYTOKINE-BASED THERAPY  
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INTRODUCTION 
The preceding studies have defined, for the first time, important roles for RKIP within the 
immune system. RKIP’s primary immunological function is to facilitate cytokine responses from 
T cells and APCs after stimulation through the TCR and PRRs respectively, and has a 
particularly important role in driving the production of Type-I and Type-II interferons. 
Additionally, we identify RKIP’s requirement for the development of competent Tc1 effectors in 
a mouse model of systemic inflammatory response syndrome, as well as, its place in providing 
appropriate adjuvant responses in B cells, specifically to nucleic acids. Finally, we also establish 
that RKIP is a druggable protein, and through its targeted inhibition, cytokine responses can be 
greatly attenuated. This highlights locostatin as a new potential therapeutic intervention for 
inflammatory diseases that involve the overproduction of interferons, including SIRS, SLE, RA, 
and others. In this final chapter, I will discuss our current working molecular hypothesis for 
RKIP’s role in Type-I IFN synthesis, as well as its impact in interferon signaling for the immune 
system at large. Also, I will outline a hypothesis for how RKIP came to be an important regulator 
of IFN signaling involving viral evasion and co-evolution. This will be followed by a discussion 
of the future directions that need to be accomplished in order to determine RKIP’s exact 
molecular mechanism for its immunological function, and what disease models should be tested 
to provide the best evidence for future translational studies. Finally, I will finish with brief 
speculation on how locostatin may be used in the clinical setting as a novel treatment modality 
for cytokine-based therapeutic strategies.             
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RKIP DRIVES TYPE-I INTERFERON RESPONSES AFTER NUCLEIC ACID 
SENSING: A WORKING MODEL 
Prior to TLR ligation, RKIP is most likely bound to Raf-1 preventing the downstream signaling 
of the Raf-MEK-ERK axis. This was the initially defined by Yeung. et. al. in 1999, that RKIP 
interacted with Raf-1 as evidenced by their co-immunoprecipitation and co-localization with one 
another by confocal microscopy. This interaction is fairly high affinity (~KD= 11±3 μM in 
humans (262) and ~KD=20μM in rats (263); however, no studies to our knowledge have been 
done in vivo to determine RKIP’s relative affinity for Raf-1 versus other potential ligands. 
Additionally, it is not known if the default binding of RKIP to Raf-1 observed in cancer cell lines 
remains true for all cell types, or whether this translates in vivo. However, our studies do indicate 
that RKIP does inhibit the phosphorylation of ERK, evidenced by an increase in p-ERK when 
RKIP is knocked out or is inhibited with locostatin (Fig. 4-1C/D, 5-2A). This increases the 
likelihood of this RKIP-Raf interaction being the default state of the cell.  
After B cells are exposed to Poly I:C, it is recognized by either endosomal TLR3 or cytosolic 
MDA-5, both of which are known to bind long dsRNA like Poly I:C (264, 265). It is unknown 
which of these is the predominantly activated pathway in B cells. TLR3 expression is very low in 
this population (and even lower in RKIP-/- B cells; Table V), even though it does retain its ability 
to signal (266). These pathways may be cooperatively activated (267), but would require 
mechanistic studies in Tlr3-/-, Ticam1-/-, or Ifih1-/- mice to determine definitively. Once Poly I:C 
ligates its corresponding PRR, downstream signaling results in the K-63 poly-ubiquitylation of 
TRAF3, which prevents its proteosomal degradation (268, 269). Subsequently, TRAF3 forms a 
critical signaling complex consisting of itself, TBK1, and IKKε which is responsible for 
146 
 
phosphorylation of IRF3 and IRF7 (270-272). These IRFs act as transcription factors (either 
homo- or heterodimers) that lead to Type-I IFN production (273).  
Because inhibition or genetic loss of RKIP results in significantly attenuated levels of IFNα 
production after Poly I:C stimulation (Fig. 5-3D, 5-8A/B), one possibility is that RKIP acts to 
provide stability to this critical TRAF3/TBK1/IKKε complex, perhaps acting as a scaffold 
protein (Figure 6-1, (1)). The change in affinity away from Raf-1 and towards this complex, most 
likely requires a post-translational modification. Protein kinase C is known to phosphorylate 
RKIP which causes an affinity shift from Raf-1 to GRK2 (212). There is additional evidence that 
RKIP phosphorylation results in dimer formation which may also be responsible for alterations 
in affinity (274) towards non-Raf targets. Irrespective of the mechanism by which RKIP gains 
affinity for the TRAF3/TBK1/IKKε complex, a critical RKIP-mediated effect on this complex is 
a very plausible hypothesis given that locostatin can inhibit both early transcription and 
translation of the Ifna gene.    
RKIP inhibition also leads to an even more pronounced reduction in IFNα during the feed-
forward phase of the reaction. This phase is critical for mediating robust immune responses to 
viruses and vaccine adjuvants (275), as well as resultant pathology in systemic autoimmunity 
(276, 277). The mechanism that mediates this enhancement is typically through increased 
coupling of the receptor to downstream signaling molecules. This usually occurs at the level of 
increased recruitment of small molecule adaptors, such as TYK2 or JAK1 in the case of IFNAR, 
to the receptor. These facts give way to another possibility that could account for the decreased 
IFNα production in the response to Poly I:C, namely that RKIP could be responsible for 
maintenance of the feed-forward phase of the response by facilitating the recruitment of these 
adaptor molecules to IFNAR (Figure 6-1, (2)). This hypothesis doesn’t account for decreased 
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IFNα production in the early phase; however, this may also be explained by the need for 
functional RKIP in the maintenance of appropriate basal circulating levels of   TRIF-Type-I IFN 
signature transcripts (Fig. 5-7A).  
Based on the two working hypotheses presented above, the mechanism for locostatin inhibition 
of IFNα production in wild type B cells may be through the destabilization of the 
TRAF3/TBK1/IKKε complex as RKIP is prevented from binding, or through abolishment of the 
ability of IFNα to feed-forward through IFNAR ligation (Figure 6-1, right panel). The exact 
mechanism of this inhibition will require identification if locostatin is to be used clinically.                          
ESTABLISHING RKIP’S ROLE WITHIN THE IMMUNE RESPONSE 
Type-I IFNs can elicit pleiotropic effects after ligation of their receptor, IFNAR (Figure 6-2). 
IFNAR is expressed on nearly every cell in the body at different levels, and the response that is 
generated after Type-I IFN signaling depends on the cell’s identity, as well as the relative 
expression of different STAT proteins within the cell (278). This makes the true nature of the 
Type-I IFN response within the immune system, and the body at large, exceedingly complex. 
Through RKIP’s ability to facilitate Type-I IFN production, it is able to affect many different 
areas of both the innate and adaptive immune response. First, after stimulation with nucleic acid 
patterns, APCs respond to Type-I IFNs through autocrine or paracrine signaling which leads to 
an up-regulation of PRRs, including TLR3 and TLR7, as well as increases in anti-viral response 
genes (279) and APC maturation (280) through the phosphorylation of STAT-1/2 heterodimers. 
Also, in B cells specifically, Type-I IFNs can elicit increases in survival due to up-regulation of 
BAFF and APRIL (281, 282), as well as promote antibody production of T cell-independent 
antigens (283). Because nearly every successful vaccine used in clinical medicine utilizes the 
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production of antibody, RKIP may be an essential player in this process, especially with the use 
of nucleic acid adjuvants on the rise.  
RKIP may also impact the ability to establish proper chemokine gradients, which are driven by 
Type-I IFN autocrine signaling to APCs and paracrine signaling on tissue mesenchymal cells. 
This is driven by the p-STAT-1/2 and IRF9 (ISGF3) trimeric complex binding to interferon-
sensitive response elements (ISREs) in the enhancer regions of Cxcl9/10/11 which recruit 
activated neutrophils and T cells via CXCR3 (284, 285). This response is also enhanced by 
Type-I IFN mediated IFNγ production which can also drive CXCL9/10/11 synthesis by p-STAT-
1/1 binding of IFNγ-activating (GAS) sites within the enhancer regions of these genes (286, 
287). Type-I IFN can also drive production of CCL2/7 which induce recruitment and pro-
inflammatory responses from macrophages and Tip-DCs (288, 289). In preliminary studies, we 
observed altered migration to liver of adoptively transferred TCR-transgenic T cells after 
immunization in RKIP-/- recipients, suggesting that RKIP may indeed be necessary for 
establishing specific chemotactic gradients.    
Through the studies presented in chapter 3, we established the importance of RKIP for the proper 
differentiation of Tc1 effector CTLs, as well as their ability to produce the effector cytokine, 
IFNγ, after TCR triggering (Fig. 3-1, 3-5). We determined that this was due, at least in part to an 
intrinsic defect downstream of the TCR signaling apparatus in Tc1 T cells devoid of RKIP (Fig. 
3-7). However, Type-I IFNs have been shown to directly affect the production of Type-II IFN, 
IFNγ, through the phosphorylation of STAT-4 homodimers after IFNAR ligation in Th1 and Tc1 
T cells, as well as natural killer (NK) cells (290-293). Type-I IFNs can also drive IFNγ 
production through the IL-12 independent differentiation of CD4+ Th1 T cells, which provide 
help to developing CD8+ Tc1 effectors (294-296), in addition to augmenting proliferation and 
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memory formation (297) of CD8+ T cell directly (298-300). To sum, the data in this thesis imply 
that RKIP may be responsible for coupling the cooperative generation of Type I and Type II 
IFNs during the immune response. The importance of this RKIP-mediated regulation is 
evidenced by the fact that RKIP seems to control the production of IFNγ at several different 
levels of the reaction including: the synthesis of Type-I IFN, the skewing of Th1 helper T cells, 
the differentiation of Tc1 effectors per se, and the direct control over IFNγ after TCR triggering 
in these cells.  
Finally, RKIP may be involved in several suppressive immunoregulatory effects of Type-I IFNs. 
Previously, Type-I IFN signaling has been shown to cause phosphorylation of STAT-3 
homodimers in certain cell types, such as T regulatory cells (Tregs) and anti-inflammatory 
macrophages (301, 302). Also, LPS can drive the production of IL-10 from both mouse (303) 
and human (304) PBMCs through a mechanism that is dependent on Type-I IFN. A controversy 
still remains to whether the exact signaling machinery required for this effect is direct 
transcription of the Il10 gene by p-STAT-3 (46), or through indirect activation of the PI3K-Akt-
mTOR axis by JAK1 after IFNAR ligation (305). Recently, a new subtype of T regulatory cell, 
characterized by the transcription factor FoxA1, has been implicated in relapsing-remitting 
multiple sclerosis patients and in experimental autoimmune encephalomyelitis as a mechanism 
for symptom abatement after IFNβ administration. These Tregs were shown to suppress by p-
STAT3 mediated up-regulation of programmed cell death ligand 1 (PD-L1), which was driven 
by exposure to Type-I IFN (306, 307). Because RKIP may be involved in both pro-inflammatory 
and anti-inflammatory processes through the actions of Type-I IFN, it will require significant 
future studies in order to determine the exact balance of these facets in different clinical contexts. 
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Only through these studies will it be possible to accurately predict which clinical scenarios 
would potentially benefit from inhibition of RKIP function.      
 
THE GREAT ARMS RACE: VIRAL EVASION, INTERFERONS, AND RKIP CO-
EVOLUTION 
Darwinian evolution is the ultimate driving force behind biological diversity, fitness, and 
survival. Nothing exemplifies this concept better that the ongoing evolutionary “arms race” 
between pathogens and their hosts. The immune system has evolved numerous mechanisms, both 
specific and redundant, that aim to prevent, control, and eliminate infection by pathogens. 
Analogously, pathogens utilize inefficient genomic replication systems to allow evolution, 
through enhanced mutation rates, to happen on an abbreviated time scale. The outcome of this 
process, in many cases, is an increased level of fitness and survivability through the development 
of mechanisms that allow for immune system subversion or circumvention.  
Viruses, because of their significant diversity and ability to rapidly evolve, present a unique 
challenge to the host’s immune system (308). One of the most evolutionarily conserved 
mechanisms for eliciting anti-viral control is the Type-I IFN response. They were initially 
discovered by work done in the 1950s from Nagano and Kojima (309-311), and later Isaacs and 
Lindenmann (312), which described novel molecules that inhibited the replication of smallpox 
and influenza virus respectively. The exact molecular mechanisms by which IFNs elicit anti-viral 
immunity have been reviewed in depth previously (313), and seem to be conserved in most 
vertebrates (314) including humans (315), as far back as bony fish (Osteichthyes) (316). 
However, they have not yet been detected in invertebrate species. The importance of type-I IFN 
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mediated control of viral pathogens is illustrated by two critical facts: 1) mice and humans that 
have deficiencies in IFN production or signaling have increased morbidity and mortality to 
viruses (317), and 2) viruses have evolved mechanisms to subvert the IFN response at nearly 
every level (308). These viral subversion techniques include sequestration of viral dsRNA from 
nucleic acid sensing PRRs by Ebola virus-VP35 (318), Vaccinia virus-E3L (319), and Influenza 
A virus-NS1 (320), degradation or cleavage of TRIF and IPS-1 by Hepatitis C virus-NS3-4A 
(321), or disruption of signaling machinery through direct inhibition (e.g. Hepatitis C virus-
NS5A (322, 323) and NS3-4A (324), Ebola viru-VP35 (318), Vaccinia virus-E3L (325) and 
A52R (326), and Influenza A virus-NS1 (327). These methods to circumvent viral immunity are 
just a few examples to highlight how extensively the IFN pathway can be attenuated by viral 
proteins.  
By analyzing which host proteins are targeted by viral factors, new innate immunological 
functions can be ascribed to poorly-defined host proteins, or can even lead to the discovery of 
new proteins. In 2011, Folly and colleagues demonstrated by two-hybrid technology that the 
PrM structural protein from the human pathogen Dengue-2 virus physically interacted with the 
human form of RKIP (PEBP-1) (328). The authors go on to posit: “As induction of [the] IFN-
alpha gene family is dependent on IRF7, it is formally possible that the PrM-RKIP (PEBP) 
complex might be inhibiting TAK1/IKK-dependent phosphorylation of the TLR3/7 receptors, 
negating the expression of IFN-alpha and therefore, IFN-alpha dependent genes.” To the best of 
our knowledge, our studies involving RKIP are the first to demonstrate experimentally that this 
hypothesis may have a high likelihood of being correct. Although future studies are required to 
determine the exact mechanism by which RKIP facilitates IFNα production, after these data are 
obtained, the purpose of PrM’s interaction with RKIP in humans should be easily extrapolated. 
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These findings, in the context of our work, strongly implicate RKIP as molecule that has co-
evolved alongside IFNs and nucleic acid sensors in order to mediate these interferon responses 
and facilitate anti-viral immunity.                 
 
FUTURE DIRECTIONS 
The current studies described herein have begun to highlight the role that RKIP plays in 
mediating interferon responses within the immune system. Although our knowledge of RKIP’s 
function in the context of in vitro and in vivo immunity have grown exponentially through this 
work, there are still significant strides to be made in terms of establishing both the exact 
molecular mechanism by which it functions in these responses, as well as if or how these 
findings translate into a broader range of in vivo disease models and human immunity.  
Currently, in order to better elucidate a molecular mechanism for how RKIP drives Type-I IFN 
production in APCs, we plan to explore what proteins RKIP co-localizes with after Poly I:C 
stimulation by confocal microscopy. Based on our cytokine and transcriptome studies, the list of 
potential RKIP binding partners is small enough to utilize this approach. We already have a 
commercially available FITC conjugated anti-RKIP antibody that works well for indirect 
immunofluorescence (Fig. 4-4A) which should be applicable for confocal microscopy as well. 
Also, antibodies for microscopy are commercially available for nearly all of our potential target 
proteins including TRAF3, TBK1, IKKε, IFNAR, JAK1, and TYK2. Unfortunately conventional 
co-immunoprecipitation of RKIP from primary cells is currently hampered by a lack of reagents 
that can bind RKIP for immunoprecipitation. RKIP can be immunoprecipitated from cell lines 
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after transfection of tagged-RKIP; however, the relevancy of this approach is unclear, given our 
interest in RKIP’s interaction in vivo, or at the very least, in primary immune cells.  
After we establish the binding partners of RKIP in our model, the next question we will seek to 
answer is whether or not these interactions can be destabilized by the irreversible inhibition of 
RKIP by locostatin. Because RKIP is covalently modified by locostatin within its ligand binding 
pocket (172), theoretically this should prevent RKIP from interacting with other proteins. An 
observable destabilization of the RKIP containing complex could then be linked to decreased 
IFNα production after RKIP blockade. This could be accomplished experimentally, once again 
through imaging by confocal microscopy, or by gel filtration. Additionally, we will seek to 
confirm our attenuated TRIF-Type-I IFN transcriptomic signature at the protein level by mining 
of the wild type and RKIP-/- proteomes by PF-2D proteomics (Figure 6-3). Through this 
approach we can not only confirm the identity of altered proteins within these specific signaling 
pathways, but also uncover new putative targets affected by RKIP during PRR signaling in 
APCs. 
Finally, the breadth of potential clinical applicability of RKIP inhibition can be tested by 
locostatin therapy in different disease models. This allows for the circumvention of caveats that 
arise when using knockout mouse models. We have already established a potential role for RKIP 
modulating IFNγ production from Tc1 effectors in a mouse model of SIRS; however, given the 
evidence presented in chapter 5, we must now expand to models that are affected by altered 
production of Type-I IFN including: SLE, IBD, Psoriasis, MS, viral infection, and hematologic 
malignancy. The rationale for studying these diseases will be discussed at length in the next 
section.         
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LOCOSTATIN: A NEW CYTOKINE-BASED THERAPEUTIC INTERVENTION? 
The clinical relevancy of these studies centers on the ability to utilize RKIP-inhibition by the 
small molecule inhibitor locostatin as a potential therapeutic intervention to treat human 
inflammatory diseases which consist of dysregulated interferon responses as part of their 
pathogenesis. Locostatin has the potential to provide therapeutic benefits over many current 
forms of treatment. First, because locostatin is a small organic molecule, it has the potential to be 
formulated for use per os, as most oxazolidinones have adequate oral bioavailability (329). This 
would provide a tremendous advantage to conventional monoclonal antibody biologics which are 
given by intravenous infusion or subcutaneous injection (330). Second, based on our studies of 
locostatin, it seems that it would fall in the middle of the spectrum in terms of 
immunosuppressive potency, of which either extreme could be disadvantageous. For example, 
the most common treatment for intense inflammatory reactions is corticosteroids which cause 
very robust immunosuppression, leaving the patient susceptible to opportunistic infections. In 
chapter 3, we show that despite the defect seen in IFNγ from CD8+ T cells, these cells were still 
able to respond with cytokine production in response to a TLR stimulus such as LPS (Fig. 3-10). 
This suggests that patients may still be able to respond normally to pathogenic invasion, even 
under RKIP-inhibition. On the other hand, in contrast to most modern anti-cytokine based 
interventions, locostatin may provide a slightly broader suppressive response compared to the 
inhibition of one particular cytokine, given its ability to affect Type-I and Type-II IFNs, as well 
as interferon-stimulated cytokines like CCL2 and CXCL10. 
The most likely clinical scenarios where locostatin therapy would have potential benefits are 
diseases that have established pathogenic connections to dysregulated Type-I or Type-II 
interferon responses. These include: SIRS, which was discussed at length in chapter 3, systemic 
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lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), 
psoriasis, coeliac disease, and multiple sclerosis (MS). In SLE, patients have abnormally high 
levels of IFNα in their serum (331, 332), as well as genes involved in the “Type-I IFN signature” 
(255, 333). Serum from these patients was able to induce APC maturation (increased MHC-II 
and the con-stimulatory molecules CD80/CD86) and differentiation of antibody secreting plasma 
cells (334). Additionally, some patients that have received recombinant IFNα therapy for 
hepatitis C infection have developed an SLE-like syndrome with the production of anti-nuclear 
antibodies (ANA) (335). Phase-I clinical trials have been conducted using anti-IFNα neutralizing 
antibodies which have shown some improvement in symptomology (334); however, it may prove 
to be more beneficial to block IFNα production rather than blocking its effects post hoc. 
Similarly, psoriasis and coeliac disease both exhibit exacerbation of symptomology in the 
presence of type-I IFN. In a xenograft model of psoriasis, development of skin lesions and 
activation of autoreactive T cells could be inhibited through the suppression of IFN signaling 
through IFNAR blockade (336) or anti-BDCA2 (337), which prevents IFNα production from 
pDCs. Th1 polarization, robust IFNγ synthesis and presentation of gluten specific peptides to 
autoreactive T cells is the main driving force behind the pathology seen in coeliac patients (338, 
339). However, anti-IFNα treatment of biopsy specimens from coeliac patients was able to 
inhibit IFNγ production (340), the mechanism of which has been discussed previously.      
On the other hand, diseases that have their pathology related to mixed Th1/Th17 responses, such 
as MS, RA, and IBD, are much more controversial in regard to their response to Type-I IFN 
inhibition. In MS, IFNβ (Betaseron) is prescribed as fairly efficacious therapeutic option (341), 
and in mouse models of MS such as EAE, IFNβ deficient mice develop worse disease (342), but 
can be improved with analogous IFNβ administration (343). Also, Type-I IFNs have been shown 
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to inhibit Th17-mediated inflammation in EAE (344), suggesting that the therapeutic action of 
IFNβ administration may be through both Th17 suppression and induction of FoxA1+ Tregs (Fig. 
6-2). Similarly, treatment with interferons in both the collagen induced arthritis model of RA 
(345) and human IBD patients (346-348) have shown promising results. However, because each 
of these three diseases are also impacted by a significant Th1 component and Type-I IFNs are 
known to drive these responses, it remains an exceptionally complex system to treat, which may 
provide insight into why some recombinant IFN therapies have exhibited contradictory results 
(349-351). Irrespective of existing experimental evidence in humans and mouse disease models, 
locostatin-mediated inhibition of IFNα and IFN-stimulated genes must be tested individually in 
each disease model in order to determine experimentally the effectiveness of this therapeutic 
strategy.            
CONCLUSIONS 
The studies presented herein were designed to test if Raf-1 kinase inhibitor protein (RKIP) 
played any functionally significant role in immunity, and to interrogate its possibility of 
providing a novel therapeutic target for modulating inflammatory responses. Based on previous 
studies from other laboratories that attributed negative regulatory functions to RKIP in the 
context of MAPK and NF-κB signaling in cell lines, we set out with the hypothesis that its 
function was to suppress the production of pro-inflammatory cytokines, proliferation, and cell 
survival. However, after extensive investigation, our data clearly demonstrate that RKIP is 
actually necessary for the production of certain cytokines, namely Type-I and Type-II 
interferons, but was less involved in cell survivability and proliferation. Additionally, this work 
has established RKIP as an important contributor to the signaling machinery downstream of TCR 
triggering in CD8+ T cells and TLR ligation in APCs. Finally, these studies have shown that 
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RKIP is a druggable protein, and through its targeted inhibition, cytokine responses can be 
significantly diminished. Thus, this provides elementary rationale for its potential clinical 
applicability in therapeutic interventions for inflammatory diseases (Figure 6-4). Through this 
current work, we have provided a solid foundation for future studies that seek to investigate 
further the molecular mechanisms of RKIP function within the immune system, as well as its 
advancement into clinically relevant inflammatory disease models. 
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Figure 6-1: Working model of RKIP’s functional role in mediating Type-I IFN production 
from APCs after Poly I:C stimulation (Left Panel) Prior to stimulation, RKIP is bound to Raf-
1, thus preventing its phosphorylation of MEK and keeping MAPK activity suppressed. 
Signaling machinery for TRIF-TRAF3-IRF axis, NF-κB, and signaling through IFNAR is 
synthesized, but not held in a functional confirmation thus preventing the synthesis of cytokines. 
(Center Panel) After Poly I:C administration, the dsRNA is sensed either through ligation of 
TLR3 in endosomes, binding to MDA-5 in the cytosol, or through the production of cyclic-di-
GMP and activation of ER-associated STING. These events (along with IL-1R signaling) lead to 
the K-63 mediated poly-ubiqutinylation of TRAF3 and prevents its proteasomal degradation. 
TRAF3 subsequently binds to IKKɛ and TBK-1 to facilitate phosphorylation of IRF3 and IRF7 
which translocate to the nucleus driving the production of Type-I IFNs. These Type-I IFNs act in 
an autocrine (or paracrine) fashion through IFNAR ligation which leads to phosphorylation of 
STAT1/2 heterodimers, and with the aid of IRF9, drives the expression of IFN-responsive genes 
such as CXCL10 by binding interferon-stimulated response elements (ISRE). After exposure to 
Poly I:C, RKIP may become post-translationally modified, and lose affinity for Raf-1 while 
gaining affinity for other proteins, thus allowing the formation of the transcription factor AP-1, 
in concert with NF-κB signaling, which drives a pro-inflammatory and co-stimulatory genetic 
program. RKIP also facilitates the production of Type-I IFNs, perhaps through direct 
stabilization of complexes upstream of IRF phosphorylation (1), or aiding in receptor coupling of 
IFNAR to its downstream elements, thus enhancing the necessary IFN feed-forward loop (2). 
(Right Panel) Treatment with the RKIP inhibitor locostatin significantly attenuates the Type-I 
IFN response, potentially through the destabilization of upstream signaling complexes or 
uncoupling of the IFNAR receptor.            
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Figure 6-2: RKIP is necessary for maintenance of interferon-mediated effector functions in 
immune cells Through these studies, we have determined that RKIP imparts positive effects on 
both Type I and Type II IFNs. First, RKIP is necessary for the generation of CD8+ Tc1 CTL 
effectors and proper production of their effector cytokine, IFNγ, during serial-TCR triggering. 
The exact molecular mechanism of this effect requires further study, however, it is clear that 
RKIP is most likely involved downstream of the TCR machinery. Additionally, RKIP is also 
necessary for the appropriate production of Type-I IFNs during sensing of nucleic acid PAMPs 
in APCs. This attenuated response in situations where RKIP function is inhibited can have wide-
reaching effects, given the pleiotropic nature of Type-I IFN function including: an indirect effect 
on IFNγ production from Th1, CTLs, and NK cells through decreased STAT4 phosphorylation, 
decreased CXCR9/10-mediated chemotactic gradients, potentially attenuated anti-viral 
responses, and a worsening of some autoimmune diseases, such as multiple sclerosis, due to a 
decrease in FoxA1+ Tregs expressing PD-L1. Nevertheless, the fact that RKIP can be inhibited 
using the small molecule inhibitor locostatin opens the door to future therapeutic interventions in 
inflammatory diseases that are mediated or potentiated by dysregulated IFN responses including: 
SIRS, SLE, RA, coeliac disease, and psoriasis.     
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Figure 6-3: Utilizing ProteomeLab PF-2D to mine proteomic changes in RKIP-/- mice 
Schematic of workflow and analysis of PF-2D proteomic mapping of naïve wild type and RKIP-/- 
naïve B cells; By using a full proteomic mining approach, we can gain new insight into the 
attenuated Type-I IFN transcriptome signature seen in RNAseq at the protein level. Additionally, 
we can determine whether transcript normalization after TLR ligation in B cells also normalizes 
the proteome. Finally, given that the PF-2D platform can also detect post-translational 
modifications of proteins by 1st dimensional pI shifts, a careful analysis of “fingerprints” may 
allow us to better understand exactly how RKIP imparts its effects in immune cells at the 
molecular level.       
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Figure 6-4: Avoiding the Tomato Effect: how much evidence is enough in the era of 
evidence based medicine? The “Tomato Effect” is a clinical rejection of potentially highly 
efficacious therapies due to a poor understanding of the mechanism by which they operate (352). 
To avoid this, especially in the era of evidence-based medicine, a significant amount of data 
must be obtained from different scientific approaches along a continuum in an effort to provide 
enough evidence for translation of a new therapeutic approach to the clinical setting. (Left Panel) 
Schematic of the “ideal” points of evidence that should be established in order to provide 
adequate scientific rationale for future human studies, ranging from low relevancy, high 
reproducibility systems approaches to highly relevant, but low reproducibility human studies; 
(Right Panel) The scientific approach utilized and evidence gathered during the current studies 
involving the interrogation of RKIP as a potential target for modulating inflammatory responses;  
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